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While every cell in an organism is genetically identical, there are marked phenotypic 
differences between tissues and organs that are controlled by epigenetic modifications. These 
epigenetic modifications provide an important role in controlling the machinery of gene 
expression. DNA methylation is the most stable epigenetic modification and is necessary for 
cellular activities. Many cancers show dysregulation of DNA methylation, with significant 
global loss of methylation. While the phenomenon of DNA methylation is well described in 
mammals, the mechanisms of reversal of methylation are incompletely understood.  
In previous studies, our laboratory observed rapid DNA demethylation in Jurkat cells (T cell 
leukaemia) after exposure to oxidative stress.  This rapid effect indicated active demethylation 
and suggested an activation of TET (Ten Eleven Translocation) proteins may be occurring. My 
research investigates the mechanism of changes in DNA methylation using a barcoded hairpin-
bisulfite sequencing technique. This high throughput hairpin-bisulfite assay provides a direct 
assessment of the methylation status of the DNA strands by linking the complementary strands 
together with a barcoded DNA hairpin linker. We established and developed a bioinformatic 
workflow to analyse hairpin-bisulfite sequencing data, initially using the Galaxy online 
platform and later using UNIX command line tools.  
We demonstrated hemi-methylation of densely methylated promoter regions, as early as 2 h 
after DNA replication in cells treated with decitabine, and this hemi-methylation increased with 
decitabine treatment. With the power of the hairpin-bisulfite sequencing assay, we were able to 
describe the kinetics and pattern of DNMT1 inhibitor treatment. Even though these results were 
predicted by previous studies, the kinetics of decitabine-induced hemi-methylation has not been 
demonstrated before in such detail and clarity. We observed an increase (40%) in unmethylated 
hairpin reads of the PCDHGA12 promoter after treatment with ascorbate/decitabine compared 
to untreated controls. This observed rapid demethylation implicates a novel mechanism of 
active demethylation that has not yet been recognised by researchers in the field. Importantly, 
we demonstrated that decitabine is capable of erasing the epigenetic memory of somatic cells 
by full removal of methyl groups from both complementary DNA strands. This study is the first 




Furthermore, in both single-gene and global investigations, we found loss of DNA methylation 
in different leukaemia cell lines (Molt4, Nalm6 and HL60) following ascorbate and DNMT 
inhibitor treatment, as well as an increase in 5-hydroxymethyl cytosine in Jurkat cells treated 
with decitabine and combined ascorbate/decitabine. We performed a low-coverage methylation 
sequencing assay (PBAT) to detect changes in global DNA methylation. We observed a gradual 
loss in global DNA methylation in synchronised Jurkat cells treated with decitabine and 
combined ascorbate/decitabine, confirming the results from locus-specific demethylation. The 
clinical relevance of our study is that it supports the premise that ascorbate is necessary to 
enhance the efficacy of decitabine by promoting the function of TET. It is likely that the 
demethylation pathways that we are studying operate during the onset of cancer and the 
existence of molecules that alter TET activity may have implications for modification of this 
process. Cancer patients are often markedly ascorbate (vitamin C) deficient, so the addition of 
ascorbate to treatment protocols may increase the clinical efficacy (or toxicity) of such drugs 
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Chapter One: Literature review. 
 
 
1.1 Overview of DNA methylation. 
Multicellular organisms start as totipotent zygotes that undergo a series of cell divisions and 
differentiation events giving arise to a whole organism that contains hundreds of specialised 
cell types (Mitalipov & Wolf, 2009). The different cell types in a multicellular organism have 
differences in both structure and function while being genetically identical. This is due to the 
fact that cell differentiation relies on differences in gene expression rather than on changes in 
the nucleotide sequence of the cells’ genomes. These stable changes in gene expression are 
called 'epigenetic' (Kohli & Zhang, 2013).  
1.1.1 What is epigenetics?  
The key to understanding the definition of epigenetics is the prefix “epi” which means “above”, 
“on the top” or “over”. The conventional definition of epigenetics is external modifications to 
DNA that change the phenotype or gene expression without changing the underlying DNA 
sequence. These modifications have the power to turn genes "on" or "off" and sometimes can 
be inherited from generation to generation (Lester et al., 2016). To date, the best understood 
epigenetic mechanisms are DNA methylation and histone modifications. 
DNA methylation is the covalent addition of a methyl group to the 5-carbon of the cytosine 
ring at CpG dinucleotides, resulting in 5-methylcytosine, a stable but reversible epigenetic 
mark, which is sometimes referred to as the fifth base of DNA (Goll & Bestor, 2005).  
Human somatic cell DNA contains approximately 1.5% 5-methylcytosine, which is mostly 
restricted to palindromic CpG dinucleotides. CpG dinucleotides represent 1% to 4% of genomic 
mammalian DNA, and are mostly located in repetitive DNA elements (Ehrlich et al., 1982). 
Cytosine methylation occurs in the context of paired symmetrical CpG sites in which a cytosine 
nucleotide is followed by guanine. Embryonic stem cells (ESCs) are an exception to this and 
have high levels of 5-methylcytosine (5-mC) in non CpG context (Holliday & Pugh, 1975; 




Methylation of cytosine is critically important during embryogenesis and cell lineage 
differentiation to maintain the function and stability of the genome as well as providing a 
defence mechanism against transposons (Jones & Liang, 2009). The majority of gene promoters 
contain areas of high CpG density referred to as CpG islands. These CpG islands are mainly 
unmethylated permitting DNA accessibility and gene transcription. Methylation of promoter 
CpG islands represses gene transcription.  
DNA methylation is necessary for normal development. It plays a crucial role in several diverse 
processes including embryonic development, genome stability and regulation of tissue-specific 
gene expression, genomic imprinting, X-chromosome inactivation, suppression of repetitive 
element transcription and transposition, and when dysregulated contributes to diseases such as 
cancer (Ehrlich et al., 1982; Moore, Toomire, et al., 2013; SanMiguel & Bartolomei, 2018). 
1.1.2 Maintenance of DNA methylation. 
In mammals, cytosine methylation seems to be the major epigenetic modification of DNA 
(Chiacchiera et al., 2013; Moore, Toomire, et al., 2013). The establishment of DNA methylation 
occurs by two catalytic activities, maintenance and de novo methylation, via the actions of DNA 
methyltransferases (DNMTs) which are responsible for catalysing the transfer of methyl group 
(CH3) from the donor S-adenosyl-methionine (SAM) to the C-5 position of cytosine (Barros & 
Offenbacher, 2009) (Figure 1.1).  
 
 
Figure 1. 1. Cytosine methylation by DNMTs. 
 
From the six DNMTs found in mammals, only three of them participate in DNA methylation 
(Uysal et al., 2017). The de novo methylation pathway establishes DNA methylation via the 
activity of DNMT3A and DNMT3B independent of DNA replication. The maintenance 
methylation pathway mediated by DNMT1 restores the methylation of newly methylated DNA 
strands by converting hemi-methylated CpG sites to fully methylated ones following DNA 
replication (Li et al., 2016; Wu et al., 2012). Three additional methyltransferase enzyme 




embryonic stem cells and appear to act either as cofactors for DNA methylation (Goll & Bestor, 
2005; Laisne et al., 2018) or as RNA cytosine methyltransferases (Goll et al., 2006).  
1.1.3 The role of DNA methylation. 
The first use of the term epigenetics is typically attributed to the British embryologist Conrad 
Waddington in an article published in 1942 (Waddington, 1942). He used the term epigenetics 
as the name for the study of the interaction between genes and the environment. However, in 
1975 DNA methylation was proposed as a silencing epigenetic mark associated with 
transcriptional repression and maintenance of transcription patterns through cell division 
(Holliday & Pugh, 1975; Jones, 2012). 
DNA modifications provide an important role in controlling the machinery of gene 
transcription. The role of DNA methylation in transcriptional regulation is widely demonstrated 
in three biological mechanisms 1) X-inactivation, 2) genomic imprinting and 3) retrotransposon 
inactivation. During embryonic development, X-inactivation describes the random inactivation 
of one of the two copies of the X chromosome in female mammals (Riggs, 1975). To maintain 
inactivation of the selected X chromosome, DNA methylation is required; the inactive X 
chromosome exhibits global hypomethylation at gene bodies, whereas hypermethylation occurs 
at many CpG island promoters to silence gene expression (Augui et al., 2011; Hellman & Chess, 
2007; Sharp et al., 2011). 
Genomic imprinting is a biological mechanism by which certain genes exhibit monoallelic 
expression that is inherited in a non-Mendelian manner. DNA methylation plays a crucial role 
in the genomic imprinting. For example, in Dnmt1-depleted mouse embryos, three imprinted 
genes had abnormal expression from both alleles (Li et al., 1993). Similarly, reduction in 
Dnmt3a in the female germ cells was found to abrogate genomic imprinting in the progeny 
(Kaneda et al., 2004).  
Retrotransposons are genetic elements that comprise more than 40% of genome and whose 
expression is suppressed through DNA methylation (Karimi et al., 2011; Rebollo et al., 2011). 
Retrotransposons, when expressed, are capable of splicing into a new genomic site, which can 
alter gene expression and induce genomic instability (Groh & Schotta, 2017; Havecker et al., 
2004). Alteration of DNA methylation by mutation of DNMTs exhibited upregulation of 
various retrotransposons, suggesting a role of DNA methylation in the repression of these 
repetitive elements (Bourc'his & Bestor, 2004; Walsh et al., 1998). 




hypomethylation and CpG island hypermethylation, is thought to induce activation of 
transposable elements that might contribute to instability of the genome (Feinberg & Tycko, 
2004; Howard et al., 2008; Wild & Flanagan, 2010). Conversely, repression of tumour 
suppressor genes is associated with hypermethylation of promoter CpG islands that might 
contribute to the cancer phenotype (Feinberg & Tycko, 2004; Hansen et al., 2011; Miranda & 
Jones, 2007). 
1.1.4 DNA-modifying enzymes: enzymes and co-factors catalysing DNA methylation  
Disruption of the DNA methyltransferase gene (Dnmt3a and Dnmt3b) in murine embryonic 
stem cells, resulted in a decrease in the level of 5mC to about one-third of wild type cells, 
without any abnormalities of cell morphology or cell growth rate. Interestingly, introducing the 
mutation into germline cells resulted in recessive lethal phenotype: embryos with the 
homozygous phenotype showed delayed development and death after mid gestation (Li et al., 
1992b; Okano et al., 1999). Furthermore, embryonic lethality and developmental defects were 
observed with other organisms including Xenopus laevis, Arabidopsis thaliana and zebrafish 
(Mathieu et al., 2007; Rai et al., 2010; Stancheva et al., 2002; Stancheva & Meehan, 2000). 
1.1.4.1 DNMT1 and UHRF1 are key-components of maintenance methylation. 
While the de novo methyltransferases, DNMT3a and DNMT3b are necessary for establishment 
of DNA methylation, the maintenance methyltransferase, DNMT1 has a major role in the 
preservation of this methylation during DNA replication. DNMT1 preferentially recognises 
hemi-methylated CpG sites, and converts hemi-methylated CpG sites to fully methylated sites 
(Santiago et al., 2014). Targeting of DNMT1 to the replicating DNA requires an accessory 
protein UHRF1 (also known nuclear protein of 95 kDa (NP95) in mouse or inverted CCAAT 
box-binding protein of 90 kDa (ICBP90) in human) that recognizes and binds to hemi-
methylated DNA sites through its unique SRA domain (Sharif et al., 2007; Zeng & Chen, 2019). 
UHRF1 contained five conserved domains which are all implicated in the function of DNMT1, 
the RING-associated SRA domain plays an important role in loading DNMT1 onto the newly 
synthesised DNA strand (Bostick et al., 2007; Sharif et al., 2007). 
DNMT1 was the first mammalian DNA methyltransferase gene to be discovered (Bestor et al., 
1988) and is characterised by several transcription start sites and three isoforms (Mertineit et 
al., 1998; Rouleau et al., 1992). The first isoform is Dnmt1s, which is expressed in somatic cells 
and encodes the full length 1620 amino acid DNMT1 protein product. The second isoform, 
Dnmt1o, lacks the N-terminal 118 amino acids and is more stable and exclusively expressed in 




spermatocytes, but has no protein product (Zeng & Chen, 2019). 
1.1.4.2 DNMT3A and DNMT3B are key-components of de novo methylation machinery. 
In mouse ES cells, genetic disruption of Dnmt1 resulted in global loss of methylation (Lei et 
al., 1996; Li et al., 1992a). Analysis of Dnmt1 knockout mouse embryonic stem cells led to the 
discovery of the existence of de novo DNA methyltransferase activity, and identification of 
DNMT3A and DNMT3B by consecutive screening of expressed sequence libraries for DNMT 
homologues. Studies of their function have shown that both DNMT3A and DNMT3B are 
required for de novo methylation and mouse development, and they play a critical role in 
maintenance methylation as demonstrated by the fact that DNMT3A and DNMT3B knockout 
in mouse embryonic stem cells leads to gradual reduction in global DNA methylation (Chen et 
al., 2003; Lei et al., 1996; Okano et al., 1999; Okano et al., 1998). 
New global DNA methylation is established by de novo DNA methyltransferases DNMT3A 
and DNMT3B. These enzymes interact together to form homo- and heterodimers which 
methylate both unmethylated and hemi-methylated CpG sites (Cheng & Blumenthal, 2008). 
Although, DNMT3A and DNMT3B enzymes are essential during embryonic development and 
their de novo methylation can be faithfully spread through mitotic division, their activity can 
be modulated by a catalytically inactive family member DNMT3L, which is involved in the 
regulation and targeting of DNMT3A/B for de novo methylation (Goll & Bestor, 2005; Hata et 
al., 2002).  
Reduction of either Dnmt1 or both Dnmt3a and Dnmt3b in mouse ES cells resulted in 
hypomethylation, which led to differentiation defects and cell apoptosis, confirming  that DNA 
methylation is necessary during differentiation. Restoration of DNA methylation levels rescued 
these defects (Damelin & Bestor, 2007; Jackson et al., 2004). Mutational changes in human 
DNMTs are correlated with pathological conditions (Cui & Xu, 2018; Jin & Liu, 2018). For 
example, mutations in DNMT1 have been identified in a neurodegenerative disorder associated 
with dementia and hearing loss (Klein et al., 2011). In addition, ICF (immunodeficiency 
centromere instability and facial abnormalities) syndrome is a rare autosomal recessive disorder 
that is caused by mutations in DNMT3B. ICF patients exhibit severe hypomethylation of 
pericentric repeats which is thought to be the cause of genomic abnormalities (Goll & Bestor, 
2005; Xu et al., 1999). Mutations in DNMT3A have been identified in some leukaemias and 





1.1.5 Epigenetics programming and reprogramming during development. 
1.1.5.1 Methylation dynamics in pre-implantation embryos. 
DNA methylation is largely established during gametogenesis, and epigenetic modifications 
are important for programming lineage determination and cellular identity. In mammals, the 
genomes of mature male and female gametes are highly methylated comparable to somatic 
cells. After fertilisation, global methylation reprogramming in the male pronucleus occurs by 
active demethylation before DNA replication (Mayer et al., 2000; Wu & Zhang, 2014; Wu & 
Zhang, 2010; Wu & Zhang, 2017) (Figure 1.2). TET3 is responsible for mediating the active 
oxidation of 5-mC followed by passive dilution, resulting in restoration of unmodified cytosine 
(Gu et al., 2011; Wossidlo et al., 2011). A second wave of demethylation occurs at the two-cell 
stage, where the maternal-derived genome undergoes a gradual passive demethylation up to the 
blastocyst stage when the methylation level reaches the lowest point. After implantation, a wave 
of de novo methylation mediated by DNMT3A and DNMT3B, re-establishes the embryonic 




Figure 1. 2. Dynamic changes of DNA methylation during development. After fertilisation the 
methylation patterns for the paternal-derived genomes are erased by active demethylation and 
the methylation patterns of maternal-derived genome are erased by passive demethylation. TE: 
tropho ectoderm, ICM: inner cell mass. 
 
1.1.5.2 Methylation dynamics in primordial germ cells (PGCs). 
The primordial germ cells (PGCs) are the primary undifferentiated stem cells that will 
differentiate towards the gametes (spermatozoa or oocytes). The erasure of DNA methylation 
in primordial germ cells is the critical step in generating the totipotent epigenome in the germ 




stage shows loss of bulk DNA methylation in a TET-independent manner between mouse 
embryonic day 8 and 9.5. The second stage shows TET1-and also potentially TET2-mediated 
loss of DNA methylation via oxidation of 5-mC to 5-hmC between day 10 and 11.5, and the 
third stage is loss of 5-hmC through replication dependent passive dilution (Hackett et al., 2013; 
Kagiwada et al., 2013). 
1.1.6 DNA demethylation. 
DNA methylation has a profound impact on genome stability, transcription and development 
in somatic cells. Although DNA methylation is relatively stable and can be maintained during 
DNA replication (Seisenberger et al., 2013; Wu & Zhang, 2010), loss of DNA methylation has 
been observed in different biological contexts, either through passive or active mechanisms.  
1.1.6.1 Passive DNA demethylation.  
During DNA replication, the maintenance DNA methyltransferase DNMT1 and its accessory 
factor UHRF1 maintain DNA methylation patterns across cell division. During the S-phase, the 
semiconservative replication of double stranded DNA leads to formation of two daughter 
strands. Intriguingly, functional deficiency in maintenance methylation may lead to replication-
dependent dilution of 5mC. Passive DNA demethylation occurs as a result of the loss of 
maintenance methyltransferase activity (Figure 1.3), through a lack of DNMT1 or loss of 





Figure 1. 3. Passive demethylation via lack of methylation maintenance during DNA replication 
(Hill et al. 2014 with permission). 
 
This mechanism is fully documented in the preimplantation embryo. The erasure of DNA 
methylation in maternally derived genomes during cleavage division is mainly via passive 
demethylation due to exclusion of DNMT1 from the nuclei (Messerschmidt et al., 2014; 
Smallwood & Kelsey, 2012). In primordial germ cells, the first phase of global loss of 




UHRF1 (Kagiwada et al., 2013).  
Importantly, alteration of cytosine methylation patterns is usually observed in cancer cells, and 
may result in activation of transforming genes and silencing of tumour suppressor genes. The 
presence of the oxidized form 5-hydroxymethylcytosine (5-hmC) (generated from oxidation of 
5-mC to 5-hmC) on the hemi-methylated parent strand reduces the DNMT1 binding affinity of 
the cytosine in the nascent strand in vitro (Valinluck & Sowers, 2007), potentially leading to 
passive demethylation (Figure 1.5,C).  
1.1.6.2 Active DNA demethylation. 
The rapid loss of DNA methylation in a replication-independent manner in slow or non-dividing 
cells is explained by active DNA demethylation (Figure 1.4) (Figure. 1.5.C, D). Interestingly, 
the discovery of rapid genome-wide loss of 5-mC of the paternal genome in the mouse zygote, 
which cannot be explained by replication-dependent dilution, gave support to the presence of 
active DNA demethylation (Gu et al., 2011; Mayer et al., 2000; Wu & Zhang, 2017). Active 
demethylation for a locus-specific region is well documented in post-mitotic cells in the adult 
brain (Guo et al., 2011b) and also during cell fate changes (Pastor et al., 2013).  
1.1.7 Mechanism of TET-mediated active demethylation. 
Due to the resilience of carbon-carbon bonds that link the methyl group in 5-mC, methylation 
was originally considered as an irreversible modification. Demethylation, by breaking this 
bond, was regarded as infeasible, (Kagiwada et al., 2013; Ohno et al., 2013). One step 
conversion of 5-methylcytosine to cytosine is unknown, and it is unlikely because of the 
difficultly in breaking the C-C bonds. It is now clear that DNA methylation can not only be 
removed by passive dilution, but also can be actively erased by enzymatic activity (Wu & 
Zhang, 2010).  
Active DNA demethylation uses enzymatic modification of 5-mC to generate 5-hmC; this 
process results in indirect removal of 5-methylcytosine. Ten-eleven translocation 1,2 and 3 
(TET1, TET2, TET3) proteins are the key component of the active DNA demethylation 
machinery (Rasmussen & Helin, 2016). The three enzymes are able to initiate the first step of 
active removal of 5-mC by oxidizing 5-methylcytosine into 5-hydroxymethylcytosine. This 
base (5-hmC) can be further processed to unmodified cytosine in two ways: firstly, by passive 
demethylation through DNA replication (Figure 1.5.C), or secondly, by further iterative 
enzymatic modifications, supporting the hypothesis that 5-hmC can be an intermediate of either 




proteins will generate 5-formylcytosine (5-fC) or 5-carboxylcytosine (5-caC), which can be 
recognized and excised from DNA by thymine DNA glycosylase (TDG) and base excision 
repair (BER) to regenerate unmodified cytosine (He et al., 2011; Ito et al., 2011; Maiti & 
Drohat, 2011; Shen et al., 2013; Wu & Zhang, 2017; Zhang et al., 2012) (Figure 1.4). 
All TET proteins are similar structures and are named after the ten-eleven translocation that 
occurs in rare cases of acute myeloid and lymphoblastic leukaemia (Seisenberger et al., 2013; 
Wu & Zhang, 2014). This translocation fuses the mixed-lineage leukaemia 1 (MLL1) gene 




Figure 1. 4. Schematic of DNA methylation and demethylation pathways in mammals. DNA 
methylation occurs by transferring the methyl group from the donor SAM to cytosine by 
DNMTs enzymes. TET enzymes oxidise 5-mC to 5-hmC, 5-fC and 5-caC, followed by TDG 






Figure 1. 5. Mechanisms of DNA methylation and DNA demethylation. A. During development, de novo methylation of unmethylated cytosine by 
DNMT3a,b proteins (left purple box). B. During cell division, maintenance DNMT1 specifically recognises hemi-methylated DNA through the 
interaction with UHRF1 at the replication fork and restore the methylation pattern of the newly synthesised DNA strands (middle green box). C. TET 
induced passive demethylation through oxidation of 5-mC to generate 5-hmC,  during cell cleavage DNMT1 is unable to recognise hemi-
hydroxymethylated strands, the presence of 5-hmC on the hemi-methylated DNA reduces the binding affinity of DNMT1 with methylated cytosine 
resulting in a passive demethylation after successive rounds of cell division. D.  TET induced active demethylation, TET converts 5-mC to 5-hmC. 
Through further oxidations, TET proteins generates two additional modified cytosines 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). Thymine 





1.1.7.1 The discovery of the TET-TDG pathway. 
The discovery of 5-hmC in mammalian DNA revealed a new potential mechanism for 5-mC 
displacement (He et al., 2011; Wu & Zhang, 2014). The three forms of TET proteins, namely 
TET1, TET2 and TET3 mediate multiple pathways of DNA demethylation including 
converting 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), and further, 
generate two additional higher oxidative products 5-formylcytosine (5-fC) and 5-
carboxylcytosine (5-caC), followed by thymine DNA glycosylase (TDG)- mediating base 
excision repair ( BER). The oxidized forms 5-hmC, 5-fC and 5-caC can be diluted through 
successive rounds of replication dependent passive demethylation caused by the low enzymatic 
activity of DNMT1 on the hemi-hydroxymethylated DNA (Kohli & Zhang, 2013; Pastor et al., 
2013; Wu & Zhang, 2010).   
The iterative oxidative reactions by TET enzymes are analogous to a key step of thymine 
oxidation by thymine hydroxylase (THase) identified in yeast (Ito et al., 2011; Smiley et al., 
2005). In this case, THase catalyses serial oxidation reactions to convert thymine to 5-
hydroxymethyluracil (5-hmU), 5-formyluracil (5-fU) and further to iso-orotate which then can 
be converted by iso-orotate decarboxylase to uracil, which then can be used for nucleotide 
metabolism (Smiley et al., 2005). Similar to iso-orotate, 5-caC might be converted to cytosine 
with removal of the carboxyl group by a decarboxylation reaction, but the process has not been 
identified yet in mammals (Ito et al., 2011). Furthermore, Iwan and his colleages 2018 showed 
that 5-fC and f-caC undergo a direct C-C bond cleavage in stem cells, which leads to direct re-
installation of cytosine (Iwan et al., 2018). 
1.1.7.2 Nucleotide replacement is the second step of active demethylation. 
Importantly, thymine DNA glycosylase (TDG) efficiently recognises and excises 5-fC and 5-
caC in mouse embryonic stem cells (Rose et al.) (Gong & Zhu, 2011; He et al., 2011; Raiber et 
al., 2012; Zhang et al., 2012). Interestingly, TDG has high affinity for 5-fC and 5-caC, but not 
for 5-mC and 5-hmC (Hashimoto et al., 2012; He et al., 2011; Zhang et al., 2012). The activity 
of TDG in active demethylation occurs via the removal of 5-fC and 5-caC by flipping the target 
nucleotide from the double-strand DNA. TDG then cleaves the N-glycosidic bond, leaving an 
abasic site, thus activating the base excision repair pathway (BER), resulting in insertion of an 
unmethylated cytosine. The TDG-BER mechanism has been proposed as an active 
demethylation machinery to remove the oxidised forms 5-fC and 5-caC, and replacement with 




Interestingly, a recent study by Fu et al. (2019) demonstrated the mechanism of how TDG 
recognize and distinguish highly similar cytosine modifications for potential demethylation. 
Using a high-resolution structure of a dsDNA decamer containing fully symmetric 5-fC and 5-
caC nucleotides, the study reported that the modified cytosines induced geometrical alteration 
of the DNA minor groove, which was recognized by finger residue, R275, of TDG (Fu et al., 
2019). 
1.1.7.3 Structure and function of TET enzymes. 
TET enzymes belong to the group of α–ketoglutarate (α–KG) and Fe+2 dependent dioxygenases 
(Lorsbach et al., 2003; Tahiliani et al., 2009). These proteins provided a mechanistic basis for 
the active DNA demethylation pathway. TET proteins were originally identified in the context 
of haematologic malignancies, with TET1 discovered as a fusion partner in a rare case of acute 
myeloid leukaemia bearing the t(10;11)(q22;q23) (Lorsbach et al., 2003; Ono et al., 2002). This 
conserved gene family contains two other members (TET2 at 4q24 and TET3 at 2p12) in 
humans (Ko et al., 2015; Lorsbach et al., 2003).  
Tahiliani et al. (2009) provided the first bona fide evidence of active DNA demethylation by 
demonstrating that TET1 enzymatic activity involved the oxidation of 5-mC to 5-hmC. Through 
bioinformatics approaches, TET enzymes were identified as human homologues of mouse Tet 
proteins (including Tet1, Tet2 and Tet3) and homologues of the J binding proteins 1 and 2 
(JBP1 and JBP2) (in trypanosome, a unicellular protozoon), which are also able to oxidize 5-
mC to 5-hmC.  
Other studies confirmed that TET proteins are Fe+2 and α-KG-dependent dioxygenases, and the 
binding motif of Fe+2 in TET enzymes includes at least two histidine residues and one 
asparagine residue, which are conserved across JBP1, JBP2, human TET, and mouse Tet 
proteins (Shen & Zhang, 2013; Tahiliani et al., 2009).  Interestingly, mutation of the Fe+2 
binding sites in TET enzymes reduced the 5-hmC signal in cultured cells (Ito et al., 2010). 
1.1.7.4 Roles of TET enzymes in regulation of DNA methylation. 
TET proteins are large (~180 to 230 kDa) multidomain dioxygenase enzymes. All TET 
enzymes contain a conserved core catalytic domain (Cys-rich, double strand beta helix (DSBH) 
regions, and binding sites for the cofactors Fe+2 and α-ketoglutaric acid that together form the 
core catalytic region in the C terminal) that uses O2 to decarboxylate α-ketoglutaric acid 
generating a high valent iron oxide that converts 5-mC to 5-hmC (as well as 5-hmC to 5-fC and 




(DSBH) fold is different for each member of α-KG – Fe+2 dioxygenases. In TET proteins, the 
DSBH domain was shown to include a conserved residue involved in the regulation of the 
cofactor Fe+2 and the co-substrate α-KG. Moreover, a cysteine-rich region identified upstream 
of the DSBH domain contains eight cysteine and one histidine residues proposed to be used for 
DNA binding activity. The core catalytical domain preferentially binds cytosine in a CpG 
context but does not interact with surrounding DNA bases (Tahiliani et al., 2009). 
TET1 and TET3 have an N-terminal conserved CXXC zinc finger domain, though TET2 does 
not (Figure 1.6). While similar CXXC domains usually bind to unmethylated CpG 
dinucleotides, in TET enzymes they bind to 5-mC and 5-hmC (Xu, Wu, et al., 2011). 
Intriguingly, eleven CXXC family members have been classified and found in human: TET1 
protein contains a CXXC domain type 6, whereas TET3 contains CXXC10 (Good et al., 2017; 
Liu, Wang, et al., 2013). The exact function of the TET CXXC domain is not fully understood, 




Figure 1.6. Human TET protein domain structure. TET1-3 harbour a cysteine-rich region (Cys) 
followed by the double-stranded β-helix (DSBH) fold characteristic of the a-KG-Fe (II) 
oxygenase. TET1 and TET3 also contain a CXXC domain. 
 
1.1.7.4.1 TET1. 
The discovery of 5-hmC, and the presence of high 5-hmC at the Tet1 DNA binding loci in ESC, 
suggesting the role of Tet1 in locus-specific 5-hmC regulation led to more studies to identify 
the various roles of TET1 protein (Xu, Wu, et al., 2011). 
In mouse embryonic stem cells, Tet1 plays a dual function in gene regulation. Inhibition of Tet1 
induced both up-regulation of some target genes and down-regulation of others. Interestingly, 
the percentage of Tet1 up-regulated genes was much higher than the percentage of down-




et al., 2011; Wu, D'Alessio, Ito, Xia, et al., 2011). Furthermore, inhibition of Tet1 only affected 
Tet1 target genes without any effect on non-Tet1 binding genes, suggesting Tet1 regulation of 
gene-specific region (Xu, Wu, et al., 2011). 
In general, Tet1 prefers to bind to exon regions rather than introns, and has increased affinity 
for high CpG promoters than intermediate, low cytosine promoters or gene bodies (Ficz et al., 
2011; Xu, Wu, et al., 2011). In general, Tet1-binding CpG promoters are hypomethylated 
compared to other promoters, suggesting an inverse correlation between DNA methylation and 
Tet1 targets (Ficz et al., 2011; Wu, D'Alessio, Ito, Xia, et al., 2011). Inhibition of Tet1 increased 
the methylation of Tet1 target genes, without any effect on non-Tet1 binding genes, suggesting 
Tet1 has a role in regulation for these genes by maintaining the hypomethylated status of these 
regions (Xu, Wu, et al., 2011). 
In mouse ESCs, Tet1 has a crucial role in maintenance and regulation of DNA methylation of 
pluripotent genes such as Nanog, a transcription factor involved in self renewal. Tet1 binds and 
regulates the expression of the Nanog promoter by maintaining its hypomethylated status. In 
contrast, inhibition of Tet1 leads to hypermethylation of the Nanog promoter which is 
associated with gene repression and a decreased proliferation rate (Ito et al., 2010). Moreover, 
Tet1 depletion induces up-regulation of Tet1 target genes used in development and 
differentiation (Wu, D'Alessio, Ito, Xia, et al., 2011), suggesting Tet1 has a dual role in 
maintaining the expression and repression of pluripotent and  developmental genes (Ito et al., 
2011; Wu, D'Alessio, Ito, Xia, et al., 2011). Furthermore, Tet1 reduction prevented embryonic 
specification towards the inner cell mass, suggesting an important role of Tet1 in ICM 
specification (Ito et al., 2010). 
Notably, Tet1-knock out (KO) mice ESCs showed a partial reduction in 5-hmC levels and slight 
DNA methylation effects. The knock out cells maintained their pluripotent state through 
expression of Oct4, Nanog and Sox2 and the cells were able to generate the three embryonic 
germ layers. Interestingly, Tet1 KO mice were viable and fertile but small in size (Dawlaty et 
al., 2011). 
Inhibition of both Tet1 and Tet2 in mice was associated with a complete depletion of 5-hmC 
and increase in 5-mC levels in both embryonic stem cells and germ cells, where both Tet1 and 
Tet2 are more highly expressed than Tet3. In addition, the double mutant embryos exhibited 
developmental abnormalities and perinatal lethality in half the offspring, whereas the rest were 
viable (Dawlaty et al., 2013). Interestingly, double knockout of Tet1 and Tet2 had a stronger 




fertility while males were fertile with only slight differences in testis size (Dawlaty et al., 2013). 
1.1.7.4.2 TET2. 
TET2 undergoes frequent somatic mutations in a wide spectrum of myeloid and lymphoid 
malignancies (Cimmino et al., 2011; Solary et al., 2014). In addition to oxidising 5-mC, TET2 
may have another function in regulation of haematopoiesis and loss of TET2 may lead to 
dysregulation of the DNA repair response, increasing genome instability (Feng et al., 2019). 
TET2 gene resides at chromosome 4q24 in human and contains 11 exons. Due to chromosomal 
inversion during evolution, TET2 lacks the CXXC domain (Iyer et al., 2009; Ko et al., 2013; 
Pastor et al., 2013). As with the other TET proteins, TET2 protein iteratively oxidises 5-
methylcytosine to generate 5-hmC and then to 5-fC and 5-caC. Intriguingly, a study using 
highly sensitive isotope showed that TET2 yields 5-fC and 5-caC by an iterative process 
directly from 5-methylcytosine without release of the 5-hmC intermediate (Crawford et al., 
2016). Normally, haematopoietic tissues such as bone marrow and spleen show high TET2 
expression compared to other TET2 expressing tissues (Langemeijer et al., 2009; Li et al., 
2011). 
TET2 gene is located in a region that shows a high frequency of microdeletions and copy neutral 
loss of heterozygosity (CN-LOH) in patients with myeloid malignancies (Ko et al., 2010). 
Moreover, patients with myeloid cancers such as acute myeloid leukaemia (AML), secondary 
AML (sAML), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPNs) and 
chronic myelomonocytic leukaemia (CMML) showed defects in TET2 (Ko et al., 2010; 
Mancini et al., 2012; Quivoron et al., 2011). Moreover, TET2 mutation was associated with the 
levels of 5-hmC, predicting the role of TET2 and 5-hmC in the progression of myeloid disorders 
(Ko et al., 2015; Quivoron et al., 2011). How TET “loss of function” promotes the progression 
of hematopoietic malignancies is largely unknown (Lio et al., 2019).  Somatic mutations in 
TET2 are present in about 15% of myeloid cancer patients (Delhommeau et al., 2009). 
Human B and T lymphoma cells were reported to have mutations in TET2 that affect the stem 
cell compartment (Quivoron et al., 2011). Intriguingly, haematopoietic stem cells were 
recognised with a somatic mutation in one of TET2 alleles compared to mutation in both TET2 
alleles in lymphoma cells, which suggested that the mutation in the second allele was acquired 
during tumour progression (Quivoron et al., 2011). Furthermore, another study by Kubuki et 
al. 2017 showed that TET2 mutations occurred in some patients with diffuse large B-cells 
lymphoma (DLBCL) and most likely these mutations contributed in the pathogenesis of their 




There is  evidence suggesting that TET2 mutations are drivers of tumorigenesis in blood cells, 
and that TET2 mutations are required at the haematopoietic stem and early progenitor cell stage. 
TET2 gene is frequently mutated somatically in both myeloid and lymphoid malignancies 
resulting in impairment of TET2 activity that interferes with the conversion of 5-mC to 5-hmC. 
Interestingly, TET2 is commonly mutated in clonal haematopoiesis in individual with no 
manifestations of blood cancer. TET2 mutation alone is insufficient to cause haematologic 
malignancy, suggesting that TET2 mutations represent an early event during tumorigenesis 
(Chiba, 2017). 
Similar to other TET enzymes, the catalytical activity of TET2 enzyme depends on the co-
factor α-KG that is generated from isocitrate by isocitrate dehydrogenase enzymes (IDH1 and 
IDH2). Interestingly, mutations in either IDH1 or IDH2 are observed frequently in myeloid 
cancers. Mutations in IDH1 or IDH2 impair the normal production of α-KG by reduction of α-
KG to 2-hydroxyglutarate (2-HG), which is a structural analogue of α-KG (Xu, Yang, et al., 
2011a). Consequently, defects in IDH1-2 enzymes induce malignant transformation through 
inhibition of α-KG dependent-TET2 by increasing production of 2-HG leading to a decrease in 
5-hmC production (Evans & Griner, 2015; Xu, Yang, et al., 2011a).  
Cancer cells are epigenetically distinct from their tissue of origin, as they frequently display 
global hypomethylation and gene promoter hypermethylation. These epigenetic aberrations can 
inactivate target genes and contribute to oncogenesis. TET enzymes that initiate DNA 
demethylation by oxidising 5-mC to 5-hmC are strongly involved as tumour suppressors. 
Interestingly, prostate cancer was characterised by TET1 mutations which also frequently occur 
in lymphoid cancers (Cimmino et al., 2015; Spans et al., 2016). TET2 mutations were observed 
frequently in myeloid cancers as well as in 12 cancer types including in solid tumours (Kandoth 
et al., 2013; Quivoron et al., 2011; Thienpont, Galle, et al., 2016).  
Recently, a genome-wide association study revealed a common SNP near TET2 linked to breast 
cancer risk. This higher risk was associated with low expression of TET2 (Guo et al., 2015). 
DNA methylation regulates the expression of TET genes: the TET1 promoter is frequently 
hypermethylated in B-cell lymphomas, and the TET2 promoter is hypermethylated in gliomas, 
where as TET1 and TET3 promoters are both hypermethylated in bladder and breast cancer 
(Thienpont, Galle, et al., 2016). 
TET2 is expressed in various tissues, with increased expression in haematopoietic tissues such 
as bone marrow and spleen (Li et al., 2011). TET2 deficient mouse models show a reduction in 




Intriguingly, depletion of 5-hmC in TET2 deficient mouse was not compensated by increase 
transcripts of TET1 or TET3, so the relationship between TET2 mutations and the 5-hmC and 
5-mC status remains unclear (Quivoron et al., 2011).  
Interestingly, myelodysplastic syndrome patients with TET2 mutations treated with DNMT1 
inhibitors, azacytidine and decitabine, showed more global loss of DNA methylation compared 
with TET2 wild-type patients (Huang & Rao, 2014). 
Moreover, retinoic acid (RA) induced TET2 to positively regulate the expression of HOXA 
genes upon induction of differentiation, through the conversion of 5-mC to 5-hmC in both 
mouse and human embryonic carcinoma cell line NT2. Treatment of NT2 cell lines with  RA 
increased TET2 expression and 5-hmC levels at lineage-specific loci, resulting in enhanced 
expression of HOXA gene. Alternatively, TET2 deficiency resulted in low 5-hmC and high 5-
mC levels leading to reduced HOXA expression (Bocker et al., 2012). 
1.1.7.4.3 TET3. 
The human TET3 gene is located on chromosome 2 and contains 9 exons with the first exon 
coding for the CXXC domain. As with TET1 and TET2, TET3 dioxygenase enzyme catalyses 
the conversion of modified genomic base 5-mC into 5-hmC and further into 5-fC and 5-caC. 
However, TET3 protein is the only TET family member with reduced expression in both human 
and mouse embryonic stem cells and is highly expressed in the zygote whereas the other TET 
proteins are poorly expressed (Gu et al., 2011; Hill et al., 2014; Huang & Rao, 2014; Wu & 
Zhang, 2010; Wu & Zhang, 2017). 
TET3 has an important role in selective active demethylation of paternal DNA in male 
pronucleus upon zygote formation and before cell division (Figure 1.2) (Bhutani et al., 2011; 
Iqbal et al., 2011; Wossidlo et al., 2011). After fertilization, TET3 rapidly mediates oxidation 
of 5-mC accompanied by accumulation of 5-hmC, 5-fC  and 5-caC in the paternal pronuclei at 
the PN3 stage and these oxidised forms were diluted passively during subsequent cell divisions 
(Inoue et al., 2011; Inoue & Zhang, 2011; Iqbal et al., 2011; Wossidlo et al., 2011).  
Interestingly, zygotic Tet3 depletion in conditional knockout mice resulted in failure of 
conversion of 5-mC into 5-hmC in the paternal pronuclei  (Gu et al., 2011). Furthermore, Tet3 
is used in demethylation of paternal Oct4 and Nanog genes after fertilization; diminished Tet3 
enzyme levels leads to impaired demethylation of these genes. Depletion of Tet3 in the germ 
cells of female mice causes a severe reduction in the fertility, and their  heterozygous mutant 




In contrast to the paternal genome, the maternal genome is largely protected against Tet3 
demethylation by PGC7/Dppa3/stella proteins, and is passively demethylated during successive 
rounds of cell division (Bhutani et al., 2011; Wossidlo et al., 2011). Similarly in bovine and 
rabbit zygotes, Tet3 show a conserved asymmetric 5-hmC accumulation between paternal and 
maternal pronuclei (Wossidlo et al., 2011). In contrast to this, another study showed that Tet3 
localises to the maternal pronucleus, similar to paternal pronucleus, suggesting that it can 
oxidise both paternal and maternal DNA in mouse zygotes, but the phenomenon was less 
pronounced in the female pronucleus (Tsukada et al., 2015). In addition, Tet3 knockout in 
oocytes had no major impact on oocyte development, maturation, fertilization or pregnancy, 
but resulted in neonatal sub-lethality suggesting that oxidation of zygotic 5-mC by maternal 
Tet3 is essential for neonatal growth rather than development (Tsukada et al., 2015). 
Few data have been reported on the roles of TET3 in cancer. However, deletion of the region 
where TET3 is located was observed in a case of myelodysplastic syndrome with ring 
sideroblasts (Kinney & Pradhan, 2013). Furthermore, the methylation of TET3 in T1 and T2 
oropharyngeal cancer and oral cancer patients was associated with poor survival (Misawa et 
al., 2018), and the methylation status of TET3 was associated with aggressive tumour behaviour 
in head and neck cancer (Misawa et al., 2018). Induction of Tet3 overexpression in glioblastoma 
by using epigenetic drugs 10 µM suberoylanilide hydroxamic acid (Sajadian et al.) and 50 
µg/mL ascorbate led to markedly reduced tumour formation in an immunodeficient mice model 
(Carella et al., 2019). Cao and colleagues 2019 showed that a high TET3 level was associated 
with poor prognosis and poor survival in ovarian cancer patients (Cao et al., 2019). The few 
present data showed that TET3 has an important roles in cancer. These roles were associated 
with the progression of some types of cancer, suggesting that further investigations are needed.  
1.1.7.5 Substrate preference of TET enzymes. 
Three out of four modified forms of cytosine, 5-mC, 5-hmC and 5-fC can act as substrates for 
TET proteins (Figure 1.7), and the substrate preference for TET enzymes can be viewed at three 









The first level is detection of the substrate; 5-methylcytosine “the modified base formed by the 
addition of a methyl group” is predominantly detected in a CpG context but also found in non-
CpG contexts. TET enzymes probably prefer CpG contexts over non-CpG contexts (Hu et al., 
2013; Pfeifer et al., 2019).  
The second level is binding of TET enzymes; TET prefers 5-mC to 5-hmC or 5-fC. In addition, 
enzyme kinetic analysis demonstrated that TET catalysed conversion of 5-mC to 5-hmC is 3 - 
5 fold faster than 5-hmC to 5-fC and 5-fC to 5-caC (Hashimoto et al., 2014; Hu et al., 2015; Ito 
et al., 2011). Interestingly, mutation of the Thr1372 residue in human TET2 prevents oxidation 
of 5-hmC to 5-fC or 5-caC, but does not affect the 5-mC to 5-hmC conversion (Liu et al., 2017). 
The third level is the symmetrical and un-symmetrical cases of CpG dyads; out of 25 different 
combinations, 21/25 are possible TET targets, 21/25 are acted on by TET (Figure 1.8), 
including the pairing of 5-mC, 5-hmC and 5-fC with unmodified cytosine as well as pairing of 
5-mC with all forms of cytosine (Crawford et al., 2016; Weber et al., 2016). TET catalyses the 
oxidation of the substrate in the same rate regardless the status of the complementary strand 




Figure 1. 8. Possible substrates for TET enzymes. CpG dyads with different combinations on 
the top and bottom strands. TET catalyse their substrate regardless of the modification status of 





1.7.5.1 5-Methylcytosine (5-mC). 
Currently, 5-mC is considered a classic epigenetic mark as it fulfils the stringent criteria of an 
epigenetic framework as being mitotically and meiotically heritable (Riggs, 1975). Cytosine 
methylation typically occurs in the context of CpG dinucleotides. Typically, the transfer of 
methyl group is catalyzed by the DNA methyltransferases enzymes (DNMTs), which allowing 
5-mC to be faithfully passed through cell division.  
5-methylcytosine was first detected in the tubercle bacillus in 1925, and two decades later in 
calf thymus DNA (Hotchkiss, 1948; Johnson & Coghill, 1925). 5-methylcytosine was proposed 
as a key epigenetic modification in 1975 (Holliday & Pugh, 1975; Riggs, 1975). Intriguingly, 
methylation of cytosine does not affect its base pairing properties with guanine, and it is thus 
replicated as cytosine (Ohki et al., 2001; Pennings et al., 2005). In general, CpG dinucleotide 
methylation displays a bimodal distribution in mammalian DNA; with the majority of CpG sites 
being methylated whereas CpG sites in promoter CpG islands are usually unmethylated 
(Illingworth & Bird, 2009; Meissner et al., 2008; Weber et al., 2007).  
Gene promoters can be classified into high-density, intermediate-density and low-density 
promoters based on their CpG island density. High-density promoters (HCPs) are usually 
unmethylated and associated with gene transcription, whereas low-density promoters (LCPs) 
are usually highly methylated regardless of their transcriptional activity. Intriguingly, ICPs 
display disparate behaviour as they are commonly unmethylated but frequently subject to de 
novo methylation which corresponds inversely with gene transcription (Weber et al., 2007). 
1.7.5.2 5-Hydroxymethylcytosine (5-hmC). 
5-hydroxymethylcytosine (5-hmC) is the first oxidative step in TET-mediated DNA 
demethylation. 5-hmC act as the “6th base” of DNA and has major roles in gene regulation and 
expression.  
In 2009, an unidentified spot “X” was detected in a study that compared the abundance of 5-
mC in Purkinje and granule cell nuclei using two-dimensional thin layer chromatography. 
Intriguingly, the spot was found in the xpG context and associated with decreased 5-mC in the 
samples. Further investigation using high pressure liquid chromatography and mass 
spectrophotometry demonstrated that “X” was 5-hmC. Since that time, 5-hmC has been 
detected in mouse brain, suggesting that 5-hmC might play a role in the epigenetic regulation 
of neuronal functions (Kriaucionis & Heintz, 2009). 




detected in T-even bacteriophages and in 1972, 5-hmC was identified in mammalian DNA and 
was regarded as oxidatively damaged cytosine that might eventually be replaced by DNA repair 
mechanisms (Ito et al., 2011).  
Typically, conversion of 5-mC to 5-hmC by TET proteins blocks the repressive methyl binding 
domain (MBD) containing proteins and DNMT proteins that would typically be recruited to 5-
mC, and promotes gene expression through active demethylation (Branco et al., 2011). 
However, generation of 5-hmC by active demethylation appears to be particularly important 
for genes involved in brain function; for example, 5-hmC is enriched in genes involved with 
synaptic function in mouse and human brain.  
1.1.7.5.3 5-Formylcytosine (5-fC). 
5-formylcytosine (5-fC) is the second oxidized derivative of 5-methylcytosine. Genomic and 
proteomics studies have suggested a role for 5-fC in transcriptional regulation through 
chromatin remodeling. The actions of DNA repair factors and chromatin regulators in selecting 
and binding 5-fC in genomic sequence suggests that 5-fC may act as an epigenetic signal in its 
own right (Iurlaro et al., 2013). 
Each oxidative derivative of TETs appears to have a different distribution. For example, 
genome-wide mapping of 5-fC showed that 5-fC is enriched at poised enhancers among other 
regulatory elements in mouse embryonic stem cells (Song et al., 2013). Raiber et al. (2015) 
revealed that 5-fC alters the structure of the DNA double helix and induces a unique 
conformation (Raiber et al., 2015). In addition, Fu et al. (2019) reported that “formyl and 
carboxyl” modifications of cytosine induce geometric alteration of the DNA minor groove, this 
alteration is recognized by (TDG) via its finger residue R275 followed by excision and DNA 
repair (Fu et al., 2019).  
1.1.7.5.4 5-Carboxylcytosine (5-caC). 
5-carboxylcytosine is the final oxidized derivative of 5-mC. Both 5-fC and 5-caC act as 
substrates for active demethylation and can be converted to unmodified cytosine by thymine 
DNA glycosylase (TDG) and base excision repair (Zhang et al., 2012). 
Some evidence suggests that 5-fC and 5-caC can act as epigenetic marks, with specific reader 
proteins (Shi et al., 2017). A previous study demonstrated that 5-fC and 5-caC affect the rate 
and specificity of RNA polymerase II (RNAPII) activity. Both 5-fC and 5-caC cause increased 
RNAPII backtracking, increased pausing, and reduced fidelity of nucleotide incorporation 




Like many other oxidatively damaged DNA nucleotides and because both formyl and carboxyl 
groups are electron-withdrawing, 5-fC and 5-caC nucleotides have weak glycosidic bonds. The 
weak glycosidic bonds make the base pairing weaker for 5-fC:G and 5-caC:G than C:G and 
presumably increase the rate of spontaneous flipping (Bochtler et al., 2017; Lenz et al., 2015) 
creating suitable substrates for excision by TDG (Dai et al., 2016; Maiti et al., 2013). 
Thymine DNA glycosylase has been named for its a monofunctional glycosylase activity 
against thymine bases, arising from deamination of 5-mC mispaired to Guanine. TDG was the 
first enzyme reported to excise 5-fC and 5-caC (Maiti & Drohat, 2011). Interestingly, the weak 
glycosidic bonds and high flipping rate for 5-fC and 5-caC make a favourable interaction 
between TDG and the flipped 5-fC and 5-caC (Hashimoto et al., 2013), and result in faster 
excision of 5-fC and 5-caC than from Thymine pairs with Guanine (Maiti & Drohat, 2011). 
1.1.8 DNA demethylation and cancer. 
Cancer growth requires the coordinated change in gene expression of different sets of genes. 
Alterations in DNA methylation can account for changes in gene expression (Baylin & Jones, 
2011; Esteller, 2007). Hypermethylation of CpG islands in gene promoters of tumour 
suppressor genes is associated with abnormal gene expression resulting in gene silencing. This 
dysregulation of the tumor epigenome is common within different types of cancer cells (Wu & 
Zhang, 2011a). Typically, hypermethylation of tumour suppressor gene promoters and global 
hypomethylation with activation of oncogenes is involved in the progression of cancer 
(Cheishvili et al., 2015).   
In cancer cells, the steady state of DNA methylation can be modulated by many reagents such 
as pharmacological reagents or other chemicals. This modulation makes DNA methylation 
attractive as a target for therapeutic treatment (Cheishvili et al., 2015; Szyf, 2005). It has been 
suggested that impairment of TET-mediated DNA demethylation may contribute to cancer (An 
et al., 2017; Wu & Zhang, 2011a). The initial story implicating TET proteins in cancer 
development came from the identification of human TET1 as a rare fusion partner of MLL in 
patients with acute myeloid leukemia (AML) (Ono et al., 2002).  Consequent research studies 
uncovered a link between TET2 gene mutations and myelodysplastic syndromes (Delhommeau 
et al., 2009; Langemeijer et al., 2009). TET2 mutations impaired enzymatic activity resulting 
in a consistent loss of 5-hmC in myeloid malignancies (Ko et al., 2010; Lio et al., 2019). 
Furthermore, bone marrow samples from patients with TET2 mutations displayed low levels of 
5-hmC in their genomic DNA compared to bone marrow samples from healthy controls (Ko et 




various myeloid cancers, a reduction of 5-hmC was also observed in myeloid cancers with 
mutations in IDH1 and IDH2 genes (Quivoron et al., 2011). 
Mutations in IDH1 and IDH2 genes generate high levels of 2-hydroxyglutarate (2-HG), which 
inhibits TET2-mediated 5-mC hydroxylation leading to reduced 5-hmC levels (Figueroa et al., 
2010; Mondesir et al., 2016; Xu, Wu, et al., 2011). Interestingly, mutations in IDH1, IDH2 and 
TET2 genes are mutually exclusive in AML, suggesting a common role in the pathogenesis of 
these diseases (Figueroa et al., 2010; Pronier & Delhommeau, 2012). 
Reduced expression of TET and IDH genes due to promoter methylation has been reported in 
many solid tumours, despite the absence of coding mutations (Hsu et al., 2012; Rasmussen & 
Helin, 2016; Sharma, 2018; Yang et al., 2013).  
Global loss of 5-hmC can be broadly used as a biomarker for many human cancers such as 
melanoma, breast, liver, lung, pancreatic and prostate. Dysregulation of gene expression of both 
IDH2 and TET genes is associated with loss of 5-hmC in melanoma cells. Interestingly, re-
introduction of IDH2 or TET2 could restore the 5-hmC level in melanoma cells, suppressing 
melanoma growth and increasing tumour-free survival in animal models (Lian et al., 2012). 
Moreover, 5-hmC appeared to be the epigenetic marker that can distinguish melanocytes in 
benign naevi from those in melanoma, as 5-hmC levels were high in naevi, whereas low or 
absent levels were seen in all primary and metastatic melanomas (Lian et al., 2012).  
Xu et al. (2011) showed a high percentage of patients with lower-grade brain tumours and 
secondary glioblastomas carried mutations in IDH1 and IDH2. IDH1 mutations were associated 
with increased histone methylation and decreased 5-hmC. Furthermore, tumours with either 
IDH1 or IDH2 mutations showed decreased a-KG levels and an increase in 2-HG (Xu, Yang, 
et al., 2011a). Moreover, IDH1 and IDH2 mutations in esophageal squamous cell carcinomas 
were associated with high 2HG levels, predicting that IDH1 and IDH2 mutations might play a 
limited role in the development and progression of esophageal squamous cell carcinomas 
(Miyake et al., 2018).  
In addition to myeloid cancer, TET2 mutations are common in lymphoid malignancies, 
especially among patients with T cell lymphomas such as angioimmunoblastic T cell lymphoma 
and peripheral T cell lymphoma (Han et al., 2015; Lemonnier et al., 2012; Odejide et al., 2014; 
Quivoron et al., 2011). It is generally accepted that Tet2 loss of function induces myeloid 
transformation, but the reason is still unclear (Ko et al., 2015). Loss of Tet2 function in Tet2-
deficient mice strains did not cause disease, suggesting that there is an unidentified factor that 




of Tet2 associated with either Asxl1 or Ezh2 mutations accelerated the development of myeloid 
disease in murine models similar to human myelodysplastic syndrome (Abdel-Wahab et al., 
2013; Han et al., 2015; Muto et al., 2013).  
TET1 and TET2 expression levels were found to be low in hepatocellular carcinoma (HCC) 
tissue and cell lines and this was associated with down regulation of global 5-hmC levels which 
might be a novel prognostic biomarker of hepatocellular carcinoma (Wang et al., 2019). 
In summary, many mechanisms may cause depletion of 5-hmC by inactivation of TET 
enzymes, but the relevant molecular targets of TET proteins that link to cancer development 
have not yet been identified. 
1.1.9 Ascorbate and epigenetics reprogramming.  
Ascorbate is an essential, water-soluble micronutrient that is naturally present in some food, 
and available as a dietary supplement. The importance of ascorbate came from its role as an 
antioxidant and free radical scavenger as well as acting as a co-factor in numerous enzymatic 
reactions (Lee Chong et al., 2019; Young et al., 2015). Ascorbate plays an essential role in 
collagen crosslinking and its deficiency can cause scurvy (Camarena & Wang, 2016; Gould & 
Woessner, 1957; Van Robertson & Schwartz, 1953). 
Most mammals, can generate ascorbate from glucose by a de novo biosynthetic pathway in the 
liver. In contrast, humans as well as primates are unable synthesise ascorbate due to the lack of 
the functional L-gulonolactone oxidase enzyme (Linster & Van Schaftingen, 2007). For 
humans, ascorbate needs to be  acquired through dietary sources and supplements.  
Primarily, ascorbate enters cells through sodium-dependent vitamin C transporters (SVCTs). 
The high-capacity, low-affinity SVCT1 transporter is primarily responsible for ascorbate 
absorption and reabsorption in intestinal and renal epithelial cells, whereas the high-affinity and 
low-capacity SVCT2 transporter is responsible for distribution of ascorbate to tissues 
(Camarena & Wang, 2016; Wilson, 2005; Young et al., 2015). 
Ascorbate as a reducing agent is predominant in the plasma of healthy humans, and can be 
oxidised to dehydroascorbic acid (May, 1998), which is no longer able to enter cells through 
SVCTs, but through glucose transporters (GLUTs) and then reduced to ascorbate (Lykkesfeldt, 
2007).  
Ascorbate acts as a cofactor for many monooxygenases and dioxygenases enzymes. Ascorbate-




amidating monooxygenase, which require Cu+2 and ascorbate as cofactors (Prigge et al., 2000). 
In contrast, dioxygenases utilise Fe+2, α-ketoglutarate and ascorbate as cofactors.  
1.1.9.1 Cofactor for TET dioxygenases. 
While, ascorbate is a cofactor for collagen prolyl 4-hydroxylase (P4H) which is well known for 
its involvement in scurvy, ascorbate also has a role in TET-mediated DNA demethylation and 
in other dioxygenase mediated process (Vasta & Raines, 2016).  
It was shown that ascorbate has the capability to cause widespread DNA demethylation of 
nearly 2000 genes and modify the status of DNA methylation in mammalian embryonic stem 
cells (Chung et al., 2010). Standard cell culture media lacks ascorbate in its formula; therefore, 
the activity of ascorbate-dependent enzymes is compromised in those conditions. 
A study by our collaborator Dr. Tim Hore (2016), suggested that ascorbate potentiates TET 
catalysis by enhancing 5-hmC production, not as a cofactor as reported previously, but rather 
by enhancing the recycling of Fe2+ (reduction of Fe3+ to Fe2+) in the catalytic centre of TET 
proteins (Hore et al., 2016). Ascorbate provides indirect role to enhance TET to induce 
demethylation.  
The Minor and Wang laboratories showed that ascorbate enhanced the generation of 5-hmC in 
mouse embryonic fibroblast cells (MEFs), most likely by acting as a cofactor for TET to 
hydroxylate 5-mC (Camarena & Wang, 2016; Dickson et al., 2013; Minor et al., 2013; Young 
et al., 2015). Intriguingly, MEFs expressed all TET enzymes at low but detectable levels. Thus, 
these cells constituted a convenient tool to analyze TET enzymatic requirement in a cell culture. 
The content of 5-hmC is very low in MEFs cultured in ascorbate free media, while addition of 
ascorbate significantly enhanced the generation of 5-hmC. The maximum level of 5-hmC was 
achieved when MEFs were treated with 10 µM ascorbate, possibly due to low expression of 
TET proteins. Surprisingly, ascorbate induced the rapid generation of 5-hmC in MEFs (< 1 
hour), while TET or IDH expression was not changed. The effect of ascorbate on 5-hmC could 
not be attributed to its role as a reducing agent, as treatment with other agent such as glutathione 
did not affect the 5-hmC levels (Minor et al., 2013).  
The presence of ascorbate at physiological concentrations has been shown to enhance the 
uptake of iron by cells, suggesting that ascorbate might have an indirect effect on 5-hmC by 
increasing the cellular uptake of iron (Lane et al., 2010). Additionally, using ascorbate 
transporter inhibitors, such as phloretin or sulfinpyrazone, decreased ascorbate’s effect on 5-




TET dioxygenases (Lane et al., 2013; Lane et al., 2010). 
Yin and colleagues demonstrated that ascorbic acid could directly enhance the catalytic activity 
of Tet dioxygenases for the oxidation of 5-mC (Yin et al, 2013). Ascorbic acid interacted with 
the purified C-terminal catalytic domain of TET enzymes, thereby promoting their folding 
and/or the recycling of Fe2 (Yin et al., 2013). In contrast, other reducing agent such as 
spermidine, vitamin B1, vitamin E, glutathione, nicotinamide adenine dinucleotide phosphate 
and L-cysteine did not enhance the oxidation effect on 5-mC (Yin et al., 2013). Interestingly, 
in cells in which Tet1 and Tet2 were deleted, ascorbic acid altered neither 5-mC oxidation nor 
the overall level of 5-mC, but the ascorbate effects were restored when Tet2 was re-expressed 
(Yin et al., 2013). 
1.1.9.2 Ascorbate and DNA demethylation. 
As a co-factor, ascorbate participates in the cascade oxidations of 5-mC to generate the 
unmodified form ‘cytosine’ (Young et al., 2015). In regulatory T cells, demethylation of CpG 
motifs of the conserved noncoding sequence 2 (CNS2) in the Foxp3 intronic element is essential 
for the expression of Foxp3 (Nair et al., 2016). An in vitro study found that ascorbate enhanced 
the demethylation of CpG motifs of CNS2 in the Foxp3 intronic element. Additionally, the 
methylated CpG motifs of CNS2 became demethylated rapidly after ascorbate treatment with 
efficient conversion of 5-mC to 5-hmC in a TET2-dependent manner (the activity of ascorbate 
disappeared in TET -/- cells). Collectively, for Foxp3 expression, ascorbate was required for the 
CNS2 demethylation mediated by Tet proteins, suggesting that environmental factors, such as 
nutrients (ascorbate) could cause changes in immune homeostasis through epigenetic 
mechanisms (Nair et al., 2016).  
Sajadian (2016) showed that the combination of ascorbate and 5-azacytidine (5-AZA) enhanced 
TET activity in hepatocellular carcinoma (HCC) cell lines leading to enhanced active 
demethylation (Sajadian et al., 2016b). Ascorbate enhanced the anti-proliferative and apoptotic 
effect of 5-AZA in these cells. Interestingly, the combination of 5-AZA and ascorbate led to 
downregulation of SNAIL expression and cell cycle arrest (Sajadian et al., 2016b).  
Dickson (2013) showed that ascorbate can induce generation of 5-hmC independent of the 
levels of iron and 2-oxoglutarate in mouse embryonic fibroblasts (MEFs). However, removing 
iron from the culture medium did not affect the induction of 5-hmC by 10 µM ascorbate, and 
the effect of ascorbate did not involve increased expression of Tet1-3 or isocitrate 
dehydrogenases, which overall suggests that ascorbate may directly participate in the 




In contrast, in vitro enzymatic analysis suggested that hydroxylation of 5-mC mediated by TET 
enzymes was not affected by ascorbate, as recombinant TET1 was able to convert 5-mC to 5-
hmC at the same efficiency in the presence or absence of ascorbate (Tahiliani et al., 2009).   
1.1.9.3 Epigenetic regulation by ascorbate in early embryonic development. 
To date, there are few studies investigating the effect of ascorbate on DNA methylation and 
demethylation during embryonic development (Young et al., 2015). Women with lower 
leukocyte ascorbate concentration had a higher risk for neural tube defect (NTD) compared to 
low-risk women (Brender et al., 2011; Schorah et al., 1983).  
The exact mechanism of DNA demethylation in pre-implanted embryos was unclear for a long 
time, but now it is known that both TET mediated oxidation and passive dilution participate in 
this process. A complex epigenetic reprogramming with DNA demethylation and re-
methylation occurs during mammalian embryonic development. The expression level of TETs 
is much higher in embryonic tissues, especially at early developmental stages.  
There is potential for ascorbate levels to affect these TET-mediated process, but no data or 
direct evidence are available. Ascorbate enhances the generation of induced pluripotent stem 
cells (iPSCs) from differentiated cells, which is associated with genome-wide loss of 
methylation (Esteban et al., 2010; Stadtfeld et al., 2012). This observation indirectly supports a 
similar role of ascorbate in early embryonic development. 
Recent study by Gao and his colleague showed that ascorbate enhanced the expression of 
TET1,2,3 proteins in PA (parthenogenic) mice embryos, whereas, DMOG 
(Dimethyloxalylglycine) treatment inhibits TET1,2,3 expression. Furthermore, treatment with 
ascorbate during early embryonic development increased the blastocyst rate, in contrast, 
DMOG reduced the rate, (Gao et al., 2019). 
The first round of epigenetic reprogramming occurs, immediately after fertilization and before 
the pro-nuclei merge, the paternal genome goes through a complex epigenetic remodeling 
process that includes rapid erasure of DNA methylation. Paternal 5-mC is rapidly replaced by 
5-hmC via Tet3-mediated oxidation, leading to passive demethylation and erasing of the 
paternal methylation patterns (Kohli & Zhang, 2013). In contrast, maternal DNA methylation 
is unaffected at the one cell stage, but the maternal genome passively demethylates by dilution 
due to inhibition of DNMT1 (Kohli & Zhang, 2013; Wang et al., 2014). 
TET-mediated active demethylation also involved in the second round of epigenetic 




demethylation in PGCs is started upon the entry of the embryonic day 11.5 post-coitum (dpc). 
PGCs exhibited dynamic changes on day 12.5 dpc, by erasure of methylation by active 
demethylation (Hajkova et al., 2002). Mechanistically, the phenomenon loss of DNA 
methylation in mouse PGCs results from the consequence suppression of the maintenance and 
de novo methylation enzymes by PRDM14 and activation of active DNA demethylation 
pathways (von Meyenn & Reik, 2015).  
1.1.9.4 Inhibitor of TET function. 
Although, TET activity can be modulated by many substances including vitamin C, Fe2+ and 
a-ketoglutarate, another citric acid cycle intermediates 2-hydroxyglutarate (2-HG) acts as a 
competitive inhibitor of multiple a-ketoglutarate dependent dioxygenases, including the TET 
enzymes (Xu, Yang, et al., 2011b). 2-HG occupies the same space as a-ketoglutarate in the 
active sites of TET enzymes, and reduces its activity. Similar compounds can bind the active 
site and competitively downregulates TET, Dimethyloxalylglycine (DMOG) is a 2-
oxoglutarate (2-OG) analogue which acts as a competitive inhibitor of dioxygenase protein 
(Babosova et al., 2019). In addition, TET activity can be inhibited by metals such as cobalt 
(Rose et al., 2011). Furthermore, Yin and colleagues found that natural Ni2+ ion can selectively 











It is likely that, as yet, unidentified molecular pathways of DNA demethylation occur in cancer. 
Global changes in DNA methylation that occur in diverse reprogramming networks are likely 
to need the cooperative action of several DNA demethylation mechanisms. 
We know that DNA methylation is altered during development, tissue differentiation and in 
response to various physiological factors (Moore, Le, et al., 2013). It has been postulated that 
DNA methylation is dysregulated in various human diseases, involving both gain and loss of 
DNA methylation (Feil & Fraga, 2012). Nevertheless, the mechanisms involved in this 
dysregulation are unclear. 
Despite the observed dysregulation of DNA methylation in human disease, methylation patterns 
of differentiated cells are paradoxically believed to be stable. Thus, many questions remain to 
be answered; for example: 1) how is DNA methylation deregulated in cancer? 2) how does 
passive and active demethylation interact during reprogramming that happens in the zygote and 
germ cells? 3) does demethylation occur in somatic cells, and if so, by what mechanism does it 
occur? 4) what are the mechanisms of demethylating agents in cancer patients? 
Professor Mark Hampton and Dr. Karina O’Connor (University of Otago, Christchurch) 
observed a mark reduction in DNA methylation during the first 6 hours of DNA replication 
after exposing human Jurkat T cell leukaemia cells to a mild physiological oxidant glycine 
chloramine (O'Connor et al., 2020). They postulated that the effect of this oxidative stress might 
be mediated through inhibition of the maintenance DNA methyltransferase (DNMT1). Using 
low throughput techniques, the Morison group found active loss of methylation in cultured 
human cells exposed to physiologic oxidative stress. They showed rapid replication-
independent demethylation in these cultured cells, suggesting novel mechanisms of active 
demethylation that have not yet been identified.  
A previous PhD student Dr. Helena Magrath, from the Morison laboratory, used hairpin-
bisulphite methylation sequencing and confirmed that oxidative stress leads to passive hemi-
methylation (Figure 2.1). As expected, similar hemi-methylation could also be induced by 




In addition, Dr Magrath observed complete demethylation within two hours of the start of 
synchronised DNA synthesis. These demethylated hairpin-sequences were seen at genes that 
are consistently densely methylated in untreated Jurkat cells. This was interpreted as active 
enzymatic demethylation occurring in the presence of hemi-methylated strands. 
 
                    
Figure 2. 1. Loss of DNA methylation in synchronized Jurkat cells, 2 hours after exposure to 
oxidative stress. DNA hairpin sequences showed total demethylation of some reads, which was 
never seen in untreated cells. Each row represents a PCDHGA12 DNA hairpin containing 12 
CpG sites. 
 
Until recently, the loss of DNA methylation was not well understood, and it was believed that 
somatic cells are protected from demethylation (Lee et al., 2014; Wu & Zhang, 2014). Indeed, 
in a comprehensive review on demethylation, Wu and Zhang made no mention of 
demethylation in adult tissues except to comment that: “Intriguingly, the broad expression 
patterns of TET enzymes and other components of active DNA demethylation pathway in 
somatic tissues such as brains imply that dynamic DNA demethylation may be more prevalent 
than previously thought” (Wu & Zhang, 2014). 
2.2 Evidence of active demethylation. 
Prior research has demonstrated that gain and loss of methylation is a key regulator in the 
process of tissue differentiation (Boland et al., 2014). For instance, global loss of DNA 
methylation is seen in the paternal genome after fertilisation before the first cell division 
(Hackett & Surani, 2013). Replication-independent demethylation in a B cell lymphomas cell 
lines correlated with induction of the lytic EBV viral cycle (Falk & Ernberg, 1999). The Tat 
gene is demethylated during development of the rat late fetal liver to allow expression of 
tyrosine aminotransferase (Thomassin et al., 2001). Many genes lose DNA methylation during 




during haematopoiesis (Calvanese et al., 2012; Hodges et al., 2011). During monocyte 
differentiation, replication-independent demethylation has been detected in some genes (Klug 
et al., 2010; Klug et al., 2013). Similarly, in many cancers, DNA methylation is globally 
decreased (Ehrlich, 2009). 
2.3 Specific hypotheses. 
There are known enzymes that covalently bind methyl group (CH3) to the C5 position of the 
cytosine. Simultaneously,  it is likely that other enzymes or mechanisms remove the methyl 
group from methylated cytosine. 
The present work offers two hypotheses summarised in Figure 2.2: 
1) TET proteins are key components of active demethylation in human somatic cells.  
This hypothesis will be addressed by upregulating TET enzyme activity with ascorbate (Minor 
et al., 2013). This will be done in synchronised Jurkat cells in G1 phase and then, at the time of 
release, cells will be exposed to demethylating drug. 
2) Hemi-methylated DNA markedly enhances the rate of TET-induced active demethylation.  
This hypothesis will be addressed by inducing hemi-methylation in Jurkat cells. Hemi-
methylation occurs when the activity of DNMT1 is blocked by either oxidative stress or a 
demethylating agent (decitabine or azacytidine). Then, TET activity can be enhanced by 




Figure 2. 2 The two hypotheses in this study. It is hypothesised that addition of ascorbate will 





2.4 Overall aims of the research. 
The project is divided into three major goals.  
The first goal was to optimise DNA hairpin protocols and techniques for further work. 
The second goal was to confirm the recent observations of DNA demethylation that have been 
observed by the Morison laboratory, by using the high throughput sequencing (MiSeq).  
The third goal in this study was to investigate the role of ascorbate in upregulating TET 
enzymes leading to methylation changes.  
To achieve these goals:    
1- Develop and optimise methods for assessment of the kinetics of demethylation. 
First. Optimisation of the hairpin bisulfite sequencing protocols. 
Second. Develop and establish bioinformatic tools to analyse DNA methylation of hairpin 
sequences. 
2- Investigate whether TET proteins mediate the active demethylation in somatic 
cells.   
This goal will be addressed by modifying TET activity and measuring whether the proportion 
of unmethylation is altered (see Figure 2.1). 
TETs are dioxygenases that can be up-regulated by ascorbate (Blaschke et al., 2013; Minor et 
al., 2013) and blocked with cobalt (Rose et al., 2011) allowing manipulation of the activity of 
TET enzymes in vitro. We hypothesise that if the TET proteins are responsible for the observed 
active demethylation, then co-treatment with ascorbate should increase the proportion of fully 
demethylated (hemi- and unmethylated) sequences, whereas cobalt treatment should reduce 
proportion of fully demethylated sequences. Documentation that the TET proteins mediate 
active demethylation in somatic cells will be an important step in determining the factors that 
might alter the epigenomic profile of human cells.  
An Illumina MiSeq sequencer will be used to sequence hairpin libraries by performing 
sequencing for multiple genes of multiplexed libraries within a single run. High throughput 
sequencing (Illumina MiSeq) will be used to generate sufficient sequence reads for accurate 
quantification. 
3- Determine whether hemi-methylation enhances the rate of active demethylation. 
Based on observations by the Morison laboratory, we hypothesise that active TET-mediated 




observation, Jurkat cells (synchronised at G1 phase) will be treated with decitabine (DNA 
methyl transferase inhibitor DNMTi) to generate hemi-methylated alleles. Based on this 
approach, we predict that four different methylation patterns will be detected in Jurkat cells 
(Figure 2.3). 
First: Jurkat cells grown in standard ascorbate-deficient media, will show little or no 
demethylation.  
Second: Jurkat cells treated with decitabine (DNMTi) will show hemi-methylation. 
Third: Jurkat cells grown in media loaded with ascorbate will show enhanced demethylation 
as previously demonstrated in ESCs (Blaschke et al., 2013). 
Fourth: Jurkat cells treated with a  combination of DNMT1 inhibition (decitabine) and 
ascorbate will showed complete demethylation in Jurkat cells. 
Confirmation of these hypotheses will help explain the kinetics of demethylation in cancer cells, 
and will have major implications for the current models of physiologically induced 
demethylation.  
4- Investigate the effect of long-term exposure of decitabine, ascorbate and glycine 
chloramine on DNA demethylation. 
To investigate DNA demethylation, we started by using glycine chloramine treated Jurkat cells 
from the Hampton laboratory (UOC), but this model was unreliable. Therefore to create a stable 
system we used a hypomethylating drug decitabine to generate hemi-methylated DNA. 
This will be investigated by: 
First: Examine the effects of decitabine and glycine chloramine on DNA methylation. 
The experiments for aim 1 & 2 will be extended to measure the proportion of unmethylated 
hairpin sequences at 24 and 48 h and continued for several cell cycles (4-5 days) to compare 
the short-term and long-term effect after a single exposure. Cell number and viability will be 
measured throughout. 
We predict progressive loss of methylation at genes including RASSF1 and PCDGHA12. The 
alternative hypothesis is that, since the effect of glycine chloramine is short-lived, restoration 





Second: Investigate the roles of TET enzymes in chronic exposure model by adding ascorbate. 
As above, we hypothesise that the addition of ascorbate will upregulates TET enzymes and 
enhance DNA demethylation. 
Third: Assess the roles of TET enzymes in leukaemia cell lines (Molt4, Nalm6 and HL60). 
Fourth: Perform low coverage genome-wide methylation sequencing, to assess the global 
impact on methylation levels if significant demethylation is observed at our test genes. 




Figure 2. 3. Prediction of methylation patterns in Jurkat cells after 500 µM sodium ascorbate 
and DNMT1 inhibition. 
2.5 Rationale behind this project. 
It has been suggested that human disease may result from failure to control the methylation 
process, leading to gains and losses of DNA methylation (Ehrlich et al., 1982). However, in 
cancer DNA methylation is markedly disrupted, globally decreased and locally increased, the 
particular mechanisms involved in DNA demethylation are still unknown. 
The potential impact of understanding the underlying mechanisms include: 1. increasing our 
knowledge of environmentally/physiologically-induced methylation changes, especially in the 
context of oxidative stress; 2. revealing factors that contribute to the observed hypomethylation 
in cancer; 3. understanding the interaction between passive and active demethylation 
reprogramming that occurs in the zygote and in germ cells; and 4. modulating the therapeutic 









3.1.1 Chemicals and kits 
Chemicals and kits used in experiments are listed in Table 3.1 below. 
Table 3. 1. Chemicals, kits and instruments. 
Reagent Supplier 
MethylFlashTM  Global DNA Hydroxymethylation  ELISA Easy 
Kit (Colorimetric) (Colorimetric) 
EPIGENETEK 
Tris-hydroxymethyl aminomethane (TRIS) 
Ethylenediaminetetraacetic acid (EDTA)  
Acetic acid 
2-deoxycytidine  
5-aza-2’-deoxycytidine (Decitabine)  
Ethidium Bromide  
Thymidine  
Dimethyl Sulfoxide (DMSO)  
Dimethyloxalylglycine (DMOG) 
10x Orange G loading Dye 
β-hydroxybutyrate ((±)-Sodium 3- hydroxybutyrate) 
D-(+)-Glucose 





Agarose LE Roche 
Agarose, Certified Molecular Biology BioRad 
Ethanol Normapur 
2-mercaptoethanol 
Leukaemia Inhibitory Factor (LIF) 
Propidium Iodide + RNase  
Trypsin-EDTA  
Dulbecco’s Modified Eagle Medium (DMEM)  
Minimum Essential Medium Non-Essential Amino Acids (MEM 
NEAA)  
RPMI 1640  
RPMI + Glutamax 
1 Kb+ DNA Ladder 
Life Technologies 
QIAamp DNA MinikitTM. Qiagen 
EZ DNA Methylation-GoldTM Kit. 
DNA Clean & Concentrator-5TM. Zymo Research 
Agencourt AMPure XPTM. Beckman Coulter 




0.4% (w/v) Trypan Blue Gibco 
Agilent 2100 Bioanalyzer Agilent Technologies 
Agilent High Sensitivity DNA Chips Agilent Technologies 
Agilent High Sensitivity DNA Reagents Agilent Technologies 
TriGene Advance Ethical Agents 
International LTD 
QubitTM 4 Fluorometer Thermofisher Scientific 
UV Gel dock – Mini HD9 Unitec Cambridge 
 
3.1.2 Enzymes 
Table 3. 2. Enzymes and their suppliers. 
Reagent Supplier 
KAPA HiFi Hotstart Uracil+ 2x Readymix Illumina 
Taq FastStart DNA Polymerase Roche 
T4 DNA ligase (400,000 units/ml; Catalogue number: M0202S) New England BioLabs  
BamHI (20,000 units/ml; Catalogue number: R0136S) New England BioLabs  
SacI (20,000 units/ml; Catalogue number: R0156S) New England BioLabs 







Integrated DNA Technologies (IDT) synthesized all primers and hairpin linkers. 
Table 3. 3. Primers used for amplification of regions of interest from bisulfite treated DNA. 
Illumina-specific tag sequences are highlighted in grey. 
Gene name Primers 








NEFM Forward:  
ACGACGCTCTTCCGATCT-TTATAAGTAGTTTGGGATTGAAAGG 
Reverse:   
CGTGTGCTCTTCCGATCT-TAACTCATCTTAAAAACCTTAAAAC 





















3.2.1 Leukaemia cell lines. 
Jurkat T cell leukaemia and other leukaemia cell lines (MOLT4, NALM6 and HL60) were 
obtained from the American Type culture collection (Rockville, MD, USA) and maintained by 
Rob Weeks (Department of Pathology, University of Otago, Dunedin) and by Dr. Karina 
O’Connor (University of Otago, Christchurch). Cells were grown in RPMI 1640, DMEM and 
RPMI Glutamax medium supplemented with 10% heat inactivated fetal bovine serum, 4.5 g/L 
glucose, 1mM sodium pyruvate at 37℃ in a humidified incubator with 5% CO2. 
3.2.2 Mammalian cell culture. 
Cell lines were obtained from Robert Weeks (Department of Pathology, University of Otago) 
and Karina O’Connor (Department of Pathology, University of Otago, Christchurch). Stock 
vials were stored in liquid nitrogen with 3-5 x 106 cells in 1 mL. All the procedures were done 
in sterile conditions within a class II biological safety cabinet. The hood was cleaned using 70% 
ethanol and TriGene prior to use.  
3.2.2.1 Cryopreservation and thawing. 
To preserve Jurkat cells, cell suspensions (6 x 106 cells) from the exponential growth phase 
were centrifuged at 300 g for 5 minutes and resuspended in cold medium with 10% dimethyl 
sulfoxide (DMSO). Resuspended cells were transferred to cryo vials, placed in freezing 
containers at -80℃ for 20 h to facilitate slow freezing, and then transferred to liquid nitrogen. 
For thawing, cells were thawed by placing in a 37℃ water path for 2 minutes followed by 
dropwise addition of 1 mL of pre-warmed culture media. Cells were transferred to 15 mL plastic 
tube and pelleted by centrifugation (300 g for 5 min) to remove DMSO resuspended in pre-
warmed media and transferred to fresh T25 flask. 
3.2.2.2 Media preparation. 
Cells were grown in RPMI, RPMI + glutamax and DMEM media composed of 10% v/v heat 
inactivated fetal calf serum, 1 µM sodium pyruvate and glucose (4.5 g/L).  Cells were cultured 
in suspension at a starting cell density of 8 x 105 within a T25 or T75 flask at 37℃ in a 
humidified atmosphere incubator with 5% CO2. Cell density was maintained between 0.8-1.2 




3.2.2.3 Measurement of cell count and viability. 
Cell viability was determined by utilization of the Trypan Blue method using a 
haemocytometer. A suspension of Jurkat cells (50 µL) was mixed with 10 µL Trypan Blue, 
then the mix was loaded into a haemocytometer. Viable cells in the four large corner squares 
were counted and the mean of the squares was calculated. Live cells appear unstained shiny 
and transparent. The number of viable cells calculated according to the following equation: 
 Number of viable cells = cell counts ´ 60/50 ´ 104. 
3.2.2.4 Thymidine block procedure. 
The normal cell cycle is composed of two main phases: interphase (G1, S and G2) and mitotic 
(M) phase (Chen & Deng, 2018b; Leger et al., 2016; Rodriguez-Ubreva et al., 2010). During 
interphase, the nuclear DNA is duplicated and the cell prepares itself for division, which occurs 
during mitosis. Cell synchronisation is particularly useful protocol to investigate process that 
occur during specific stages of the cell cycle. Excess thymidine is an inhibitor of DNA synthesis 
that can be used to arrest the cells at the  G1/S checkpoint by depletion of intracellular cytosine. 
The use of thymidine is known as a thymidine block. 
3.2.2.4.1 Double thymidine block. 
Cells were grown to required concentration 1 x 106 /mL. Then, thymidine was added to the 
culture media (final concentration 2 mM) and incubated in a tissue culture incubator at 37 ℃ 
for 18 h. Thymidine was removed by washing the cells twice with pre-warmed media, and the 
cells released from thymidine block by incubation with deoxycytidine for 9 h. A second round 
of thymidine incubation at a final concentration 2 mM was repeated for another 14 hours 
followed by release from thymidine using deoxycytidine (Chen & Deng, 2018b).  
Cells were collected at 0, 2, 4, 6 and 8 hours for cell cycle analysis by DNA staining using 
propidium iodide (PI).  
3.2.2.4.2 Single thymidine block. 
Cells were grown to 1 x 106 /mL in RPMI-Glutamax media. Cells were incubated with 
thymidine (2 mM) at 37℃ for 18 hours. Jurkat cells were washed two times with pre-warmed 
media and released from thymidine block by incubation with deoxycytidine  (Chen & Deng, 
2018b; Cude et al., 2007).   
Cells were collected at 0, 2, 4, 6, 8, 24, 48 and 72 hours of cell cycle analysis by DNA staining 




3.2.2.5 Reagent preparation. 
2’-deoxythymidine (thymidine). 
100 mM 2’-deoxythymidine solution was freshly prepared for each experiment, thymidine 
crystals were dissolved in MilliQ water on the day of use. Jurkat cells at density 1 x 106 cells/mL 
were incubated with media containing thymidine to give final concentration 2 mM. Cell 
suspension was gently mixed by pipetting and cells were incubated 18 hours at 37 ℃.  
2’-deoxycytidine. 
10 mM 2’-deoxycytidine solution was freshly prepared for each experiment, 2’-deoxycytidine 
crystals were dissolved in MilliQ water on the day of use. Jurkat cells were released from 
thymidine block by incubation with 2’-deoxycytidine at final concentration 50 µM. 
5-Aza-2’-deoxycytidine (decitabine). 
10 mM 5-Aza-2’-deoxycytidine (decitabine) solution was freshly prepared for each experiment, 
decitabine crystals were dissolved in MilliQ water on the day of use. Jurkat cells were incubated 
with decitabine with final concentration 5 µM. 
Glycine chloramine. 
Glycine chloramine was prepared by Dr Karina O’Connor on the day of use as the following: 
hypochlorous acid was added drop wise to five molar excess of glycine in an equivalent volume 
of milliQ water or PBS with vortexing. The concentration of glycine chloramine was 
determined spectrophotometrically using ε252 = 415 M-1 cm-1. Absorption spectra from 200 – 400 
nm were also monitored to ensure the absence of dichloramine (λmax 300 nm) and any unreacted 
hypochlorous acid (λmax290 nm). Jurkat cells were incubated with glycine chloramine so that the 
final concentration 500 µM. 
Sodium L-ascorbate. 
100 mM Sodium L-ascorbate and ascorbic acid solutions were prepared on the day of use. 
Ascorbate and ascorbic acid were dissolved in MilliQ water and incubated with Jurkat cells at 





3.2.2.6 FACS/cell cycle analysis. 
Flow cytometry was used to confirm the synchronization process by comparing untreated 
control cells with cells treated with thymidine. Briefly, treated and control cells were 
centrifuged at 300x g for 5 min before washing twice with 1 mL cold PBS. Cells were 
resuspended in 100 µL of cold PBS and fixed with 900 µL of ice-cold 70 % ethanol added 
dropwise slowly and stored at 4 ℃. 
Prior to flow cytometry analysis, fixed cells were centrifuged at 350 g for 5 minutes and washed 
twice with 1 mL PBS. Then, cells were resuspended in 250 µL PBS and 250 µL of propidium 
iodide/RNase staining solution (catalogue number: F10797) and incubated in the dark for 30 
minutes at room temperature prior to flow cytometric analysis. After incubation in darkness, 
DNA content was determined by using a flow cytometer (Beckman Coulter). 
3.2.2.7 Cell viability assay following decitabine exposure. 
A titration assay was performed to determine the effect of increasing decitabine concentration 
on the viability of Jurkat cells, Molt4 cells, Nalm6 cells and HL60 cells. 
Cells at a density of 1 x 106 cells/mL were synchronized by single thymidine block described 
in section 3.8.5.2. Upon release from thymidine block, cells were treated with decitabine at 0, 
0.5, 1, 2 or 5 µM. Samples were incubated for 24 hours followed by manual live and dead cell 
counts as described in section 3.2.2.3. 
3.2.2.8 Experimental design and cells treatment. 
The diagram below represents the tissue culture protocol. Briefly, Jurkat cells (1x 106 cells/mL) 
were divided into two main groups (untreated control cells and ascorbate treated cells), cells 
were synchronised by incubation with 2’-deoxythymidine at final concentration 2 mM for 18 






Figure 3. 1. Scheme of the experiment designed for Jurkat cell treatment. A) Flask of Jurkat 
cells (1x 106 cells/mL) were divided into two main flasks. Flask B) Jurkat cells were treated 
with 2’-deoxythymidine at final concentration 2 mM for 18 hours. Flask C) Jurkat cells were 
incubated with 2’-deoxythymidine at final concentration 2 mM and ascorbate 500 µM for 18 
hours. After synchronization, Jurkat cells were washed twice and each flask divided into two 
flasks. Flask D) Jurkat Cells were released from thymidine block by incubation with 50 µM 2’-
deoxycytidine (considered as control sample). Flask E) Jurkat Cells were released from 
thymidine block by incubation with 50 µM 2’-deoxycytidine and supplemented with 5 µM 
decitabine at the time of release. Flask F) Jurkat cells (pre-incubated with ascorbate) were 
released from thymidine block by incubation with 50 µM 2’-deoxycytidine and replenished 
with 500 µM ascorbate. Flask G) Jurkat cells (pre-incubated with ascorbate) were released from 
thymidine block by incubation with 50 µM 2’-deoxycytidine and replenished with 500 µM 
ascorbate and supplemented with 5 µM decitabine. H) Cells were harvested in triplicate at 
increasing time point during DNAreplication. Collected samples were divided into two groups. 
One group for genomic DNA extraction and sequencing, and the other group for cell cycle 
analysis. 
 
3.2.3 Genomic DNA preparation. 
3.2.3.1 Identification of densely methylated regions in Jurkat cells. 
PCDHGA12 and RASSF1 gene promoters were reported to be hypermethylated in 
haematological cancers (Gordon et al., 2012; Milani et al., 2010; Taylor et al., 2007). 
The dense methylation of these gene promoters was confirmed by Rob Weeks and Helena 




Additionally, MARCH11, NEFM, KCNA4, C10orf53 and GOLSYN gene promoters were 
confirmed to be densely methylated in Jurkat cells after being identified from publicly available 
450K methylation array data sets with the R package, ABC.RAP (CRAN depository; Alsaleh 
et al., in preparation).  
3.2.3.2 Identification of densely methylated regions in other leukaemia cell lines. 
The PCDHGA12 gene promoter was found to be densely methylated in MOLT4, NALM6, 
HL60 leukaemia cell lines and Myelodysplastic syndrome MDS cell line. Whereas, RASSF1 
gene promoter was found to be densely methylated only in the MOLT4 cell line and was hemi- 
or un-methylated in the other cell lines. 
3.2.3.3 DNA extraction. 
Genomic DNA was extracted from cell lines using the Qiagen QIAamp DNA Blood MinikitTM 
system, according to the manufacturer’s instructions. Cell pellets were resuspended in 200 μL 
of PBS, before the addition of 20 μL of proteinase K and 200 μL lysis buffer and incubation at 
56°C for 2 hours. Then, 200 μL of 100% ethanol were added, pulse vortexed and spun. The 
total 600 μL was transferred to a Qiagen minispin column, and centrifuged at 6000 x g (800 
rpm) for 1 minute. Columns were transferred to a new collection tube. AW1 buffer 500 μL was 
added, and centrifugation at 6000 x g (8000 rpm) for 1 minute. Columns were transferred to 
new collection tubes and 500 μL of buffer AW2 was added and centrifugation at 20,000 x g for 
3 minutes. A dry spin was performed for 1 minute at 20,000 x g. To elute DNA, each column 
was transferred to a 1.5 mL tube and 150 μL of AE buffer was added. All columns were 
incubated at room temperature for 5~10 minutes prior to eluting DNA by centrifugation at 6,000 
x g for 1 minute. DNA concentration was quantified using NanoDropTM. 
3.2.3.4 Quantification of DNA. 
DNA concentration was determined using a NanoDropTM spectrophotometer and AE buffer as 
a blank. The ratio of the absorbance at 260 nm was used to assess the purity of DNA, good 
quality DNA has an A260/280 ratio above 1.8. 
3.2.4 Generating DNA hairpin molecules. 
3.2.4.1 Overview and method development. 
To determine the symmetry of CpG methylation, and similar to Laird et al. (Laird et al., 2004) 
who first illustrated the use of hairpin linkers, the Morison laboratory developed a hairpin 




simultaneously. This technique allowed comparison of parent-daughter strand CpG methylation 
symmetry, enabling assessment of global methylation fidelity. 
To design barcoded hairpin bisulfite linkers for genomic DNA, sequence within and adjacent 
to a CpG Island of interest were mapped for restriction endonuclease recognition sites. The 
favoured restriction enzymes are those that 1) produce long sticky ends, 2) are not affected by 
potentially methylated target sequence. Requirement one increases the specificity of subsequent 
PCRs for the region of interest, and requirement two allows the presence of hypermethylated 
and hypomethylated alleles in the final PCR products (Pingoud et al., 2014).  
3.2.4.2 Hairpin linker design. 
The hairpin DNA linker structure allows the binding of the two DNA strands together, so that 
both strands can be interrogated and the DNA methylation of complementary CpG sites can be 
determined. Hairpin needs to have a stem, sticky ends and loop structure; the presence of the 
loop allows us to include a random nucleotide sequence unique to each hairpin molecule, which 
will permit monitoring of over-amplification and contaminating molecules. The molecular 
barcodes are a random sequences arranged from adenine, thymine and guanine nucleotides. 
Hairpin linkers were designed to be complementary to the targeted cut-site of genomic DNA 
(Figure 3.2). Hairpin molecules are ~ 36 base-long oligonucleotides designed to connect the 
parent-daughter strands together (Table 3.4). Each hairpin is composed of three regions:  
1. Hairpin loop. The sequence in the loop had no complementary bases and incorporate a 
random 14-nucleotide molecular barcode consisting of three nucleotides, adenine, 
thymine and guanine as these nucleotides are insensitive to bisulfite treatment (Clark et 
al., 1994). Thus, this barcode region has ≈ 4 million (314) possible, unique sequences by 
which duplicate or contaminating sequences can be recognized and excluded.  
2. Complementary stem sequence. Sequences around the hairpin barcodes that allow the 
molecules to loop back on itself. 
3. Sticky end. Hairpin sticky ends are complementary to the targeted cut-site of genomic 
DNA. To provide successful ligation of the hairpin linker to the 3’ end of the desired 







Figure 3. 2. The structure of a hairpin linker., with three components: (i) Hairpin loop with a 
unique 14 bp barcode embedded into the loop; (ii) Complementary stem sequence and (iii) 
Sticky end with a phosphate group at the 5’end.  
 
 
Table 3. 4. Hairpin linker sequences for RASSF1 and PCDHGA12 promoters. The letter D 
represents A, G or T bases that were added randomly in the barcode sequence. 
Hairpin 
linker 
Sequence Amplicon length 








3.2.4.3 DNA digestion. 
Hypermethylated genes were cleaved with either SacI (for the RASSF1 promoter) or BamHI 
(for the PCDHGA12 promoter) restriction enzymes in separate reactions. 1 μg DNA isolated 
from each sample was digested with BamHI or SacI for three hours at 37 °C, in a total volume 





Table 3. 5. Reaction mixtures for BamHI and SacI restriction enzymes. 
BamHI mixture Volume (μL) SacI mixture Volume (μL) 
BamHI 1.0 ( 20 units) SacI 1.0 ( 20 units) 
NEBuffer  5.0 NEBuffer 5.0 
gDNA  (100 ng/µL)   10.0 gDNA  (100 ng/µL)   10.0 
Milli Q water 34.0 Milli Q water 34.0 
Total  50.0 Total  50.0 
Digestion: 37 °C for 3 hours 
 
Successful digestion was confirmed by electrophoresing the digested DNA on 0.8% agarose 





Figure 3. 3. Jurkat genomic DNA digested with SacI and BamHI restriction enzymes. The gel 
photo shows the restriction enzyme assay for Sac1 and BamH1 compared with undigested. The 





3.2.4.4 DNA clean up. 
To remove restriction enzymes and undesirable waste products of the digestion step, digested 
DNA samples were cleaned using a Zymo Research Clean and Concentrate kit, according to 
manufacturer’s protocol. Briefly, digested DNA was added with binding buffer (1:5 ratio) to a 
Zymo-SpinTM Column in a collection tube. Tubes were centrifuged for 30 seconds at 20,000 
x g. DNA samples were washed twice with washing buffer and eluted with 20 μL elution buffer.  
3.2.4.5 Hairpin ligation. 
Purified DNA (400 ng) with sticky complementary ends was ligated to hairpin linkers using T4 
DNA ligase (Thermo Fisher Scientific). The hairpin linker concentrations were optimised using 
different hairpin concentration (0.1, 1, 2 and 5 μM); optimum ligation results were obtained by 
using 5 μM hairpin. DNA-hairpin ligation was performed in 20 μL reaction mixture at 4°C 
overnight (Table 3.6). 
 
Table 3. 6. Ligation reaction mixture for PCDHGA12 and RASSF1 hairpins linkers. 
Reagents PCDHGA12  Volume (μL) 
RASSF1 
Volume (μL) 
T4 ligase enzyme 0.5 ( 200 units) 0.5 ( 200 units) 
10X ligase buffer 2  2  
Hairpin linker  (RASSF1 or 
PCDHGA12) 
5  5  
Milli Q water 4.5  4.5  
DNA (400 ng digested DNA) 8  8  
Total 20 μL 






3.2.4.6 Principle of generating PCDHGA12 hairpin molecules. 
The densely methylated PCDHGA12 promoter region was cleaved with BamHI restriction 





Figure 3. 4. Generation of PCDHGA12 DNA hairpins. Upper panel shows the PCDHGA12 
promoter region, green colour shows the BamHI restriction site, yellow colour shows forward 
primer sequence and red colour shows CpGs within PCDHGA12 promoter. Lower panel shows 
the protocol of generating DNA hairpin molecule, DNA was digested with BamHI restriction 
enzyme. Hairpin linkers (with a unique 14 bp barcode) complementary to BamHI digested 




3.2.4.7 Principle of generating RASSF1 hairpin molecules. 
The densely methylated RASSF1 promoter region was digested with SacI restriction enzyme 
and ligated with a barcoded hairpin oligonucleotide (Figure 3.5). Every hairpin linker contained 




Figure 3. 5. Diagram showing generation of the RASSF1 DNA hairpins. Upper panel shows 
the RASSF1 promoter region, Green colour shows SacI restriction site, yellow colour shows 
forward primer sequence and red colour shows CpGs within the RASSF1 promoter. Lower 
panel shows the protocol of generating DNA hairpin molecule. DNA was digested with SacI 
restriction enzyme. The hairpin linkers (with a unique 14 bp barcode) complementary to SacI 




3.2.5 Bisulfite conversion and PCR workflow. 
Bisulfite conversion is the gold standard technique used to study and analyse DNA methylation. 
Unmethylated cytosine residues are deaminated through a series of conversion steps to generate 
uracil and subsequently to thymine upon PCR amplification, whilst leaving 5-methylcytosine 
intact (Figure 3.6) (Laird et al., 2004). Briefly, the steps are: 1) Denaturation, by incubating 
DNA at 98 °C; 2) Conversion, deaminates cytosine residues in DNA by incubation with sodium 
bisulfite at 64°C; 3) Desulphonation, by incubating the DNA at high pH at room temperature 
for 15-20 minutes to generate uracil; 4) PCR amplification, during which uracil is converted to 
thymine during the subsequent PCR. 
 
Figure 3.6. Bisulfite conversion of cytosine. 
 
3.2.5.1 Bisulfite conversion of hairpin-ligated DNA  
Bisulfite conversion for the hairpin-ligated DNA was performed using Zymo Research “EZ 
DNA Methylation-GoldTM” kit, according to the manufacturer’s instructions. Briefly, 130 μL 
of prepared CT sodium bisulfite conversion reagent was added to 20 μL DNA solution (500 
ng). Then, DNA was denatured at 98°C for 10 minutes and incubated at 64°C for 2.5 hours, 
and the DNA was desulphonated for 15-20 min at room temperature. DNA was eluted in 10 μL 




deaminated and converted to uracil, which are read as thymine in subsequent PCRs (Figure 
3.7).  
           
Figure 3. 7. Diagram of bisulfite conversion of hairpin molecule. The bisulfite reaction 
linearises the hairpin after bisulfite conversion. Primers designed for the bisulfite convert 
hairpin DNA within 150-200 bp of the linker. 
 
3.2.5.2 Primers design and gene specific amplification. 
Primers were designed to anneal the bisulfite genomic sequence 150-200 bp each side of the 
hairpin linker creating an amplimer of 350-450 bp which is ideal for Illumina MiSeq (Figure 
3.7 & Figure 3.8). Primers were designed by Rob Weeks using the online software MethPrimer 
(Li & Dahiya, 2002) and the following criteria: 1) primers should not contain any CpG 
dinucleotides to avoid discrimination between unmethylated and methylated DNA; 2) primer 
length should be longer than 20 nucleotides to enhance specificity. In addition, Illumina 










Figure 3. 8. Modified MethPrimer image of RASSF1 hairpin sequence that was used as an input 
for primer design. CpG island(s) was found in the sequence (shaded in blue) and hairpin primers 
(non-complementary) were picked for each side of the hairpin barcode (yellow). 
 
3.2.5.3 PCR workflow and preparation for MiSeq sequencing. 
Preparation for Illumina sequencing required two separate rounds of PCR. The advantage of 
the two rounds PCR approach is to allow us to amplify the target amplicons using nonspecific 
adapters that can then be used as a template for unique adapter sequences in the second round 
PCR.  
During the PCR reaction, index sequences on both ends of the DNA were added, that enables 
dual-indexed sequencing of pooled libraries on any Illumina Sequencing System (Figure 3.9).  
A 2-step PCR protocol was used that enabled a small amount of input DNA (2 ng), and requires 
only a single set of non-indexed primers for each amplicon, whatever the number of samples to 
be multiplexed. This protocol provided a low-cost method as an alternative to purchasing 
individual sets of indexed primers for PCR amplicons of each sample. In brief,  
1) DNA was amplified using gene specific primers with Kapa HiFi HotStart Uracil + ReadyMix 
polymerase.  
2) The different amplicons for each sample were pooled, 2 µL of each amplicon from each 
sample were pooled. As each amplicon had the same 18 bp tag sequence at the end of each 
product, they could be pooled and amplified in the second PCR reaction.  
3) A clean-up step. The purified products were quantified using qubit dsDNA HS kit and diluted 
to 1 ng/µL for the second round PCR reaction.  
4) Second round PCR for adapter ligation. In the second round of PCR, unique indexes were 




designed with non-specific adapter sequences. These sequences contain the necessary primer 
binding sites for paired end sequencing and dual index sequencing. 
5) Pooling all the samples.  




Figure 3. 9. An overall diagram of the two step PCR pooling workflow.  
 
 
3.2.5.4 Thermocycler Protocols. 
 
Table 3. 7. First round PCR protocol for RASSF1 & PCDHGA12 promoters. 
Step Temp ℃ Time Cycles 
Initial denaturation 95 ℃ 4 min X 1 
Denaturation 98 ℃ 20 sec X 34  
Annealing 56.1 ℃ (RASSF1) 15 sec 
57.2 ℃ (PCDHGA12) 30 sec 
Extension 72 ℃ 30 sec 
Final extension 72 ℃ 7 min X 1 
Hold 4 ℃ Forever  
 
3.2.5.5 PCR verification. 
Gel electrophoresis was used to verify successful amplification, absence of contamination and 
no secondary products. 4 μL of PCR product was stained with 1 μL blue xylene cyanol loading 
dye (0.25% bromophenol blue, 0.25% xylene cyanol, 15% Ficoll in TE) and visualised on 2 % 




at 100 V. DNA samples were compared to the 1 kb Plus DNA Ladder to determine the size of 
DNA products. UVIDOC HD6 DNA/protein gel imaging system (Cambridge) was used to 
visualise products (Figure 3.10).  





Figure 3. 10. Shows 1st round PCR product of A) RASSF1 hairpin product (428 bp) and B) 
PCDHGA12 hairpin product (384 bp) visualised on 2% agarose gel. Electrophoresed for 30 
min at 100V. 
 
3.2.5.6 Ampure XP bead clean up. 
Agencourt AMPure beads are solid-phase paramagnetic beads used for high-throughput 
purification of PCR amplicon. The purification process requires no centrifugation or filtration. 
A bead to sample volume at 1:1 was used to selectively bind DNA >100 bp to paramagnetic 
beads and residual primers, nucleotides and primer dimers were removed by washing of the 
DNA. 
PCR products were purified using Ampure XP beads following the manufacturer’s protocols. 
The procedure was performed in three stages: 1) Selective binding of DNA to paramagnetic 




dimers and contaminants; 3) Elution of the purified DNA from the magnetic beads (Figure 
3.11).  
Detailed protocol:  
1. An aliquot of Ampure XP beads was taken from the fridge, mixed thoroughly and left 
to equilibrate to room temperature for 30 min.  
2. 10 µL of specific pooled sample was added to 10 µL of Ampure beads, mixed well by 
pipetting and incubated for 5 min. 
3. Beads were collected on the side of the tube using a neodymium magnetic plate and 
stand for 5 min, aspirated and the supernatant discarded. 
4. Samples were washed to remove salts, dNTPs, primers and primer-dimer sequences (< 
100 bp), by adding 200 µL of freshly prepared 70% ethanol, incubated for at least 30 
sec, aspirated and the ethanol discarded. 
5. Repeat the wash step: add 200 µL of freshly prepared 70% ethanol, incubate 30 sec, 
aspirated and the ethanol discarded. 
6. The pellet was dried completely. Then tubes were removed from the magnetic plate. 
7. Samples were resuspended in 40 µL of elution buffer. Incubate 10 min at room 
temperature.  
8. Then the tubes were placed on the magnetic plate for 5 min. 
9. The supernatant containing the DNA was removed carefully, so as not to disturb the 
bead pellet and stored at 4 ℃ until needed. 
 
 
Figure 3. 11. Shows Ampure bead purification steps. 1) Mixing the Ampure beads solution with 
PCR products, 2) Binding the beads to DNA molecules, 3) The solution placed in the magnetic 
plate to draw the beads onto the side of the wells, supernatant and beads discarded to wash out 
primer dimers and small DNA molecules, 4) Ethanol wash followed by 5) Elution and 6) 





3.2.5.7 Quantification of PCR products. 
The product of the 1st round PCR was quantified using a Qubit fluorimeter and the 1x High 
Sensitivity dsDNA kit (ThermoFisher), as per the manufacturer’s protocol. Briefly, 2 µL of 
PCR product was added to 198 µL 1x dsDNA HS buffer and measured using the dsDNA 
program. 
3.2.5.8 Second round PCR. 
The aim of the second round PCR is to incorporate the Illumina indices onto the PCR product 
of the first round PCR, so only 10 cycles of amplification was used to label each sample with 
specific Illumina adapter sequence (Figure 3.12). These unique indexes identified each sample 
after pooling. KAPA HiFi Ready mix (Roche) was used in each reaction. Samples were diluted 
to 2 ng/µL. Master mix and protocol details for second round PCR are in Tables 8 and 9. 
 
Table 3. 8. Second round PCR master reaction mix. 
PCR 2nd Round reagents Volume (μL) 
KAPA Hi Fi Mix 5 
10 mM Forward Primer 0.5  
10 mM Reverse Primer 0.5  
MilliQ H2O 3  
Bead-purified 1st round PCR product (2 ng 
total) 
1  
Total 10  
 
Table 3. 9. Second round PCR thermocycler protocol. 
Step Temp ℃ Time Cycles 
Initial denaturation 95 2 minutes  
Denaturation 95 20 seconds Repeat 10 cycles 
Annealing 58 20 seconds 
Extension 72 20 seconds 
Final extension 72 40 seconds  








Figure 3. 12. Diagram of two PCR steps. Step one, 1st round PCR to amplify region of interest 
using gene specific primers tagged with non-specific universal adapter. Step two, 2nd round 
PCR to label the samples with a unique index using Illumina primers. There is a 96-base 
increase in amplicon size at this step. 
 
3.2.5.9 Sample confirmation, pooling and purification. 
PCR amplification was confirmed on 2% agarose gel (Figure 3.13). There was an increase in 
amplicon size during electrophoresis, the final MiSeq PCR products length for RASSF1 and 
PCDHGA12 hairpins are: 
RASSF1 hairpin molecule = 428 + (68-18) + (63-17) = 524 bp  
PCDHGA12 hairpin molecule = 384 + (68-18) + (63-17) = 480 bp. 
“428 and 384 are the amplicons size” + “68 is the Illumina FP size - 18 is the overlapped adapter 
sequence between the forward primers of the first round and second round PCR” + “63 is the 
Illumina RP size” - 17 is the RP overlapped adapter sequence between the reverse  primers of 








Figure 3. 13. Shows PCDHGA12 second round PCR product visualized on 2% agarose gel. 
Electrophoresed for 30 min at 100V. 
 
All samples were pooled into one single tube. 5 µL of each post PCR reaction was pooled into 
one tube, except where a sample had a lower band intensity in comparison to other bands so the 
volume of the sample increased accordingly. The intensity of the band in the agarose gel image 
specified the volume of the sample that was added to the pooled library. 
The pooled library was cleaned up to remove primer-dimer and short non-specific amplification 
products using Ampure XP beads using the protocol described previously. Specific cut-off 
points for the size selection was obtained by altering the bead to DNA ratio during DNA 
purification (Figure 3.14). The ratio 0.7:1 (volume of beads : volume of DNA) was determined 
to be optimum for my amplicons, as this purification ratio removed non-specific amplification 
products < 350 bp length. 
 
 
Figure 3. 14. Effect of bead : DNA ratio on DNA purification. Ampure bead to DNA ratio used 
for specific cut-off points for size selection (e.g. 0.7 beads : 1 DNA). A) RASSF1 and 
PCDHGA12 second round PCR products cleaned with two different beads : DNA ratios. B) 
optimal size exclusion of PCDHGA12 PCR products was achieved by adjusting the beads to 





3. 2.5.10 Quantification of the second round PCR products. 
The bead-cleaned indexed amplicons were quantified on Qubit using high sensitivity DNA 
Qubit kit (Invitrogen) and then diluted to 1 ng/µL. 
3.2.5.11 Agilent 2100 Bio Analyzer. 
Pooled PCR products were assessed using a High sensitivity DNA protocol (Bio Analyser, 
Agilent Technology, Germany). The Agilent Bio Analyser is an automated device that uses 
capillary electrophoresis for the analysis of DNA integrity, quality and quantity. The device 
generates electropherogram peaks and an electrophoretic image for the DNA samples (Figure 
3.15).  
All the solutions and reagents were prepared according to the manufacturer’s protocol and 
stored in the fridge. Before use, the reagents were allowed to reach room temperature for 30 
minutes. Briefly, a new high sensitivity DNA chip was placed onto the chip priming station. 
Then, 9 µL of the gel was loaded in a specifically marked wells of the DNA chip. The chip 
priming station was closed and the plunger of the syringe was set at 1.0 mL, and the plunger 
was pressed down until a clip held it. After 60 seconds, the clip was released and the plunger 
was moved back to 0.7 mL mark. After 5 seconds the plunger pulled back to 1.0 mL mark and 
the chip was removed. Then 9 µL of the gel was loaded in two wells. The ladder and the samples 
were loaded to separate wells respectively. The chip was run in the Agilent 2100 Bio Analyzer 
within 15 min.  
 
The final molarity of each library was calculated based on the Bio Analyser average fragment 
size. 





=103 (Qubit conc (nM))è volume to make 25 µL 4 nM= 25	F (4/103) 
= 1 µLè add water 24 =25 µL. 
After that, 4 nM final concentration was prepared for each library, and then all the DNA 
libraries were pooled into 20 µL tube based on the number of amplicons in each library. 
To calculate the ratio =Number of my samples/total number of samples=250/313=0.8. 





After that, each library was diluted to 4 nM, and then all the DNA libraries were pooled into a 
20 µL tube based on the amount of DNA in each library. The final pool (4 nM) of DNA was 
taken to Dr. Rob Day (Department of Biochemistry, University of Otago) who performed the 




Figure 3. 15. A representative example of Agilent 2100 Bio Analyser results of the pooled PCR 
products. The peak labelled “483” represents the pooled library of 480 bp PCDHGA12 
amplicons.  
 
3.2.6 Measurement of intracellular ascorbate concentration. 
Intracellular ascorbate concentration was measured by Professor Margreet Vissers’ laboratory 
(Department of Pathology, University of Otago, Christchurch).  
Jurkat cells were treated for 18 hours with 250 µM and 500 µM sodium –L-ascorbate added 
during the beginning of synchronization (2 mM thymidine block). After release from thymidine 
block, Jurkat cells were collected at 0 and 6 hr time points. Collected cells (1 million cells per 
sample) were washed 3 times with PBS to remove extracellular ascorbate and the pellet sent to 




in 50 µL of H2O and 50 µL of 0.54 M perchloric acid with 50 mM diethylenetriamine-penta-
acetic acid (DTPA) added to precipitate the protein and stabilize the ascorbate. Samples were 
centrifuged to remove the protein followed by measurement of the supernatant ascorbate 
content using HLPC-ECD (Aqua 5-µM C18 column and ESA Coulochem II detector; mobile 
phase of 80 mM sodium acetate, pH 4.8, containing 0.54 mM DTPA) (Kuiper & Vissers, 2014). 
3.2.7 Global low coverage methylation sequencing (PBAT). 
Whole genome bisulfite sequencing (WGBS) is a technique that can be used to assess DNA 
methylation across the genome. It typically requires 5 µg DNA and large sequencing runs, with 
large numbers of aligned reads, in order to generate sufficient read depth for analysis. 
Post-bisulfite adaptor tagging (PBAT) was developed as an alternative novel and cheap method 
that requires sub-microgram quantities of DNA (< 100 ng). PBAT is a highly efficient 
procedure to create libraries for whole genome bisulfite sequencing. PBAT analysis was 
performed by Dr Tim Hore’s laboratory (Department of Anatomy, University of Otago).  
Preparation of PBAT libraries was undertaken using the method adapted from Peat et al., 
(2014). Briefly, 100 ng of purified DNA was subjected to bisulfite conversion, followed by heat 
denaturation step for additional fragmentation. Then, bisulfite-converted DNA underwent 
synthesis of the first strand with a biotin–labelled adapter sequence possessing seven random 
nucleotides at its 3’ end (BioP5N7, biotin-ACACTCTTTCCCTACACGACGCTCTTCCGAT 
CTNNNNNNN), followed by purification using streptavidin-coated Dynabeads (Thermo, 
11205D) and magnetic immobilization. Immobilized first strand was used as a template for an 
additional adapter that possess seven random nucleotides at its 3’ (P7N7, 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNN) to create double-strand 
DNA. PCR was used to add a unique molecular barcode and adapter sequences necessary for 
binding to Illumina flow cells using KAPA HotStart Uracil+Mix. Libraries were sequenced on 
a MiSeq instrument (Illumina) and at least 15,000 mapped CG calls were attained per sample 
(Peat et al., 2014). 
3.2.8 Global hydroxymethylcytosine quantification. 
Quantification of global 5-hydroxymethylcytosine was done using The MethylFlash™ Global 
Hydroxymethylation (5-hmC) ELISA Easy Kit (Epigenetek), according to manufacturer’s 
protocol. The protocol is summarised in 3 steps: 1) 100 ng of sample DNA was bound to a high 




mAb-based detection complex; 3) the samples were quantified calorimetrically by reading the 
absorbance in microplate spectrophotometer.  
In brief, the working buffer and solution were prepared according to kit protocol. Standard 
curve was prepared by diluting 1 µL of positive control (PC) with 9 µL negative control (NC), 
and preparing solutions of different concentrations by combining PC, diluted PC and NC 
according to the chart below (Table 3.10). Standard curve was generated by plotting the optical 
density OD values at 450 nm versus the PC at each percentage point and the slope of the 
standard curve was determined using linear regression. The percentage of hydroxymethylated 
DNA is proportional to the OD intensity measured, and the 5-hmC standard curve can be seen 
in chapter seven (Section 7.4.2). All DNA samples were measured in duplicate (Table 3.11). 
 
Table 3. 10. Positive control concentrations for preparation of standard curve. 
Control  PC (1.0%) (µL)  Diluted PC (0.1%) (µL)  NC (µL) 
0.02 % PC/well = 0.0  + 1.0  + 9.0  
0.04 % PC/well = 0.0  + 1.0  + 4.0  
0.10 % PC/well = 0.0  + 3.0  + 3.0  
0.20 % PC/well = 1.0  + 0.0  + 9.0  
0.40 % PC/well = 1.0  + 0.0  + 4.0  
1.00 % PC/well = 3.0  + 0.0  + 3.0  
 
Table 3. 11. The configuration of the strip well-plate. 
Well # Strip 1 Strip 2 Strip 3 Strip 4 Strip 5 Strip 6 
A NC 0.02%PC Sample 2 Sample 6 Sample 10 Sample 14 
B NC 0.02%PC Sample 2 Sample 6 Sample 10 Sample 14 
C 0.02%PC 0.40%PC Sample 3 Sample 7 Sample 11 Sample 15 
D 0.02%PC 0.40%PC Sample 3 Sample 7 Sample 11 Sample 15 
E 0.04%PC 1.0%PC Sample 4 Sample 8 Sample 12 Sample 16 
F 0.04%PC 1.0%PC Sample 4 Sample 8 Sample 12 Sample 16 
G 0.10%PC Sample 1 Sample 5 Sample 9 Sample 13 Sample 17 
H 0.10%PC Sample 1 Sample 5 Sample 9 Sample 13 Sample 17 











Chapter Four: Establishing and optimising sequencing 
tools and bioinformatics protocols. 
 
4.1 Introduction. 
The hairpin bisulfite sequencing technique is a novel developed method used to determine the 
methylation pattern of two complementary DNA strands together. Hairpin linkers were 
specifically designed with a unique molecular barcodes to ligate the densely methylated 
RASSF1 and PCDHGA12 promoter regions. The methylation patterns for these genes were 
assessed by using bisulfite treatment followed by PCR amplified with barcoded index adaptors. 
Illumina MiSeq sequencing was used to sequence the hairpin molecule using MiSeq Reagent 
Kit v2 that provides 500 bp reads (paired end x 250 bp). The indexing allowing 200 samples to 
be sequenced in parallel, and the sequencer yields hundred thousand reads per sample.  
To process and analyse the MiSeq data and to compare the methylation status of complementary 
CpG sites, several bioinformatic tools were used. Most of the tools are publicly available and 
extensively used like RStudio, Galaxy software, Pear merger, and FASTQC. To facilitate the 
data analysis we contributed to the development of an automated workflow to improve the 
identification of unique reads for each hairpin sample. In addition, we have developed a script 
run in macOS that allowed the automated piping of command-lines programs together, which 
replaced the user-intensive Galaxy pipeline. We also optimised a new method for comparing 
the methylation status of complementary CpG sites using RStudio. 
4.1.1 The aim of this chapter. 
To document the development of the bioinformatic workflow and to demonstrate the 
reproducibility of the hairpin bisulfite protocol. 
Specific aims are:  
A- Design automated workflow for hairpin bisulfite analysis. 
B- Confirm the reproducibility of the hairpin bisulfite sequencing protocol. 
C- Process hairpin methylation data to measure the percentage of hemi-methylation. 
D- Optimise scripts to calculate the percentage of methylated/hemi/un-methylated hairpin 




4.2 High throughput sequencing (Illumina MiSeq). 
4.2.1 Library multiplexing.  
This part will detail the multiplexing and tools used to analyse the hairpin bisulfite sequences. 
Firstly, multiplexing allows pooling and sequencing of large numbers of libraries (~ 350 
libraries) in a single sequencing run. Multiplexing of libraries is possible due to unique 
barcoded index sequences added during library preparation of each DNA sample, such that each 
read can be identified and assigned to its originating sample. With multiplexing, the MiSeq 
sequencing  time for multi-sample studies can be considerably reduced. Multiplex sequencing 
is gaining increasing interest because it is cost effective, large numbers of amplicons can be 
assessed, library preparation is faster and high quality data is obtained.  
For library construction, RASSF1 and PCDHGA12 hairpin DNA libraries were prepared for 
each sample using our modified protocol (details in Chapter three). Two rounds of multiplexing 
occurred during library preparation; the first level of multiplexing mixed all amplicons for each 
sample (multiplexed amplicons RASSF1 and PCDHGA12), and the second level of 
multiplexing mixed many samples in one pooled library. 
4.2.2 Sequencing of hairpin libraries. 
An Illumina MiSeq System (highly automated workflow) was used to perform sequencing for 
multiple genes of multiplexed libraries within a single run with high yields of data. Before 
sequencing, libraries were quantified and validated using an Agilent 2100 Bio Analyser (Agilent 
Technologies). Quantified and pooled libraries were contained with samples from other groups, 
and sequencing was carried out on the MiSeq System (Illumina) using MiSeq Reagent Nano 
kit V2 500 bp to generate 2 x 250 bp paired end reads for each sample according to 
manufacturer’s instructions (Quail et al., 2009).  
4.2.3 Illumina MiSeq principles. 
MiSeq sequencing provides information about the methylation status of many hairpin 
sequences by allowing parallel reading and outputting hundreds of thousands reads for each 
sample. Template DNA is hybridised to a small piece of single-stranded DNA (adapter) that is 
attached to the polymer-coated glass surface of a flowcell (Bronner et al., 2014) (Figure 4.1). 
Templates are amplified by flowing enzymes and reagents through the channel of flowcell 






Figure 4. 1. Diagram of Illumina flowcell. Template DNA and reagents flow through a hollow 
glass slide. Modified from Bronner et al., 2014.  
 
Sequencing was performed by Dr Rob Day at the Centre for Translational Cancer Research, 
Department of Biochemistry, University of Otago, Dunedin.  
4.2.4 Libraries demultiplexing. 
The sequence data was then demultiplexed based on the Illumina index sequence and saved as 
two sequence files (fastq.gz files) for each sample, one for each reading direction of the 
fragment (read 1 and read 2 files). Both files contain the same number of reads. Quality metrics 
of the sequencing data was then manipulated using web-based platform Galaxy (section 4.3.1). 
4.3 Raw MiSeq data processing. 
To process and analyse the MiSeq data, several publicly available programs were used. In 
addition, we contributed to the development of a framework to facilitate the methylation 
analysis of the complementary CpG sites of hairpin data. A brief overview of the tools and 
software used in this study is described in the following sections.   
4.3.1 Galaxy platform and workflow. 
Galaxy is an open source web-based application for interactive data analysis 
(https://usegalaxy.org). The system provides a base on which to build multiple analyses steps 
through a graphical user interface (Calvanese et al., 2012). Data can be imported to Galaxy 
from the user’s computer or directly from many online resources such as the UCSC table 
browser. The application provides a collection of command line tools (FASTX-Toolkit) which 
are used to process Next Generation Sequencing (Pennings et al.) data. 
This section summarise the stages used to process the raw hairpin MiSeq sequence data. We 
established a bioinformatics framework for hairpin DNA methylation analysis (Figure 4.2). The 
online Galaxy software was used to process the raw files, forward read R1 and reverse read R2.  
1. Paired-end fastq.gz files produced by the Illumina MiSeq sequencer were uploaded onto 
the Galaxy server (usegalaxy.org) and converted to Illumine 1.8+ format by the 




2. The barcode splitter function was used to select gene specific reads. Forward and 
reverse primers were used to split gene specific sequences in read 1 and read 2 files 
respectively. 
3. Barcode-split files were downloaded and checked for quality analysis per-base using 
FASTQC function, then uploaded files were groomed to Illumine 1.8+ format using 
FASTQ Groomer tool . 
4. Filter by quality function was used to select the reads with PHRED score >30 with a 
cut-off 80% of read length. The PHRED score measures of the quality of the 
nucleobases generated by DNA sequencing and calculates the errors of base calling in 
the sequenced nucleotide.  
5. If the amplicon size is more than 250 bp and less than 500 bp “Trim sequences function” 
were used for trimming the reads to make the size of both reads equal to the full length 
of sequenced amplicon.  
6. Read 2 was modified by “Reverse Complement”. 
7. Read 1 and Read 2 were joined using “FASTQ Joiner” function. 
8. The unique reads in FASTA file were selected by “Collapse” function, and PCR 
replicates were removed.  








Figure 4. 2. Galaxy workflow diagram shows the main steps used in processing the MiSeq 
sequence data. Step 1) MiSeq sequence output R1&R2 were uploaded to Galaxy online 
platform. Step 2) Paired-end sequence files were joined to generate the joined file (FASTQ), 
then FASTQC was used to check the quality of the joined sequence, followed by quality filter 
to remove the poor-quality sequences. Step 3) ‘Barcode splitter’ on the joined file with forward 
primer reference. Step 4) Barcode collapser was used to remove repeated sequence based on 
unique hairpin barcode and output the collapsed reads in FASTA format. Step 5) FASTA files 
were imported to ‘BiQ Analyzer’ to facilitate locus-specific analysis and visualisation of high 





4.3.2 Multiple mergers used to join paired-end reads. 
When the amplicon size is more than the length of individual read and smaller than twice the 
length of the single-end reads, the corresponding paired-end reads can be merged into a 
fragment to get the full length of the sequence (Figure 4.3). The overlapping sequence between 
the two reads can be deployed for correcting sequencing errors and yield higher quality 
sequences. Several packages are available to merge paired-end sequencing reads and these 
include PEAR (Zhang et al., 2014), FLASH (Magoč & Salzberg, 2011), PANDAseq (Masella 
et al., 2012) and COPE (Liu et al., 2012). Two of the joiner packages (PEAR and FLASH) were 





Figure 4. 3. Typical scenario of read overlapping. Forward reads (250 bp; R1) and reverse reads 
(250 bp; R2) overlap.  
 
4.3.2.1 ‘PEAR’ – Paired-End reAdmergeR (v0.9.8). 
‘PEAR’ is a highly accurate paired-end merger designed to join corresponding reads based on 
the unique sequence identifiers (Zhang et al., 2014). PEAR evaluates all possible overlap 
sequences using a minimum overlap size of 10 bp and minimum possible length of the 
assembled sequences of 50 bp. PEAR determines highest alignment score by recording all 
possible overlaps for each pair of corresponding paired-end reads. Using this method, the 
sequence accuracy was enhanced as PEAR compares the base quality scores for the overlapping 
regions. Therefore, PEAR can merge sequences with varying fragment length. PEAR uses 
statistical testing to generate a P value for each overlap and to minimise the likelihood of false 





4.3.2.2 ‘FLASH’ – Fast Length Adjustment of Short Reads (v1.2.6) 
‘FLASH’ is another paired-end merger used to extend the short sequence length from next-
generation sequencing experiments by overlapping paired-end reads of short fragments. FLASH 
requires compatible input fastq paired-end reads where the reads with a unique sequence 
identifier overlap the read generated from the opposite end of the same DNA sequence. FLASH 
joiner processes each pair of reads separately and searches for the correct overlap between the 
paired end reads (Magoč & Salzberg, 2011). There are a few limitations of the FLASH program: 
1) FLASH failed to merge the majority of reads with short overlap sequence, since it requires a 
minimum overlap value to work correctly. 2) FLASH is slow when tested on a larger dataset of 
paired-end reads from human chromosome 14 compared to PEAR program. (Zhang et al., 
2014). 
4.3.3 Splitting reads by gene specific primers (‘FASTQ Barcode splitter’).  
Barcode splitter function was used to demultiplex gene-specific reads from the pooled sequence 
output of high throughput sequencing. This third step of data pre-processing splits reads by the 
gene specific primer sequence to allow identification of the origin of the reads. The barcodes 
here are different than the hairpin barcodes used to identified the hairpin sequences. The 
barcode files are input text files that contain amplicon name and primer sequence used to split 
Illumina sequencing library (FASTQ file) to multiple files. This tool used forward primer 
sequences (with a maximum of 2 mismatches) as identifiers to match the sequences that belong 
to these primers. As a result, the sequences matching the forward primer sequence will be stored 
in FASTQ files for “matched files” created for each primer. Sequences not matching the 
barcode sequence will be stored in additional FASTQ files created for the un-matched 





4.3.4 FASTQC (Babraham Bioinformatics). 
FASTQC (www.bioinformatics.babraham.ac.uk/projects/fastqc) is a JAVA application used to 
check the quality of the raw sequence data coming from high throughput sequencing. FASTQC 
provides a summary of quality assessment of each file including per-base and per-sequence 
quality scores (better known PHRED score) (Figure 4.4). PHRED is used to assess sequencing 
quality by estimating the sequence call error; high quality reads are defined as having a PHRED 
score >30, representing a greater than ‘1 in 1000’ probability of an incorrect base call; the higher 
the PHRED score the more confident the base calling. The Y-axis on the graph shows PHRED 
quality scores, the background of the graph divided into three parts according to the base call 
quality; 1) green, very good quality with PHRED score of 28 to 38; 2) orange, medium quality 
with PHRED score of 20 to 28; and 3) red, poor quality with PHRED score below 20 (Cock et 
al., 2010). 
4.3.5 ‘Collapsing’ (removing redundant reads).  
In bisulfite sequencing, an excessive number of PCR cycles can result in over-amplification of 
sequences with the same hairpin barcode. To deal with the effects of PCR amplification, the 
tool ‘collapsing’ was used to “collapse” the duplicate sequences into a single sequence. The 
hairpins incorporate random 14 bp barcodes with four million unique sequences by which 
replicated or contaminating sequences can be recognised and excluded. Since each sample will 
have up to only 10,000 reads, it is not expected that the same barcode will be observed, unless 
this was due to PCR amplification.  
The Galaxy platform provides a collapsing function tool that compares the reads along their 
full length, and retains only one identical sequence per sample. The Galaxy collapse tool 
depends on the entire sequence of the reads (including any errors introduced during PCR or 
sequencing). The Galaxy collapse tool might recognise sequences as distinct reads in spite of 
having the same hairpin barcode. After collapsing of the reads, inspection of the barcodes 










Figure 4. 4. Quality metrics interface for Illumina MiSeq data. A) FASTQC per-base sequence 
quality chart. The x-axis shows the base position in the reads, and the quality score is on the Y-
axis. This box and whisker plot shows the quality scores for each base within the merged 
sequence file calculated as mean PHRED score (blue line), median PHRED score (red line), 
and interquartile range (yellow box). The upper and lower whiskers indicating the 10th and 90th 
percentile scores. The plot background is colour-coded to determine the good (green), 
acceptable (beige) and bad (red) quality scores. B) Per sequence quality assessment (PHRED 







Figure 4. 5. FASTQ collapsing. Multiple PCDHGA12 hairpin sequences from the alignment 
file visualised a different hairpin barcode for each sequence (labelled with blue rectangle, and 
the hairpin reference sequence labelled in green) with the constant region of the hairpin 
(GTGATGT located before the hairpin molecular barcode, labelled with purple colour). Each 
row represents different hairpin reads with a unique molecular barcode. A few hairpin reads 
share the same barcode (highlighted in yellow).  
 
 
Figure 4. 6. Redundancy of hairpin sequences following FASTQ collapser. Most of the hairpin 
reads contain one unique molecular barcode. Few hairpin reads shared the same barcode after 





In a fully collapsed file, each read should be repeated once and contain a unique hairpin 
molecular barcode. The nature of a unique hairpin present in our DNA sequences provides a 
possible pathway to search for the constant region of the hairpin (located before the 14 bp 




Figure 4. 7. Multiple PCDHGA12 hairpin sequences from a fasta file showing the different 
hairpin barcode for each sequence (blue rectangle) with the constant stem of the hairpin 
(TGTGATGT located before the hairpin molecular barcode, green square). Each row represents 
a different read with a unique molecular barcode. 
 
4.3.6 Hairpin barcode collapsing (remove redundant barcodes) using UNIX command line. 
To solve the incomplete collapsing of the hairpin sequences resulted from the online Galaxy 
fastQ collapser, a bash script command was developed to search for the hairpin stem sequence 
and to write a FASTA sequence file containing only the collapsed sequences with a unique 
barcode (one barcode for each sequence), ready for further analysis. The bash script used to 











for filename2 in *.fastq;  
do  
awk '{if(NR%4==2) print;}' < $filename2 | 





#Allowing one mismatch, searches for the constant region of the hairpin immediately 
prior to the molecular barcode, and replaces it with a “.”. 
 
  sort -t . -k 2.1,2.14 -u |   
#Sort each file based on the first 14 characters after the “.”; and keep one unique 
read per match. 
 
  cat -n | sed 's/^/>/' |  
tr "[\t]" "\n" > ${filename2/%.fastq/.fasta};  
rm ./*unmatchedf.fasta;  
#Numbers each line, then inserts a “>” before every line number, then replaces 
every tab “\t” with a newline “\n” to create a .fasta format file. 
 
done);  





For the RASSF1 sequencing files, the above bash script was amended by replacing the 
PCDHGA12 hairpin stem sequences with the RASSF1 hairpin stem sequences: 
GTGATGT|.TGATGT|G.GATGT|GT.ATGT|GTG.TGT|GTGA.GT|GTGAT.T|GTGATG 
However, using these RASSF1 stem sequences resulted in truncated, collapsed reads, as two of 
these (GTGA[A]GT) and (GT[T]ATGT) hairpin stem sequences are located in other parts of 
RASSF1 read  sequences (Figure 4.8). 
 
Figure 4. 8. Bisulfite converted sequence of RASSF1 hairpin molecule. Two of the sequences 
mismatched (GTGA[A]GT) and (GT[T]ATGT), highlighted yellow and green. 
 
The presence of these mismatches was corrected by adding a T to the beginning of the hairpin 
constant sequence. 
 


















To determine the efficiency of the developed script, and its capability to resolve the 
incompletely collapsed sequences, hairpin barcodes were selected from a collapsed FASTA 
for filename2 in *.fastq;  
do  
awk '{if(NR%4==2) print;}' < $filename2 | 




GTGATG./,".")}; 1’  
#Allowing one mismatch, searches for the constant region of the hairpin immediately 
prior to the molecular barcode, and replaces it with a “.”. 
 
  sort -t . -k 2.1,2.14 -u |   
#Sort each file based on the first 14 characters after the “.”; and keep one unique 
read per match. 
 
  cat -n | sed 's/^/>/' |  
tr "[\t]" "\n" > ${filename2/%.fastq/.fasta};  
rm ./*unmatchedf.fasta;  
#Numbers each line, then inserts a “>” before every line number, then replaces 
every tab “\t” with a newline “\n” to create a .fasta format file. 
 
done);  




files, and a clustering analysis was done to show that all barcode sequences were unique and 
there were no groups of similar barcode sequences. The analysis was done in R using Jaro-
Winkler distance method (Figure 4.9). A fully collapsed file should only show one read for 
each unique molecular barcode. Similar sequences apparently are PCR replicates possessing 
the same barcode, and the generation of these similar sequences leads to a biased heatmap, 






                  
 
Figure 4. 9. Dendrogram showing the results of Clustering analysis for hairpin barcodes using 






4.4 High throughput data visualisation. 
4.4.1 BiQ Analyzer HT. 
To further analyse and visualise the FASTA files resulting from the collapse function of Galaxy, 
BiQ Analyzer HT program was used. BiQ Analyzer is a Java-based software tool used to process 
and analyse the output of high throughput bisulfite sequencing files (Lutsik et al., 2011). The 
application implements a data processing pipeline to generate quality-controlled output results 
for the inferred DNA methylation for each sample. 
CG methylation is the most common epigenetic modification of eukaryotic DNA (Lee et al., 
2010). By default, BiQ Analyzer focused on this modification by comparing the sequences at 
the corresponding positions of the aligned sequence read, and creates a binary methylation 
output directory (“1” methylated, “0” unmethylated and “X” missing value) for each sequence. 
4.4.1.1 Inference of DNA methylation pattern. 
BiQ Analyzer HT supports the alignment analysis of bisulfite sequencing data for many target 
loci in multiple samples. The program is available as a downloadable installation package and 
can be run on any computer with an appropriate version of Java. BiQ Analyzer analyses can be 
done using a graphical interface, or alternatively can be run from the command line with 
automated data processing scripts. The BiQ Analyzer program is designed to analyse a dataset 
with precise mapping to a single locus.  
The galaxy and BiQ Analyzer workflow showing the main steps used in processing the MiSeq 
sequence data is shown in (Figure 4.10). To prepare for analysis, 
1. High throughput bisulfite sequencing files are converted to FASTA format (Galaxy 
collapsed files). 
2. FASTA files are imported into BiQ Analyzer and aligned with genomic reference 
sequences (Lutsik et al., 2011).  Based on these alignments and by comparing the read 
sequence with the genomic reference sequence, the methylation status of every CpG in 
all sequence reads can be determined . 
3. After alignment, BiQ Analyzer outputs DNA methylation data in several different file 
formats (Figure 4.10).  
4. Results files can be imported into R, Excel or Prism (GraphPad) for further analysis, 








Figure 4. 10. Example of the output files produced by BiQ Analyzer HT. A) the results file 
(results.tsv) summarises all the satisfactory information for each read of demultiplexed sample 
after alignment, for example, alignment score, sequence identity, mean methylation score, 
conversion score results for each read. The binary CG- methylation output is (1 = methylated, 
0 = unmethylated, X = missing value). B) Multiple alignment of sequencing reads for each 
amplicon in each sample. C) Example of a methylation pattern map (heatmap.png). Each row 
represents an individual hairpin read, while each column reflects CpG sites across different 
hairpin reads. Methylated CpG were labelled red, unmethylated in blue and missing value in 
white. D) Example of a Pearl necklace diagram (pearlNecklace.png), which summarises the 
methylation frequency (methylated, unmethylated and missing value) per CpG sites across all 
sequenced reads for each sample. Results files were uploaded to R, Excel and Prism (GraphPad) 






4.4.1.2 Alignment score inflection point. 
BiQ Analyzer generates an alignment score for every read and high alignment score is essential 
for analysis of bisulfite sequences. To ensure only good quality reads were analysed, poorly 
aligned reads were removed. The modified “Needleman-Wunsch algorithm” was used to 
calculate the alignment score for each sequence read. The modified algorithm has highly 
optimised implementation and provides excellent performance for large read numbers in the 
order of 104 per CpG site (Lutsik et al., 2011). 
BiQ Analyzer generated an alignment score for each hairpin read when sequences were aligned 
to the predicted reference sequence. The higher alignment scores reflect the sequence of 
interest. Cumulative frequency for reads alignment scores was calculated to determine the 
inflection point cut-off for each amplicon, i.e. the cut-off value obtained when the curve 
increases exponentially. Sequences with alignment score less than 2000 and 1800, for RASSF1 
and PCDHGA12 respectively, were regarded as low-quality sequences and were discarded 
(Figure 4.11).  
 
Figure 4. 11. Cumulative analysis plot for BiQ Analyzer alignment scores. BiQ Analyzer 
alignments score inflection point (cut-off) for A) RASSF1 and B) PCDHGA12 hairpin reads.  
 
4.5 Command line sequence processing (automated analysis). 
While the Galaxy workflow is reliable and successful in analysing and interpreting hairpin 
MiSeq data, the program depends on user-operated, online tools and manual inputs which 
limited the sequence processing. The data processing workflow is time consuming and 
repetitive with large amounts of high throughput sequence samples. In view of this limitation, 
the Morison laboratory group established an automated bioinformatic framework for DNA 




the online Galaxy workflow using locally installed UNIX tools. This approach used a Mac OS 
terminal bash script to analyse the demultiplexed paired end fastq.gz files (read 1 and read 2). 
The bash script was set to perform all steps described above automatically using MacOS 
terminal and the output of each step was monitored to ensure accurate analysis. The full script 
with annotation can be found in the Appendix 1.  
4.5.1 Quantification process and data analysis. 
BiQ Analyzer generates a result.tsv file for each sample describing the methylation information 
for each read (Figure 4.10A). For calculating demethylation, it was necessary to quantify the 
number of meth/unmeth/hemi-methylated hairpin reads for each amplicon in each sample. The 
lines containing this binary methylation data (‘1’- methylated, ‘0’-unmethylated and ‘x’-
undetermined) were extracted from the results.tsv file, with each character being tab-separated 
and output to a methylation.tsv file (Figure 4.12.A). The full terminal script with annotation 
can be found in the Appendix 1. All methylation.tsv files were uploaded to RStudio for 
automated analysis.  
4.5.2 Processing hairpin data. 
RStudio was used to process the binary methylation data (methylation.tsv files) by comparing 
the methylation of the complementary CpG sites across the entire hairpin strand. An R script 
was written to bioinformatically “fold” each read at the hairpin (Figure 4.12B) and to classify 
the resulting methylation pattern of complementary CpG sites as methylated, hemi-methylated 
or unmethylated (Figure 4.12C).  
Each read was classified according to the status of complementary CpG sites: if the proportion 
of complementary CpGs was ³ 0.51 the read was called ‘methylated’, ‘hemi-methylated’ if the 
proportion of hemi-methylated CpGs was ³ 0.51 and ‘unmethylated’ if the proportion of 
unmethylated CpGs was ³ 0.51. Finally, the script calculated the overall proportion of fully 
methylated, hemi-methylated and unmethylated reads for each sample (Figure 4.12). The full 
R script with annotation can be found in the Appendix 2. 
One of the limitations in calculating the overall methylation proportion of reads was discovered 
for samples in which the proportion of methylated/hemi-methylated or unmethylated was 
(0.5:0.5) or (0.33:0.33:0.33). The proportion of these reads was negligible (< 2%) and they were 







Figure 4. 12. Processing hairpin DNA data using terminal commands and R scripts. A) Binary 
methylation data (‘1’ and ‘0’) extracted from ‘results.txt’ file and output as a ‘methylation.tsv’ 
file. B) Folding of the binary data to calculate the status of complementary CpG methylation 
sites. C) The ‘output.tsv’ file generated by the R script showing the proportions of methylation 
(‘unmethylated’, ‘hemi-methylated’ and ‘methylated’) for each sample.  
 
4.5.3 Folding the hairpin reads using RStudio. 
To visualise the methylation status of the hairpin reads, a heat map was generated using BiQ 
Analyzer to represent the methylation pattern. Each row in the heat map represents an unfolded 
hairpin read (Figure 4.13, left); columns represent CpG dinucleotides; blue squares show 
unmethylated CpGs; red squares show methylated CpGs; white squares show missing sequence 
information. An R script was written using ggplot in RStudio to “fold” each hairpin read, and 
generate a heat map to show the methylation of two complementary CpGs across hairpin reads 





Figure 4. 13. BiQ Analyzer output showing the methylation pattern of the PCDHGA12 
promoter.  The left panel shows the results of the methylation analyses by deep bisulfite 
sequencing. Rows represent unfolded hairpin reads; columns represent CpG dinucleotides 
across hairpin reads; blue squares show unmethylated CpGs; red squares show methylated 
CpGs; white squares show missing sequence information. The right panel shows the 
methylation status of the “folded” hairpin reads, demonstrating the methylation of the two 
complementary CpGs at each of 12 CpG sites; red show methylated CpGs; blue show 
unmethylated CpGs; green show hemi-methylated CpGs; white show missing sequence 
information. 
 
4.5.4 Comparison of methylation mapping between PEAR merger and FASTQ merger. 
The efficiency and fidelity of different sequence joiner programs were investigated using a 
single sample (sample treated with decitabine for 8 h after release from thymidine block). The 
DNA methylation pattern by the two merger programs were compared. The figure below shows 
different heatmaps pattern of hairpin PCDHGA12 promoter after using different read joiners 
(PEAR and FASTQ). Fastq merger performs a blunt join based on the unique sequence identifier 
(Blankenberg et al., 2010), which resulted in loss of some of the aligned CpG sites at the middle 
of the hairpin sequences which leads to short incomplete sequences compared to a full aligned 
sequences joined with PEAR merger. 
After alignment by BiQ Analyzer, multiple tools were used to compare different methylation 
sorting across a single sample joined with two different joiners PEAR and FASTQ. The 
methylation patterns of these heatmaps depends on whether the data are sorted by alignment 





Figure 4. 14. Comparison of joiner performance. The paired reads from a single sample 
sequences were joined with two different joiners (FASTQ & PEAR). The heatmaps show 
different methylation patterns of the PCDHGA12 promoter.  
 
4.6 Reproducibility of MiSeq sequencing platform. 
Illumina MiSeq sequencing is a popular next generation sequencer due to high accuracy, high 
throughput and great flexibility. The MiSeq method introduced a new type of library 
preparation protocol for NGS that require only small amounts of input 1 ng DNA for library 
construction. Illumina provided paired-end sequencing of both ends of the DNA and aligning 
the forward and reverse reads as paired reads. 
However, numerous technical problems such as PCR bias or sequencing itself, inherent in gene 
sequencing errors have been reported in various sequencing platforms. Low overall 
reproducibility among technical replicates has been reported in samples sequenced in different 
runs (Wen et al., 2017). 
To determine the reproducibility of the MiSeq platform, PCDHGA12 PCR products were 
prepared from technical replicates of the same sample but at different stages: 1) from the same 
bisulfite converted DNA, 2) from the first-round PCR products; and 3) from genomic DNA 
with separate ligation and bisulfite conversion for each replicate (see Figure 4.15A). To confirm 
the amplification, 4 µL of the PCR product for each library were assessed by agarose gel 






Figure 4. 15. A) Schematic representation of experimental design illustrating the technical 
replication. B) Gel electrophoresis image confirming the successful of PCDHGA12 PCR 
amplifications. 
 
The library was sequenced on a Illumina MiSeq sequencer using 2 x 250 bp paired end 
sequencing. The high throughput output data for the technical replicates were processed and 
the mean DNA methylation was calculated (Table 4.1) 
Similar methylation patterns of the PCDHGA12 amplicon were observed in technical replicates 
confirming the reproducibility of the sequencing pipeline (Figure 4.16). Interestingly, one 
sample showed differences in the methylation pattern in replicates repeated from genomic DNA 
compared to the replicates repeated from bisulfite converted DNA or replicates repeated from 
first PCR products (Figure 4.16 sample 5). This dissimilarity in DNA methylation indicated 
that the change in DNA methylation happened during sodium bisulfite conversion steps, most 
likely due to contamination or deamination of 5-mC which might include the conversion of 5-
mC to thymine residues (Wang et al., 1980). Lapet et al. (2009) suggested that under certain 
condition deamination of 5-mC can occur (Labet et al., 2009). Future experiments could explore 
whether the well-optimised kit that we use could cause such deamination in certain conditions.  
Although, bisulfite conversion is the gold standard method for evaluating DNA methylation by 
achieving the base pair resolution of the CpG methylation, the challenge of this method is the 









Figure 4. 16. Overall comparison of library methylation patterns between different MiSeq runs. 
These diagrams display the methylation pattern of hairpin-linked PCDHGA12 sequences 
obtained from two independent MiSeq runs for six different samples separated by green dotted 
lines. Three replicates for each sample were repeated from different steps during MiSeq 
protocol 1) DNA sequencing was repeated from bisulfite converted DNA, 2) DNA sequencing 
repeated from the 1st round PCR products, and 3) DNA sequencing was repeated from genomic 
DNA with new ligation and bisulfite conversion. Similar mean methylation was observed in 
technical replicates confirming the reproducibility of the MiSeq protocol. 
 
The precision of this approach is very high; e.g., based on 50,000 unique sequences per sample, 
the 95% confidence interval for the mean, in a sample containing 15% demethylated hairpin 
sequences, is 14.7-15.3%. In addition, the hairpins themselves incorporate random 14-bp 
barcodes that distinguish around four million unique sequences by which duplicate or 




Table 4. 1. Raw methylation data for the technical replicates from two independent 
experiments. 
Sample Replicate 1 
Methylation % 
Replicate 2 Methylation % 
bisulfite 1st PCR gDNA 
R1 R2 R3 R1 R2 R1 R2 R3 
Control at 8h 0.938 0.935 0.946 0.923 0.932 0.938 0.929 0.945 0.939 
Control at 12h 0.928 0.941 0.944 0.936 0.922 0.922 0.937 0.923 0.938 
Control at 24h 0.940 0.925 0.934 0.919 0.937 0.944 0.937 0.924 0.930 
Dec at 8 h 0.937 0.943 0.907 0.946 0.925 0.926 0.933 0.932 0.928 
Dec  at 12h 0.704 0.722 0.706 0.749 0.731 0.725 0.929 0.931 0.934 
Dec at 24h 0.938 0.943 0.919 0.913 0.940 0.933 0.927 0.931 0.911 
Asc/Dec at 8 h 0.890 0.952 0.944 0.932 0.893 0.897 0.955 0.927 0.922 
Asc/Dec at 8 h 0.935 0.941 0.898 0.945 0.935 0.943 0.927 0.944 0.943 
Asc/Dec at 8 h 0.936 0.942 0.928 0.925 0.935 0.932 0.931 0.935 0.848 
 
4.6.1 Precision of MiSeq sequencing. 
Another example of baseline levels of DNA methylation from two independent MiSeq runs for 
the same samples, was performed in November 2018 and February 2019 (Table 4.2) The mean 
DNA methylation for a particular sample showed high reproducibility of MiSeq sequencing 
data among replicates. The Bland-Altman plot shown below (Figure 4.19) compares the mean 
DNA methylation value for each sample between the two MiSeq runs. Each data point shown, 
therefore, represents the mean DNA methylation value for each sample compared to the mean 




Figure 4. 17. Bland-Altman plot showing the difference in mean DNA methylation of the 
PCDHGA12 promoter between two independent MiSeq datasets. Y-axis represents the 
difference between the respective means, and x-axis represents the average of the two 
respective means. The two dotted lines represent the upper and lower 95% limits of agreement 
(-0.018 and 0.021). 
 

























Difference vs. average: Bland-Altman of Bland-Altman





Table 4. 2. Mean DNA methylation for PCDHGA12 from two independent MiSeq runs.  








1 0.937 0.938 45 0.95 0.957 
2 0.925 0.933 46 0.797 0.798 
3 0.888 0.9 47 0.957 0.957 
4 0.91 0.92 48 0.79 0.776 
5 0.948 0.951 49 0.977 0.981 
6 0.982 0.978 50 0.837 0.843 
7 0.972 0.964 51 0.981 0.977 
8 0.976 0.973 52 0.901 0.89 
9 0.955 0.942 53 0.97 0.969 
10 0.9 0.897 54 0.951 0.95 
11 0.938 0.932 55 0.957 0.964 
12 0.917 0.908 56 0.958 0.944 
13 0.97 0.969 57 0.931 0.939 
14 0.964 0.964 58 0.686 0.702 
15 0.973 0.971 59 0.935 0.936 
16 0.956 0.957 60 0.696 0.691 
17 0.971 0.971 61 0.963 0.96 
18 0.946 0.952 62 0.759 0.759 
19 0.974 0.97 63 0.948 0.93 
20 0.948 0.955 64 0.858 0.856 
21 0.948 0.938 65 0.982 0.981 
22 0.92 0.941 66 0.859 0.858 
23 0.958 0.959 67 0.932 0.952 
24 0.916 0.912 68 0.876 0.887 
25 0.902 0.895 69 0.976 0.972 
26 0.66 0.68 70 0.891 0.895 
27 0.912 0.914 71 0.956 0.944 
28 0.713 0.72 72 0.844 0.842 
29 0.974 0.953 73 0.94 0.93 
30 0.882 0.879 74 0.711 0.70 
31 0.957 0.961 75 0.94 0.935 
32 0.894 0.905 76 0.736 0.731 
33 0.971 0.969 77 0.967 0.967 
34 0.932 0.924 78 0.809 0.78 
35 0.981 0.972 79 0.964 0.955 
36 0.901 0.918 80 0.803 0.826 
37 0.972 0.97 81 0.981 0.978 
38 0.95 0.941 82 0.896 0.886 
39 0.972 0.969 83 0.979 0.973 
40 0.946 0.952 84 0.909 0.895 
41 0.927 0.925 85 0.968 0.964 
42 0.639 0.657 86 0.934 0.944 
43 0.919 0.92 87 0.967 0.965 







In summary, we have successfully developed and optimised a high-throughput, hairpin bisulfite 
sequencing protocol for investigating the DNA methylation states of the PCDHGA12 and 
RASSF1 promoters. We developed an automated bioinformatics pipeline to analyse MiSeq 
methylation for hairpin sequencing data (using terminal and R), that can reliably collapse 
sequences based on unique molecular barcodes. This replaced the cumbersome, time-
consuming Galaxy workflow and ‘FASTQ collapser’, which collapsed sequences based on the 
entirety of the read sequences.  
The automated pipeline using Terminal and RStudio is more user-friendly, accurate and much 
faster than completing the tasks by repetitively using graphical user interface (GUI) approach 
using Galaxy. Furthermore, we were able to confirm the reproducibility and the precision of 
MiSeq platform by conducting many replicates from different steps during MiSeq protocol, as 








Chapter Five: The impact of DNA methyltransferase 




Decitabine or ‘5’-aza-2’deoxycytidine’ is a synthetic nucleoside analogue of cytosine used as 
an anti-cancer chemotherapy drug (Figure 5.1); for example, in the treatment of leukaemia 
(Vogler et al., 1976). Decitabine is incorporated into DNA during DNA replication or the S-
phase of the cell-cycle, inhibiting DNA methylation by formation of covalent bond with DNA 






Figure 5. 1. Chemical structure of decitabine and deoxycytidine. Decitabine is an analogue of 
deoxycytidine in which the carbon in position 5 is replaced by nitrogen. 
 
Once incorporated, decitabine irreversibly binds DNMT1, otherwise known as the maintenance 
methyltransferase, depleting DNMT1 levels and resulting in failure to reproduce methylation 
on newly synthesised daughter strands and loss of methylation (Ghoshal et al., 2004). 
Decitabine, like natural cytosine, enters human cells through equilibrative nucleoside 
transporters hENT1, hENT2 and hENT3. Decitabine becomes an active nucleoside triphosphate 




deoxycytidine kinase to produce 5-aza-deoxycytidine-5’-monophosphate (5-aza-dCMP). And 
this monophosphorylated decitabine undergoes further phosphorylation to produce 5-aza-
deoxycytidine-5´-diphosphate (5-aza-dCDP) and 5-aza-deoxycytidine-5´-triphosphate (5-aza-
dCTP) via the activity of deoxycytidine-5’- monophosphate (dCMP) kinase and the nucleoside 
diphosphokinase enzymes, respectively (Momparler, 2005b). Finally, with the aid of DNA 
polymerase, the active form, 5-aza-deoxycytidine-5’-triphosphate (5-aza-dCTP), is 
incorporated into the replicating DNA during S phase instead of dCTP, blocking the 




Figure 5. 2. Molecular mechanism of decitabine. Inactivation of DNMT1 by formation of 
covalent bond with 5-aza-dCTP present in the newly-synthesised daughter DNA strand. 
 
This chapter is divided into two main parts. The first part discusses gene-specific methylation 
in response to decitabine treatment, and the second part discusses the cell cycle progression and 






5.2 Part one: Cell growth characteristics. 
The aims of this part are: 
1. To determine the effect of different treatments on the viability of Jurkat, Molt4, Nalm6 
and HL60 cells. 
2. To study the impact of decitabine on cell cycle progression. 
3. To distinguish the effect of indicated decitabine concentration on cell viability.  
4. To optimise the thymidine block for the four leukaemia cell lines. 
The purpose of this section was to confirm the validity and to support the interpretation of 
results shown in part one. 
5.2.1 Effect of decitabine on cell cycle progression. 
Decitabine is a DNA methyltransferase inhibitor (DNMTi) which has anti-tumour activity and 
is approved for treatment of leukaemia and myelodysplastic syndrome (Jabbour et al., 2008). 
Relatively, low decitabine doses lead to passive demethylation resulting in re-expression of 
silent tumour suppressor genes and induction of apoptosis (Jabbour et al., 2008; Qin et al., 
2007). We assessed the effect of single dose treatment of decitabine on cell cycle progression 
to determine whether the cells are sensitive to decitabine and determine the cell toxicity for 
different doses and longer incubation time. 
5.2.1.1 Cell cycle analysis. 
The cell cycle comprises four different phases: G1, S, G2 and M. During the G1 phase, cells 
grow in size and prepare for DNA replication. S phase (or synthesis phase) starts when the cells 
pass the G1/S checkpoint and begin DNA synthesis. Once the cells reach G2, the DNA is 
duplicated and the cells prepare to divide by passing the G2/M checkpoint into M-phase (or 
mitosis). Determining the effect of decitabine on cell cycle progression requires a reliable cell 
cycle assay. The DNA content of the proliferating cells can be used to determine the proportion 
of cells in each stage; this can be assessed by binding of nucleotide-binding dye such as 
propidium iodide followed by flow cytometric analysis.  
To monitor the cell cycle progression and determine the success of the thymidine-block induced 
synchronisation, Jurkat cells were grown to the required concentration (1 million cells/mL), 
then fixed with 70% ethanol and stained with propidium iodide RNAse to measure the DNA 
content. Propidium iodide staining was measured using flow cytometry and histogram plots 
were used to observe the changes in the distribution of the Jurkat cell populations through the 




The flow cytometric results for asynchronous Jurkat cells showed a large peak of cells in G1/G0 
phase (diploid DNA content), a middle S-phase in which fewer cells contained increasing 
amounts of DNA, and G2 phase cells represented by a smaller peak (tetraploid) (Figure 5.3).  




Figure 5. 3. Histogram showing DNA content distribution of live unsynchronised Jurkat cells 
stained with propidium iodide (PI) stain and analysed by flow cytometry. 
 
5.2.1.2 Synchronisation of Jurkat cells. 
Cell synchronisation is the process by which cells in different phases of cell cycle were brought 
into one phase. This step is crucial to study specific events during the cell cycle progression. 
To ensure the simultaneous replication of DNA, thymidine (a DNA synthesis inhibitor) was 
used to synchronise the cells in G1 phase boundary prior to DNA synthesis, such that all cells 
will go through S-phase together (Chen & Deng, 2018a).  
To arrest the cells in G1 phase, a single thymidine block protocol was used. Jurkat cells were 
incubated with 2 mM 2´-deoxythymidine (Sigma-Aldrich) for 18 h. Thymidine depletes the 
intracellular cytidine levels, leading to growth arrest of most cells in the G1 phase, and therefore 
significantly reducing the cell numbers in the G2. 
After synchronisation, Jurkat cells were washed twice with pre-warmed fresh media 
supplemented with 50 μM 2´- deoxycytidine (dC). Cells were harvested at increasing time point 




Flow cytometry histograms were used to monitor the changes in cell population during cell 
progression. Histograms of thymidine blocked Jurkat cells showed a large peak of resting cells 
in G1 phase, with a significant reduction in G2 population (Figure 5.4, 0 h). At 1-2 h 
synchronised cells show very slow progression,  at 4 h the synchronised cells start progression 
into the S phase showing a large peak in the S phase and two small peaks of G1 and G2. At 6 h 
cells are undergoing DNA replication in S phase and some start G2 phase showing a peak 
combined of S phase and early G2. 
 
 
Figure 5. 4. Analysis of synchronised Jurkat cells following release of cell cycle arrest. Cells 
were treated with thymidine for 18 h followed by supplementation of 50 μM 2´- deoxycytidine 
(dC). The cells proceeded through S phase with time. The first column shows Forward scatter 
(FS)/Side Scatter (SS) plots of cells. The second column (Ungated) shows plots of number of 
cells  vs PI-fluorescence across 1024 ‘bins’, with some doublets and aggregates of dead cells. 
The third column (Gated) shows data from the second panel that falls within the arbitrarily 
labelled gate “G” from the second panel to exclude most of the doublets and aggregates.  
 
5.2.1.3 Roles of 2´-deoxycytidine (dC) in cell cycle progression. 
To show the necessity of deoxycytidine in initiating the cell cycle progression, synchronised 




used to monitor cell cycle progression through S phase. Briefly, Jurkat cells were cultured in 
RPMI media and synchronised to G1 phase with 2 mM thymidine (as above). Cells were 
divided into two groups, the first group was supplemented with fresh media loaded with 50 μM 
2´-deoxycytidine and the second group, supplemented with fresh media without deoxycytidine, 
acted as a control. Thereafter, cells were collected at 0, 2, 4, 6 h. The cell cycle transition was 
analysed with flow cytometry by DNA staining using propidium iodide (PI). Deoxycytidine 
initiates the cell cycle by providing the cytosine molecule required for DNA synthesis. Jurkat 
cells supplemented with 50 μM 2´-deoxycytidine start cell progression and proceeded through 
S phase. In contrast, Jurkat cells not supplemented with 2´-deoxycytidine remained arrested at 
G1 phase (Figure 5.5). 
 
 
Figure 5. 5. Flow cytometry results showing the reliance on dC to allow progression through 
the cell cycle. The first column; NB (un-blocked) asynchronous cells with a large peak of cells 
in G1/G0 phase and small peak of cells in the G2/M phase. The second column shows 
thymidine-blocked cells supplemented with 50 μM 2´- deoxycytidine (dC). The cells proceeded 
through S phase. The third column shows thymidine blocked cells not supplemented with 50 





5.2.2 Effect of decitabine on cell cycle progression. 
To examine the cytotoxic effect of decitabine on cell growth and cell cycle progression, 
synchronised Jurkat cells were treated with a single dose of decitabine (5 μM) and incubated 
for 72 h. Briefly, Jurkat cells (1x106/mL) were arrested in G1 using thymidine as before, washed 
and transferred to fresh media, supplemented with 50 μM 2´-deoxycytidine (dC). Immediately, 
thereafter, the cells were treated with 0 or 5 μM decitabine and collected at 0, 1, 2, 4, 6, 24, 48 
and 72 h time points. Cells were pelleted by centrifugation (2000 rpm for 4 min at 4 °C), washed 
twice with cold PBS and suspended in 250 μL propidium iodide/RNase staining solution (Pub.  
No. MAN0007554) and incubated at 4 °C for 1 h in the dark. The cell cycle analysis was 





Figure 5. 6. Cell cycle analysis of synchronised Jurkat cells. A) Treatment and collecting 
timepoints. B) Cell cycle progression of control Jurkat cells. C) Cell cycle progression of Jurkat 
cells treated with 5 μM decitabine. All cells were supplemented with 50 μM dC at the time of 
release from the thymidine block. The arrows show the S phase (cells population) between 
untreated and decitabine treated cells.  
  
Cell cycle distribution analysis revealed that decitabine had little to no effect on cell cycle 
kinetics compared with the control. The cells continued to progress through the S phase of the 




of cells in S phase at 24 h timepoint in decitabine treated cells compared to the control cells 
(Figure 5. 6).  
In conclusion, cell cycle analysis of synchronised Jurkat cells treated with 5 μM decitabine 
demonstrated little effect on cell cycle progression. A level of growth arrest was observed after 
24 h of exposure to decitabine compared to control cells; this was accompanied by an increase 
in cells in the S phase of the cell cycle compared to untreated control cells.  
5.2.3 Inhibition of cell viability in Jurkat cells. 
To assess the efficacy of decitabine and other reagents in inhibiting cell growth and 
proliferation, cell viability of Jurkat cells was assessed, cells were stained by propidium iodide  
and analysed using flow cytometry. Cells were treated with 5 μM of decitabine, 500 μM glycine 
chloramine, 100 μM cobalt chloride, 500 μM ascorbate or different combinations of these 
reagents, and incubated for three days. Cells were harvested and washed with PBS and prepared 
for analysis as described in section 3.8.9.  
Cell viability of Jurkat cells was examined during the treatment with different reagents at 0 h, 
24 h, 48 and 72 h. Reagent concentrations were used according to two previous independent 
studies performed in the Morison and Hampton laboratories. Viability of Jurkat cells treated 
with ascorbate or decitabine was not affected and remained similar to the viability of the control 
cells, whereas, the combination of ascorbate and decitabine reduced the viability of Jurkat cells 
by 25% after 72 h. There was a 30% reduction in the viability after 24 h in cells treated with 
glycine chloramine. Interestingly, the combination of ascorbate and glycine chloramine 
increased the viability of Jurkat cells and reduced the cell toxicity induced by glycine 
chloramine alone. Glycine chloramine is a short-acting oxidative compound that is unstable. 
There was a high likelihood that most of the glycine chloramine would have been neutralised 
by the antioxidant ascorbate.  
As expected, as it is known that cobalt is a toxic compound, cobalt chloride was detrimental to 
cell viability. Cell viability was significantly reduced in cells treated with cobalt chloride alone 







Figure 5. 7. The effect of different treatments on the viability of Jurkat cells over time. Cell 
viability was measured using flow cytometry. Cells were stained by propidium iodide (PI).   
 
5.2.4 Growth inhibition of four haematopoietic cell lines by decitabine.  
In addition to Jurkat cells, our study was extended to investigate the growth inhibitory effect of 
decitabine in another three haematopoietic cell lines: Molt4, Nalm6 and HL60. Evaluation of 
decitabine toxicity was performed using different concentrations of decitabine for 24 h. Cells 
were blocked by thymidine for 18 h, released by supplementation with fresh media loaded with 
dC and different concentrations of decitabine (0 to 5 μM) were added at the time of release. To 
measure the viability of cells, cells were stained with trypan blue and counted using a 
haemocytometer.  
Minor changes in the proportions of live and dead cells were seen between decitabine 
concentrations (up to 2 μM) in the three cell lines Jurkat, Molt4 and Nalm6, while a marked 
change was seen in HL60 (Figure 5.8). Additionally, decreased cell number was observed in 







Figure 5. 8. Cell death in the four cell lines (Jurkat, Molt4, Nalm6 and HL60) following 
incubation with increasing concentrations of decitabine for 24 h. Viability was determined by 




Figure 5. 9. Effect of decitabine on number of viable cells. Jurkat, Molt4, Nalm6 and HL60 cell 
lines were exposed to different concentrations of decitabine for 24 h. Cell viability was assessed 
by trypan blue. NB: represents the number of cells at 0 timepoint, Value are means of three 
replicates ± SEM. 
 
The addition of 5 μM decitabine to cells resulted in a reduction of cell viability and increase in 
the number of dead cells. Minimal variation in the percentage of dead cells were observed in 
treated Jurkat, Molt4 and Nalm6 between concentrations of 0.5 and 2 μM compared to HL60 
cells which found to be sensitive to decitabine concentration of 1 μM (decitabine LC50 for 
HL60 is 10 times less compared to Jurkat, Molt4 or Nalm6 cells). Based on the results obtained 
from the decitabine toxicity experiment and to ensure cell cycle progression through DNA 
synthesis, the decitabine concentration was decreased to 1 μM for the three cell lines and 0.5 




5.3 Part two: Gene specific methylation response to decitabine. 
The goal of this part is test the hypothesis that hemi-methylated DNA enhances the rate of TET 
enzyme induced active demethylation in somatic cells. The hypothesis was developed based on 
the surprising observation by Dr. Helena Magrath from the Morison laboratory, that active 
demethylation occurs within just two hours of exposure of cells to physiological oxidative 
stress.  
Hypothesis:  
1. The hemi-methylation induced by the DNMTi inhibitor, decitabine, enhances the rate 
of TET induced active demethylation. 
The aims of this section: 
1. To assess the impact of decitabine on DNA methylation status of RASSF1 and 
PCDHGA12 promoters. 
2. To document the hemi-methylation induced by decitabine. 
3. To study the role of TET enzyme in active demethylation. 
5.3.1 Use of MiSeq hairpin sequencing to assess the RASSF1 and PCDHGA12 promoters 
in Jurkat cells. 
Bisulfite conversion and sequencing is the gold standard method for describing DNA 
methylation (Feng et al., 2011). However, standard bisulfite conversion techniques result in 
separation of double stranded DNA and amplification of one strand only. Therefore, to 
investigate the methylation state of both strands together during DNA synthesis requires the 
development of a novel experimental technique. RASSF1 and PCDHGA12 gene promoters have 
been reported to be highly methylated in haematological malignancies (Gordon et al., 2012; 
Taylor et al., 2007). The hairpin bisulfite technique with a barcoded hairpin linkers was 
developed to determine the symmetry of CpG sites for both complementary strands in the 
promoter regions of RASSF1 and PCDHGA12 genes similar to protocol described by (Laird et 
al., 2004). Hairpin linkers were designed to specifically binds the two DNA strand together, so 
the methylation pattern of both (parental and daughter) strands can be determined. 
The method is described in detail in chapter 3. In brief, the experiment was carried out on Jurkat 
cells. Jurkat cell DNA was digested with two different restriction enzymes SacI and BamHI 
and ligated with hairpin linkers. RASSFI and PCDHGA12 regions were then amplified using 




The experimental protocol requires two rounds of PCR, which allows tagging of the target 
amplicons with unique Illumina adapter sequences and enables multiplexing during sequencing 
of the pooled libraries. The libraries were sequenced on an Illumina MiSeq using Reagent Kit 
v3 (Illumina, San Diego, USA; 500 cycles) in paired-end mode. The output sequencing files 
were analysed using our established bioinformatics framework for hairpin DNA methylation 
analysis (details in chapter four). 
5.3.2 Methylation patterns of RASSF1 and PCDHGA12 promoters in Jurkat cells. 
The standard heatmap output of BiQ Analyzer represents the linear forms of the RASSF1 and 
PCDHGA12 hairpin reads, with methylated and unmethylated CpG sites represented as red and 
blue rectangles, respectively (Figure 5.10). Each column represents a CpG site and every row 
a single sequencing read, with each read being the linear form of the hairpin molecule. Each 
hairpin molecule most likely reflects a separate cell after PCR amplification. On the basis of 
the output of the BiQ Analyzer, the RASSF1 and PCDHGA12 hairpin sequences were shown to 
be heavily methylated in control/untreated Jurkat cells (Figure 5.10) (Figure 5.11), confirming 




Figure 5. 10. BiQ Analyzer output showing the methylation pattern in untreated Jurkat cells of 
the linearised hairpin of the RASSF1 promoter. Rows represent individual hairpin reads; 
columns represent CpG dinucleotides; blue rectangles – unmethylated CpGs; red rectangles – 








Figure 5. 11. BiQ Analyzer output showed the methylation pattern in untreated Jurkat cells of 
the linear form of the hairpin of the  PCDHGA12 promoter. Rows represent unfolded hairpin 
reads; columns represent CpG dinucleotides; blue rectangles – unmethylated CpGs; red 
rectangles – methylated CpGs; white rectangles – missing sequence information. 
 
5.3.3 Documentation of short-term decitabine induced hemi-methylation in the 
PCDHGA12 promoter. 
To study the impact of short-term effect of decitabine on the DNA methylation of Jurkat cells, 
the methylation pattern of the PCDHGA12 promoter was investigated in synchronised Jurkat 
cells treated with decitabine for 12 h compared to untreated control. Briefly, Jurkat cells were 
grown to a concentration of 1 x 106 /mL and synchronised in G1 phase by incubation with 2 
mM 2¢-deoxythymidine for 18 hours. Synchronised Jurkat cells were divided into two groups 
(control and decitabine) and released from cell cycle arrest by supplementation with 50 µM 2¢-
deoxycytidine. At the time of release, cells were treated either with or without 5 µM decitabine 
and the cells were harvested at different time points during DNA replication. In all experiments, 
decitabine was added at the time of cell release from synchronisation (0 h). 
With the hairpin bisulfite technique we monitored the changes in  DNA methylation in Jurkat 
cells during DNA synthesis. The percentage of hemi-methylated DNA strands gradually 
increased during DNA replication in a time dependent manner in synchronised Jurkat cells 
treated with decitabine compared to control.  
The heatmaps clearly show that decitabine induced a gradual increase in hemi-methylated DNA 




methylation is shown when one side of the hairpin is methylated and the other side is 
unmethylated (Figure 5.12).  
Based on the mechanism of decitabine, it was predicted hemi-methylation, but the hemi-
methylation never been clearly shown before in the literature. We clearly described the dynamic 
of decitabine mechanism and demonstrated a gradual increase in hemi-methylated DNA with 




Figure 5. 12. Representative example of decitabine-induced hemi-methylation in Jurkat cells, 
A) Heatmap output of PCDHGA12 promoter from synchronised Jurkat cells at time 0 h. B, C) 
One example showing increase in hemi-methylation with decitabine treatment during DNA 
replication in PCDHGA12 promoter compared to untreated control. The dotted line represents 
the location of the hairpin barcode. (red = methylated CpG, blue = unmethylated CpG, white = 
missing sequence).  
 
Interestingly, we were expecting fully hemi-methylated DNA reads at 12 h after inhibiting the 
DNMT1 by decitabine, as all the cells were initiated into the S phase. We observed 15~20% 
fully methylated hairpin reads at 12 h, this value represents the cells that did not respond to 




which still having the fully methylated strands, 2) death of the cell as a result of decitabine 
toxicity, 3) might be due to slow replication, 4) might be due to cellular repair mechanisms 
during decitabine treatment. No evidence of delay or cell cycle arrest was seen from cell cycle 
analysis at 12 h (see section 5.2.2), but we observed an increase in cell population in S phase at 
24 h in decitabine treated cells compared to untreated control, which might have reflected a  
slower replication process (Figure 5.6 c), or 5) incomplete synchronisation, meaning that some 
of the cells were not at the G1 phase, and might be passed the S phase to G2 or entered mitosis. 
To calculate the percentages of hemi-methylated hairpin reads, the binary methylation data (1, 
0 or x) were extracted from the BiQ Analyzer output result files using UNIX terminal scripts. 
Using an R script, the data were further analysed after “folding” the hairpin reads to calculate 
the methylation proportion of each hairpin read. The hairpin reads were classified based on the 
methylation pattern of the complementary CpGs sites as methylated, hemi-methylated or 




Figure 5. 13. Calculating the proportion of complementary CpG methylation by “folding” the 
binary methylation data. A) Linear binary methylation data. B) Folded binary methylation data. 
 
A sequence read was classified as ‘methylated’ when the proportion of methylated 
complementary CpGs ³ 0.51; ‘hemi-methylated’ if the proportion of hemi-methylated CpGs ³ 
0.51 and called ‘unmethylated’ if the proportion of unmethylated CpGs ³ 0.51. The percentage 
of fully methylated, hemi-methylated and unmethylated CpGs sites for each sample was 









Figure 5. 14. Percentage of hemi-methylated sequence reads following treatment with 
decitabine. Decitabine induced hemi-methylation of PCDHGA12 promoter in post-
synchronised Jurkat cells. The data presented are means of three replicates ± SEM.  
 
After 2 h, the hairpin reads displayed 4% fully hemi-methylated reads, which increased to 18% 
at 4 h, 35% at 6 h, 45% at 8 h and 65% at 12 h. Complete loss of methylation (active 
demethylation) was observed at 6 h time points with 7% fully unmethylated hairpin reads. 
5.3.4 Long-term impact of decitabine on methylation of the PCDHGA12 promoter. 
To validate the short-term impact of decitabine, and to investigate the long-term effect of a 
single dose of decitabine treatment, the experiment was repeated with extended timepoints. I 
performed this experiment in Prof Hampton’s laboratory (University of Otago, Christchurch) 
and the resulting cells were collected and transferred to the Morison lab for DNA extraction 
and sequencing. This experiment was conducted using the same protocol mentioned in section 
5.3.3. Three technical replicates were prepared and sequenced for each sample (replicates were 
prepared from genomic DNA with separate digestions and bisulfite conversions). The figures 
below show the methylation patterns of the PCDHGA12 promoter following decitabine 
treatment, compared to untreated control (Figure 5.15, Figure 5.16). 
The percentage of fully methylated, hemi-methylated and unmethylated strands was calculated 
for each sample and stacked plots for the three replicates were generated (Figure 5.9). The 
following figures show the changes in DNA methylation levels, especially the increase in hemi-
methylated reads in decitabine treated PCDHGA12 promoter compared to untreated control. 
The effect of decitabine appeared as early as 4 h after release, and increased with time for all 





Figure 5. 15. Heatmap outputs from BiQ Analyzer showing the methylation pattern of the 
PCDHGA12 promoter after decitabine treatment for up to 72 h. A) control Jurkat cells. B, C 
and D) show the results of three technical replicates.  
 
 
Figure 5. 16. Hairpin-based methylation of PCDHGA12 promoter following decitabine 
treatment for up to 72 h. A) control Jurkat cells. B, C and D) show the results of the three 





To show the distribution of methylation of reads within an individual sample, the methylation 
values for each sequence were extracted from the results file and plotted using a ‘violin-points’ 
plot. The plot presents the distribution methylation for each sample and provides a similar 
reflection of the methylation patterns as the heatmaps for the control and decitabine treated 




Figure 5. 17. CG methylation reads distribution of PCDHGA12 promoter through multiple 
timepoints among different groups of Jurkat cells. A) decitabine treated compared to, B) 
untreated control. The data correspond to Figure 5.9 B. The longitudinal lines are the means ± 
SEM. 
 
While short-term demethylation in response to decitabine treatment is mechanistically 
informative, we extended the treatment to examine the extent of long-term demethylation as a 





5.3.5 Long term exposure to single dose decitabine associated with methylation changes 
of PCDHGA12 promoter. 
To test the hypothesis that decitabine leads to long-term changes in methylation , we took three 
approaches, 1) we extended the decitabine treatment to 120h so that it would reflect several cell 
cycles after a single dose exposure, and measured the DNA methylation changes at 48 h, 72 h, 
96 h and 120 h; 2) we extended the experiment to primary cell lines Molt4, Nalm6 and HL60 
to confirm that the observations of decitabine-induced demethylation are widely applicable; 3) 
genome wide methylation (PBAT) was used to assess the global impact on methylation levels 
(Chapter Seven). 
To investigate the chronic effect of single dose of decitabine on the methylation patterns of 
PCDHGA12 promoter, synchronized Jurkat cells were incubated with 5 µM decitabine and 
proceeded through DNA synthesis by supplementation of 50 µM dC. Cells were collected at 0 
h, 2 h, 4 h, 6 h, 8 h and 12 h and furthermore at the extended timepoints 24 h, 48 h, 72 h, 96 h 
and 120 h after a single dose of decitabine at 0 h. Media was changed every two days. 
A substantial decrease in gene specific methylation of PCDHGA12 promoter was observed in 
decitabine treated cells. The decrease in methylation was associated with an increase in the 
percentage of hemi-methylated reads in cells treated with decitabine compared to control 
untreated cells (Figure 5.18). The amount of hemi-methylation reached 65% at 12 h. 
Interestingly, slight re-methylation on day three of decitabine free growth was observed. This 
re-methylation continued through days four and five of decitabine-free growth. These results 
were observed and confirmed ‘locally’ by gene specific methylation analysis (Figure 5.19) and 







Figure 5. 18. Gene specific demethylation and re-methylation in Jurkat cells. Heatmaps of 
sequencing results showing the methylation pattern of PCDHGA12 promoter at different 
timepoints in cells treated with decitabine compared to controls. Jurkat cells were treated with 




Figure 5. 19. Hairpin-based methylation of PCDHGA12 promoter in synchronised Jurkat cells 
over 120 h . A) methylation pattern of PCDHGA12 in untreated control cells, B) methylation 
pattern of PCDHGA12 in decitabine treated cells. This figure shows the same data as 5.18, but 




5.3.6 Impact of decitabine on RASSF1 promoter. 
To investigate the effect of decitabine on the methylation pattern of the RASSF1 promoter, 
RASSF1 hairpins were prepared according to the protocol detailed in Chapter Three. The hairpin 
bisulfite sequencing technique was used to demonstrate the methylation changes in the 
complementary CpG sites of the RASSF1 promoter. 
Similar to the methylation finding of the PCDHGA12 promoter, the RASSF1 promoter showed 




Figure 5. 20. Hairpin based methylation of the RASSF1 promoter in synchronised Jurkat cells 
treated with A) decitabine (5 µM)  for 24 h compared to B) untreated control cells. 
 
In this experiment, RASSF1 sequencing results showed that decitabine induced minor hemi-
methylation percentages of only 5% and 13% at the 2 h and 4 h timepoints, respectively. 
Interestingly, the percentage of hemi-methylated reads increased to 29% at 8 h, 40% at 12 h 
and 55% at 16 h compared to 0% in the control.  
5.3.7 Active DNA demethylation in synchronised Jurkat cells induced by decitabine.  
The hairpin bisulfite sequencing method was used to show methylation changes in both parental 
and daughter DNA strands and to explore active demethylation in RASSF1 promoter. Active 
demethylation can be interpreted from the hairpin results, and defined as a full removal of DNA 
methylation pattern of the two strands within an individual hairpin sequence. Surprisingly, 
decitabine displayed 50% of fully unmethylated reads in RASSF1 hairpin sequences as early as 
2 h and 6 h timepoints compared to control cells (Figure 5.21).The RASSF1 promoter 




replication times between these genes. The results are consistent with previous results obtained 




Figure 5. 21. Impact of decitabine in RASSF1 promoter methylation. A) BiQ Analyzer heatmaps 
for control and decitabine treated DNA samples at 2 h and 6 h post release of synchronisation. 
B) CpG based methylation of decitabine treated RASSF1 promoter at 2 h and 6 h post release 
of synchronisation compared to control. 
 
It is highly likely this demethylation is real. Firstly, contamination was excluded as each read 
has a hairpin barcode, and all hairpin sequences were unique. And secondly, Jurkat cells take 
20 h to complete one cycle of cell division (Fimognari et al., 2002)(Karina O’Connor 2009 
unpublished data), so it is highly improbable that Jurkat cells divided twice within 2 h of release 
from synchronisation. We propose therefore that the parent strand must have undergone active 
demethylation. This active demethylation was observed in some experiments but not in others; 
(section 6.4.8) discusses the factors that might affect the rate of active demethylation. 
Decitabine may have a direct impact on hemi-methylated strands by activating TET enzymes 
which enhance iterative oxidation of 5-mC to 5-fC, 5-caC or unmodified cytosine. 




epigenetic alterations and apoptosis in leukaemia cells (Shin et al., 2012). This is discussed in 
more detail in Chapter Eight. 
5.3.8 Low decitabine concentrations induce hemi-methylation in RASSF1 and 
PCDHGA12 promoters of Jurkat cells. 
Based on the results obtained from viability and toxicity experiment (Section 5.2.4), decitabine 
was found to be slightly toxic and associated with a reduction in cell viability at higher 
concentrations. To minimise the cytotoxicity, the concentration of decitabine was decreased 
from 5 µM to 1 µM. To test whether the lower decitabine concentration has an impact on DNA 
methylation, the methylation pattern of the complementary CpG sites at each of 16 CpG sites 
of RASSF1 and at each of 12 CpG sites of PCDHGA12  promoters were explored in Jurkat cells 
treated with 1 µM decitabine. Jurkat cells were synchronised with thymidine and released by 
adding fresh media loaded with 50 µM dC and low decitabine concentration compared to 
untreated control. Cells were harvested at 0, 4, 8, 12, 16 and 24 h after release from cell arrest. 
Similar to high dose decitabine, when administered at low doses, decitabine induced substantial 
changes in the methylation levels of RASSF1 and PCDHGA12 promoters. This effect was 
largely attributable to an increase in hemi-methylated hairpin reads compared to control 
untreated cells (Figure 5.22) (Figure 5.23).  
 
 
Figure 5. 22. Hairpin based methylation of RASSF1 promoter in synchronised Jurkat cells 








Figure 5. 23. Hairpin based methylation of PCDHGA12 promoter in synchronised Jurkat cells 
treated with A) decitabine (1 µM) for 24 h compared to B) control cells. 
 
5.3.9 Impact of decitabine on PCDHGA12 promoter of Molt4, Nalm6 and HL60 cell 
lines. 
Based on our observation on Jurkat cells, we expanded our scope of analysis by investigating 
the effect of decitabine on a further three leukaemia cell lines, Molt4, Nalm6 and HL60. The 
PCDHGA12 promoter was found to be densely methylated (details in Chapter Six) in these 
leukaemia cell lines.  
Molt4, Nalm6 and HL60 cells were arrested in G1 phase by incubation with 2 mM thymidine 
for 22 h. Cells were then washed twice and incubated with fresh media containing 0.5-1 µM 
decitabine and 50 µM dC. Cells were harvested at 0, 2, 4, 8, 12 and 24 h time-points following 
release from cell cycle arrest. PCDHGA12 hairpin molecules were prepared for each cell line 
according to standard protocol (details in Chapter Three). 
Decitabine induced demethylation was observed in the Molt4 and Nalm6 cell lines. Decitabine 
treatment elicited an increase in the proportion of hemi-methylated hairpin reads in both Molt4 
and Nalm6 cells (Figure 5.24-25 and Figure 5.26-27) compared to control cells. However, we 
did not observe any noticeable decitabine-dependent increase in hemi-methylated hairpin reads 
in HL60 cell line compared to control untreated cells, except the anomalous observation of 10% 






Figure 5. 24. Heatmap output of BiQ Analyzer showing the methylation pattern of the 
PCDHGA12 promoter in Molt4 cell lines treated with A) 1 µM decitabine for 24 h compared 




Figure 5. 25. Hairpin based methylation of PCDHGA12 promoter in synchronised Molt4 cells 








Figure 5. 26. Heatmap output of BiQ Analyzer showing the methylation pattern of the 
PCDHGA12 promoter in Nalm6 cell lines treated with A) 1 µM decitabine for 24 h compared 





Figure 5. 27. Hairpin based methylation of PCDHGA12 promoter in synchronised Nalm6 cells 






Figure 5. 28. Heatmap output of BiQ Analyzer showing the methylation pattern of the 
PCDHGA12 promoter in HL60 cell lines treated with A) 0.5 µM decitabine for 24 h compared 






Figure 5. 29. Hairpin based methylation of PCDHGA12 promoter in synchronised HL60  cell 






5.4 Validation of decitabine effect using publicly available methylation data. 
This part describes the DNA demethylation induced by decitabine and combined 
ascorbate/decitabine from relevant data extracted from publicly available human methylation 
data for RASSF1 and PCDHGA12 promoters. The publicly available data were analysed by a 
pipeline (ABC.RAP package) developed by a previous PhD student, Abdulmonem Alsaleh from 
the Morison laboratory. The program is composed of a list of R scripts that utilised basic R 
functions to identify differentially methylated genes in publicly available data using 450K 
methylation array analysis. Basically, the ABC.RAP pipeline applies Student’s T test and delta 
beta analysis to identify methylated genes that are both statistically significant different and 
have a minimum absolute difference in DNA methylation between two sets of samples such as 
treated and untreated control. 
Our methylation sequencing results obtained from short and long-term exposure experiments 
are consistent with the analysis obtained from publicly available human methylation datasets 
for densely methylated RASSF1 and PCDHGA12 promoters. Datasets from Tsai et al. (2012) 
was examined and analysed and their result was clearly consistent with our hairpin PCDHGA12 
results. They reported a global methylation changes following treatment of three leukaemia cell 
lines KG1A, KG1, and Kasumi-1 and breast cancer cell lines MCF7 with 10 nM decitabine 
(Tsai et al., 2012).  
Then, methylation data for RASSF1 and PCDHGA12 genes were analysed. There was a 
substantial decrease of DNA methylation in PCDHGA12 gene treated with 10 nM decitabine 
over 72 h in the four cell lines (Figure 5.30). The RASSF1 gene also showed a substantial 





Figure 5. 30. Publicly available data showing effect of decitabine on PCDHGA12 promoter 
methylation. DNA methylation changes of PCDHGA12 in KG1A, KG1 leukaemia cell lines 
and MCF7 breast cancer cell lines incubated with 10 nM decitabine over 72 h. Data extracted 





Kasumi-1 cell lines treated with 10 nM decitabine showed a decrease in DNA methylation of 
PCDHGA12 genes during the first three days of incubation, but by the 28th day of decitabine 
incubation, the methylation levels of the gene approached those observed prior to decitabine 
treatment (Figure 5.31). 
 
Figure 5. 31. Gene re-methylation in Kasumi-1 leukaemia cell line. Line plots show the 
proportion of DNA methylation for PCDHGA12 in Kasumi-1 cells treated with 10 nM 
decitabine over 28 days. Data extracted from Tsai et al. 2012. 
 
In addition, the ABC.RAP R package was used to analyse publicly available data from Öz et al. 
(2014). U937 acute myeloid leukaemia cells were treated with 100 nM decitabine for 24 h. 
Genomic DNA was extracted, sheared into 300 bp fragments, and  adapters were added and 
cluster generation was performed on the Illumina cBot and sequenced (Öz et al., 2014). The 
ABC.RAP R package analysis produces two plots. The first boxplot shows the median 
methylation value of U937 cells treated with 100 nM decitabine compared to control (Figure 
5.32), and the second plot shows the mean methylation and the difference in DNA methylation 
between decitabine treated and untreated control cells) for individual CpG sites within the 




Figure 5. 32. Global methylation level of U937 AML cells treated with 100 nM decitabine for 
24 h compared to control cells. The boxes show the median methylation of decitabine treated 







Figure 5. 33. Methylation difference between decitabine-treated U937 cells and untreated 
control cells. Upper panel: Mean DNA methylation for RASSF1 and PCDHGA12 promoters, 
red circles = decitabine treated and blue triangle = untreated control. Lower panel: The 
difference in DNA methylation for RASSF1 and PCDHGA12. 
 
Global DNA methylation levels declined from 80% and reached 40% in U937 cells line 
incubated with 100 nM decitabine for 24 h. The difference in DNA methylation (delta beta 
values) analysis showed that decitabine had a high demethylation impact on PCDHGA12 gene, 
and less on RASSF1 gene, due to the RASSF1 gene promoter being largely unmethylated in 
U937 cells. 
In addition, publicly available data extracted from (Imanishi et al., 2017) and analysed by the 
ABC.RAP package shows loss in DNA methylation in U937 cells incubated with 5 µM 







Figure 5. 34. Global methylation level of U937 cells treated with 5 µM decitabine for 24 h 
compared to untreated control cells. The boxes show the median methylation of decitabine 




Figure 5. 35. Global methylation level of U937 cells treated with 5 µM decitabine for 72 h 
compared to untreated control cells. The boxes show the median methylation of decitabine 





The objective of this chapter was to investigate the impact of decitabine on cell cycle 
progression and DNA methylation. Development of a novel method linking the two DNA 
strands together by a unique DNA hairpin linker permitted the study of methylation at 
complementary CpG sites, allowing the percentage of hemi-methylated strands to be 
determined. As a cytidine analogue, decitabine incorporates into DNA strands during 
replication and inhibits the methylation of the newly synthesised DNA strands by stopping the 
action of DNMT1. It has been shown that decitabine sensitivity depends on the expression of 
human equilibrative nucleoside transporters in the cell membrane, and that leukaemia cells 
lacking these nucleoside transporters are resistant to decitabine treatment (Damaraju et al., 
2012). Intracellularly, decitabine is activated through a series of phosphorylation steps to form 
‘decitabine triphosphate’ (5-aza-dCTP), which can be incorporated into DNA during DNA 
replication. This incorporated 5-aza-dCTP will covalently bind to and inactivate DNMT1, 
preventing maintenance methylation activity, resulting in DNA demethylation (Daskalakis et 
al., 2010; Oki et al., 2007).  
In this study we investigated the effect of different decitabine concentrations on the methylation 
and cell cycle progression of Jurkat cells. Most of the chemical assays are only allow measuring 
DNA methylation on one DNA strand, making this impossible to calculate the methylation 
percentages of complementary strands. The hairpin bisulfite sequencing assays were developed 
to simultaneously assess the impact of selected decitabine concentrations on the methylation of 
newly synthesised DNA in multiple leukaemia cell lines. Additionally, the hairpin assay was 
used to address the presence of hemi-methylation-enhanced active demethylation.  
Using the hypermethylated RASSF1 and PCDHGA12 promoters, we show clearly that 
decitabine induced rapid DNA demethylation in the RASSF1 promoter as early as 2 h and 6 h 
post release from synchronisation. The hairpin method efficiently monitored the changes in 
DNA methylation by displaying fully hemi-methylated and unmethylated individual hairpin 
reads in cells treated with decitabine at different timepoints, and proved that the selected 
decitabine concentrations significantly inhibited DNA methylation during DNA synthesis. 
Surprisingly, we observed completely unmethylated hairpin reads at 6 h after decitabine 
treatment. Normally, we would expect to observe complete unmethylation only after two 
consecutive cell cycles via the blockage of DNMT1, which is not possible within 6 h of release 




induced active demethylation (Gius et al., 2004); however their results were not repeated and 
the mechanism has not been outlined. 
In this study, we investigated the effect of decitabine on the cell cycle kinetics of synchronised 
Jurkat cells. We performed flow cytometric analysis to study the cell cycle progression of 
synchronised Jurkat cells following a single decitabine treatment. Flow cytometry analysis 
showed that synchronised cells treated with decitabine for 24 h progressed through the cell 
cycle slower than controls and that decitabine-treated cells remained in S-phase longer (Figure 
5.32 b,c). This observation corroborates previous published work stating that the incorporation 
of decitabine to DNA caused stalled replication forks and changes in the cell cycle of cells 











In cancer, locus-specific hypermethylation of DNA promoters leads to suppression and loss of 
function of tumour suppressor genes (Jones & Baylin, 2007). Methylation of DNA is controlled 
by the activity of DNA methyltransferase enzymes (DNMTs) which catalyse the addition of a 
methyl group to the C5 position of cytosine at CpG dinucleotide sites. Initially, the methylation 
was considered as non-reversible until the discovery of TET (Ten-Eleven Translocation) 
dioxygenases that act as the key mediators of active demethylation. TET enzymes are Fe2+ and 
2-oxoglutarate-dependent dioxygenases that modify DNA methylation by initiating active 
demethylation through oxidation of 5-methylcytosine to 5-hydroxymethylcytosine (Tahiliani et 
al., 2009). Furthermore, TET enzymes catalyse the iterative oxidation of 5-
hydroxymethylcytosine to 5-formylcytosine and 5-carboxylcytosine which are ultimately 
replaced with unmodified cytosine by the activity of thymine-DNA glycosylase (TDG) and 
base excision repair (Ito et al., 2011). 5-hydroxymethylcytosine deficiency is a hallmark 
epigenetic feature of many cancers (Delatte et al., 2014; Lian et al., 2012). 
Ascorbate serves as a co-factor for TET enzymes by regenerating the essential cofactor, Fe2+. 
Ascorbate catalyses the redox reaction of inactive Fe3+ to the catalytically active Fe2+ (Young 
et al., 2015). Interestingly, ascorbate dramatically modifies the status of DNA methylation of 
mouse embryonic fibroblasts (MEFs) by generation of 5-hydroxymethylcytosine (Minor et al., 
2013).  
Decitabine is an epigenetic therapeutic compound that is used in the treatment of 
myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Decitabine acts as a 
DNMT inhibitor by incorporating into the newly synthesised DNA strands and binding 
DNMT1 during cell division. Upon binding, DNMT1 is degraded resulting in loss in activity 
and hypomethylation. 
In this study, we investigated the role of ascorbate alone or in combination with decitabine on 




effects, we aimed to determine whether additive or synergistic effects on DNA methylation can 
be achieved when exposing cells to a DNMT1 inhibitor combined with ascorbate.  
6.1.1 Hypothesis and experiments design. 
The experiments were designed to address the following hypotheses: 
1. In synchronised Jurkat cells, the complementary CpG sites of tumour suppressor gene 
promoters RASSF1 and PCDHGA12 are always densely methylated. 
2. Due to inhibition of DNMT1, CpG demethylation of the newly synthesised daughter strands 
should be observed in decitabine-treated Jurkat cells. 
3. In ascorbate-treated Jurkat cells, sporadic complementary CpG demethylation should be 
noted due to upregulation of TET enzymes. 
4. In Jurkat cells treated with a combination of ascorbate and decitabine, rapid CpG 
demethylation of both parental and daughter strands should be observed due to 
enhancement of TET activity, by the presence of hemi-methylated DNA and the 
upregulation of TET enzymes. 
6.1.2 The main aims of this chapter. 
1. To investigate the short and long-term effects of combined decitabine and ascorbate on gene 
specific methylation. 
2. To develop a novel method to measure the percentages of hemi and demethylation in newly 
synthesised DNA strands. 
3. To compare the effects of different reagents on methylation between synchronised and 
unsynchronised leukaemia cell lines. 
4. To determine the effect of combined decitabine and ascorbate on cell cycle progression. 
5. To estimate the effects of different decitabine concentrations and ascorbate concentrations 
on DNA methylation. 
 
6.2 Quantification of intracellular ascorbate concentrations. 
6.2.1 Preparation for ascorbate experiments. 
To examine the effect of ascorbate on upregulating TET activity, ascorbate intracellular levels 
were measured in Jurkat cells in culture. Jurkat cells were treated with different ascorbate 
concentrations (250 or 500 µM) during synchronisation (18 h). Figure 6.1 shows the 




during a thymidine block. The cells were not refreshed with ascorbate when media was replaced 




Figure 6. 1. Intracellular ascorbate concentration. Jurkat cells loaded with 250 µM ascorbate 
for 18 h during thymidine block, were not refreshed when media replaced. Data are means ± 
SEM of two independent experiments. 
 
The Jurkat cells showed lower intracellular ascorbate concentration at the 6 h timepoint and 
failed to reach the intracellular ascorbate concentration levels achieved by Kuipers et al., 
(2014). The concentration of ascorbate was increased to 500 µM overnight during the thymidine 
block, and ascorbate was included in the media when the cells were released to cell cycle 
(Figure 6.2). Interestingly, in Jurkat cells treated with 500 µM ascorbate the intracellular 
ascorbate concentrations were increased significantly and cells maintained these levels at 6 h.  
In general, culture media is ascorbate deficient and hence cancer cells growing in culture reflect 
an ascorbate deficiency state. In accord with this, intracellular ascorbate concentration is 















































Figure 6. 2. Intracellular ascorbate concentration. Jurkat cells loaded with 0, 250, 500 µM 
ascorbate for 18 h during thymidine block. Cells were refreshed with ascorbate at a time 0 h.  
 
Next, the total and reduced forms of intracellular ascorbate concentrations in Jurkat cells treated 
with ascorbate was measured.  
Cells were preloaded with 500 µM ascorbic acid for 18 h, cells were refreshed with fresh media 
loaded with 500 µM ascorbic acid at time 0 h. Treated and untreated control cells were 
harvested at different timepoints 0 h, 4 h , 8 h and 12 h (Figure 6.3). Cells were collected and 
washed with PBS, and the cell pellets were transferred to laboratory of Professor Vissers 
(University of Otago, Christchurch) for intracellular ascorbate measurement according to 
standard  protocol (details in Chapter Three).  
Cell culture media contains no ascorbate, and supplementation optimises intracellular total and 
reduced ascorbate concentrations. We maintained sufficient intracellular ascorbate levels in the 
cells; both total and reduced ascorbate forms were increased at increasing timepoints after 
ascorbate treatment. The reduced form of ascorbate reduces Fe3+ to Fe2+ which can act as a co-














Jurkat cells loaded with 250 uM or 500 uM ascorbate for 18h with thymidine block. Cells 





























Figure 6. 3. Intracellular total and reduced ascorbate concentrations. Jurkat cells were loaded 
with 0 or 500 µM ascorbate for 18 h during thymidine block. Cells were refreshed with 0 or 
500 µM ascorbate at the time of release from thymidine.  
 
6.3 Cell viability following exposure to ascorbate/decitabine. 
6.3.1 Cell cycle analysis.  
Jurkat cells were grown to a concentration of 1 million/mL and synchronised by thymidine 
block for 18 h. To investigate the effect of ascorbate or combined ascorbate and other reagents 
on cell cycle progression, the treated Jurkat cells were collected, fixed with 70% ethanol and 
stained with propidium iodide (PI) and analysed using flow cytometry to measure the DNA 
content at different time points (details in Chapter 5). The experiment was conducted three 
times at different timepoints. 
Short term exposure to 250 and 500 µM ascorbate or in combination with decitabine had no 
marked effect on cell cycle progression compared to untreated control cells (Figure 6.4 a, b, c). 
Interestingly, growth arrest with an increase in the number of Jurkat cells in S phase were seen 
following 24 h incubation with ascorbate and decitabine, compared to untreated control (Figure 
6.4 d). This suggests that incorporation of decitabine into the DNA of treated cells delayed 
DNA replication and cells remained longer in S phase, which resulted in increased cell 










Figure 6. 4. Cell cycle analysis of synchronised Jurkat cells. A) Cell cycle progression of cells 
treated with 250 μM ascorbate and combined ascorbate with decitabine for up to 6 h compared 
to controls; B) Cell cycle progression of cells treated with 500 μM ascorbate and combined 
ascorbate with decitabine for up to 6 h; C) Cell cycle progression of Jurkat cells treated with 
500 μM ascorbate and combined ascorbate/decitabine for up to 72 h; D) Enlargement of the 
untreated control and combined ascorbate/decitabine figures from the labelled figure c. All cells 





6.3.2 Induction of cell cycle arrest and inhibition of cell division was enhanced by 
combined treatment of decitabine and ascorbate. 
To determine the effect of combined decitabine and ascorbate treatment on the cell cycle 
progression and cell division, four leukaemia cell lines were tested. The replication time of the 
four cell lines was different, and to ensure that all were arrested in G1 phase, the duration of 
synchronisation by thymidine was increased to 22 h. Jurkat, Molt4, Nalm6 and HL60 were 
synchronised for 22 h by thymidine block, and cells were released with fresh media 
supplemented with 50 μM dC. For the ‘ascorbate’ group, ascorbate was added to a final 
concentration of 500 μM during synchronisation and to the media at thymidine block release. 
Based upon the decitabine toxicity results above (section 5.4.4), the concentration of decitabine 
was lowered from 5 μM to 1 μM for Jurkat, Molt4 and Nalm6 cells and to 0.5 μM for the HL60 
cell line. The effects of decitabine and ascorbate on cell viability were compared in these of 
four cell lines.  
Decitabine reduced the number of viable cells at 24 h by 20% in three cell lines (Jurkat, Molt4 
and Nalm6) and by 10% in HL60. However, the cytotoxic effect was enhanced with the addition 
of 500 µM of ascorbate, with enhancement of 45% in Jurkat cells and approximately 20% in 
Molt4 and Nalm6. In contrast, No additional cytotoxic effect was observed in HL60 cells with 




Figure 6. 5. Effect of decitabine and ascorbate on cell viability. Cell survival measurement 
following incubation with different reagents. Cell survival was determined by trypan blue 
staining. Values are means of three counts. The starting number of cells for Jurkat, Molt4 and 





6.4 DNA methylation profile following ascorbate/decitabine treatments. 
6.4.1 Impact of different ascorbate concentrations on the DNA methylation of 
PCDHGA12 promoter. 
To study the impact of different ascorbate concentrations on promoter DNA methylation, 
synchronised Jurkat cells were incubated with different ascorbate concentrations during cell 
cycle progression, and collected at -18 (unblocked), 0, 4, 8, 12 and 24 h. 
Treatment with 0, 100, 250, 500 μM ascorbate at different time points had little effect on DNA 
methylation of PCDHGA12 promoter compared to untreated Jurkat cells, the figure below 
shows the mean methylation from the hairpin bisulfite MiSeq results for PCDHGA12 promoter 




Figure 6. 6. Impact of ascorbate on 5-mC percentages of PCDHGA12 promoter. Jurkat cells 
were exposed to increasing concentrations of ascorbate for 24 h. Effects of different ascorbate 
concentrations on the mean methylation of PCDHGA12 promoter were assessed.(-18 
unblocked, 0 blocked +18). 
 
Our results were consistent with a previous study by Gerecke et al. which demonstrated that 
treatment with ascorbate alone had no significant effect on global 5-methylcytosine levels in 
HCT116 cells (Gerecke et al., 2018). 
6.4.2 Visualisation of hairpin MiSeq sequencing data. 
We designed the hairpin bisulfite sequencing assay to provide information about the 
methylation status of the complementary DNA strands as the position of the hairpin barcode 




status, the binary methylation data of linearised hairpin sequences were extracted from the 
results file of BiQ Analyzer HT. Each sequence contains the aligned CpG sites across the arms 
of the hairpin molecule. The methylation of CpG sites at each arm of the hairpin are represented 
by lollipops and plotted next to each other (black lollipops are methylated and white are 
unmethylated) (Figure 6.7). To evaluate the methylation status of each hairpin read, hairpin 
sequences were folded to superpose the complementary CpG sites (details in Chapter 4), and 
the percentages of methylated, hemi-methylated or unmethylated complementary CpG sites 
were calculated (Figure 6.7). The CpG sites were classified as methylated (mCpG/mCpG) if the 
two complementary CpG sites were methylated; hemi-methylated (mCpG/CpG or CpG/mCpG) 
if one of the complementary CpG site was methylated and the other is unmethylated; or 




Figure 6. 7. Schematic visualisation of the hairpin molecule.  
 
6.4.3 Surprising active DNA demethylation of RASSF1 promoter caused by decitabine 
and ascorbate. 
The main aim of this experiment was to confirm the surprising active demethylation resulting 
from decitabine treatment observed using a very low throughput technique by the Morison 





Notably, the control samples in these experiments displayed stable hypermethylation of 
RASSF1 and PCDHGA12 promoters with little sporadic occurrence of unmethylated CpGs. To 
explore the DNA methylation changes in complementary CpG sites, hairpin DNA molecules 
were prepared from synchronised Jurkat DNA treated with different reagents (ascorbate, 
decitabine and combined ascorbate/decitabine), and the percentages of methylated, hemi, and 
unmethylated hairpin sequences were calculated. 
Briefly, Jurkat cells were arrested in G1 phase by single thymidine block, divided into two 
groups and incubated with or without 500 μM ascorbate. Cells were initiated into cell cycle 
progression by incubation with 50 μM dC and simultaneously treated with 5 μM decitabine, 
500 μM ascorbate or combinations of decitabine and ascorbate. Cells were harvested for 
genomic DNA at 0, 2, 4 and 6 h timepoints. RASSF1 hairpin molecules were prepared using 
the modified hairpin technique (detailed in Chapter 3). 
The experiment was designed to explore active demethylation by monitoring the DNA 
methylation changes across the complementary DNA strands of the RASSF1 promoter using 
the hairpin technique. Surprisingly, the RASSF1 promoter treated with decitabine and combined 
ascorbate/decitabine exhibited a massive reduction in DNA methylation at 2 and 6 h, by 49% 
and 67% respectively (Figure 6.8). Decitabine is known as a specific DNMT1 inhibitor that 
generates unmethylated daughter strands during DNA replications. We were expecting to see 
an increase in the hemi-methylated reads in cells treated with decitabine. The substantial change 
in DNA methylation was due to a complete demethylation of both DNA strands as early as 2 h 
and 6 h after release from synchronisation. It is most likely that the rapid effects of decitabine 
skipped the appearance of hemi-methylation status during DNA replication, by rapidly inducing 
demethylation of the parent strands. 
Interestingly, adding ascorbate to decitabine enhanced demethylation, with the RASSF1 
promoter showing a dramatic loss of methylation in ascorbate (62%) and combined 
ascorbate/decitabine treated (78%) cells at 6 h. The results displayed fully unmethylated hairpin 
reads, in which parental strands were demethylated. As synchronised Jurkat cells require 8-10 
hours to complete interphase (S and G2 phases) and then proceed to cell division (Fimognari et 
al., 2002), it is improbable that Jurkat cells had replicated their DNA  twice in 6 h; therefore 








Figure 6. 8. CpG based methylation of RASSF1 promoter at 2 and 6 h. Synchronised Jurkat 
cells were treated with decitabine, ascorbate and combined ascorbate/decitabine, or untreated. 
A) 2 h timepoint: Loss of DNA methylation in cells treated with decitabine and combined 
ascorbate/decitabine, B) 6 h timepoint: dramatic loss in DNA methylation in Jurkat cells treated 
with ascorbate and combined ascorbate/decitabine compared to untreated control. 
 
To confirm these surprising demethylation results, the experiments were repeated with a single 
dose treatment of ascorbate during thymidine block, and the hypermethylated PCDHGA12 




6.4.4 Short-term treatment of single dose ascorbate/decitabine induced active 
demethylation in PCDHGA12 promoter of Jurkat cells. 
To test the ability of ascorbate to upregulate TET activity and induce active DNA demethylation 
in Jurkat cells, we assessed the methylation changes in PCDHGA12 promoter of Jurkat cells 
treated with a single dose of ascorbate during cell cycle synchronisation. PCDHGA12 hairpin 
molecules were prepared from DNA from synchronised Jurkat treated with a single dose of 500 
μM ascorbate alone during thymidine block or combined with 5 μM decitabine at time 0 h. 
After synchronisation, cells were refreshed with new media without adding ascorbate. Cells 
were divided into four groups; control, ascorbate, decitabine and the combination of 
ascorbate/decitabine. Cells were initiated into cell cycle by supplementation with 50 μM dC. 
The treatments and the tissue culture work were done by Dr Karina O’Connor in (Prof Hampton 
laboratory, Christchurch), cell pellets were transported to the Morison laboratory for 
sequencing and further analysis. DNA extraction, digestion, ligation, bisulfite conversion and 
two sets of PCR for MiSeq sequencing were done in Morison laboratory. 
Figure 6.9 shows the relative proportions of methylated, hemi-methylated and unmethylated 
hairpin reads within the PCDHGA12 promoter region. At 6 h after treatment with decitabine, 
15% of reads showed unmethylation and 15% showed hemi-methylation. Hemi-methylation 
was also observed at 2 and 4 h. Cells preloaded with ascorbate alone during thymidine block 
(for 18 h) showed 13% unmethylated reads in the PCDHGA12 promoter. Furthermore, 
ascorbate treated cells showed and an increase in the percentage of unmethylated reads in the 
PCDHGA12 promoter by 13%. Furthermore, 12-14% hemi-methylated and unmethylated 
reads, respectively, were seen at 6 h after release from cell synchronisation (Figure 6.9). 
Notably, when ascorbate was added in conjunction with decitabine, evidence for upregulation 
of TET-mediated active demethylation was seen. Co-administration of ascorbate with 
decitabine increased the percentage of hemi-methylated reads to 50% at the 4 h timepoint. 
Interestingly, the combination  of ascorbate/decitabine induced 40% unmethylation and 33% 
hemi-methylated at 6 h. The observed active demethylation likely occurred due to generation 








Figure 6. 9. Hairpin based methylation of PCDHGA12 promoter in Jurkat cells treated with 500 
μM ascorbate, 5 μM decitabine and combinations of ascorbate/decitabine compared to control 
untreated. The left panels show the proportions of methylated, hemi-methylated and 
unmethylated hairpin reads. The right panels show the corresponding heatmap output of BiQ 
Analyzer. 
 
6.4.5 Impact of ascorbate/decitabine on the methylation pattern of PCDHGA12 
promoter in Jurkat cells over 72 h. 
While the demethylation in response to decitabine is mechanistically informative, we wished 
to examine the role of TET enzymes in long-term exposure of ascorbate. We investigated the 
long-term effect of ascorbate/decitabine on methylation of PCDHGA12 and RASSF1 




were prepared for RASSF1 and PCDHGA12 molecules from Jurkat DNA treated with ascorbate 
or/and decitabine at different timepoints. Briefly, Jurkat cells were synchronised for 18 h by 
thymidine block, preloaded with 0 or 500 μM ascorbate. At the time of release, cells were 
divided into groups and incubated with fresh media loaded with 1) 500 μM ascorbate; 2) 5 μM 
decitabine; 3) combined ascorbate/decitabine and 4) control untreated. Cells were harvested at 
0, 4, 6, 24, 48 and 72 h. Cell viability was measured for all the groups during the experiment.  
Upon treatment with ascorbate alone, the methylation levels of the PCDHGA12 promoter was 
similar to that of the untreated control, although ascorbate was associated with demethylation 
of both strands of the PCDHGA12 DNA 10% at 6 h (Figure 6.10). Application of decitabine 
resulted in an increase in the hemi-methylated PCDHGA12 hairpin reads compared to control 
cells (Figure 6.10 c). The addition of ascorbate to decitabine did not alter the demethylating 
effect of decitabine; co-treatment with ascorbate slightly increased the proportion of hemi-




Figure 6. 10. Impact of ascorbate/decitabine on DNA methylation of Jurkat cells. Hairpin based 
methylation of PCDHGA12 promoter following single or combined treatment. A) control 
untreated cells; B) cells treated 500 μM ascorbate; C) cells treated with 5 μM decitabine and 





To further elucidate the mechanism of DNA methylation loss in cells treated with 
ascorbate/decitabine, three technical replicates for PCDHGA12 were performed for treated and 
control samples. Using the same DNA samples as the above experiment, MiSeq libraries were 
prepared and sequenced from new BamHI digestions, PCDHGA12 hairpin linker ligations, 
bisulfite conversions and PCR amplifications.  
In the technical replicates, decitabine alone led to a similar increase in hemi-methylated DNA 
reads in a time dependent manner (Figure 6.11). The combined treatment of 
ascorbate/decitabine led to increases in the proportion of completely unmethylated DNA 




Figure 6. 11. Effect of ascorbate/decitabine on DNA methylation of PCDHGA12 promoter. 
One of the technical replicates to verify the methylation changes in PCDHGA12 promoter 
observed in figure 6.10. 
 
To show the methylation value for all sequences within an individual sample for treated cells 
and untreated controls at different timepoints, we constructed both box and scatter plots. The 
box plot below shows median methylation for each sample at different timepoints (Figure 6.12). 
Furthermore, the scatter plot was constructed to show the methylation distribution for each 




allows the visualisation of methylation of every single reads within individual sample; however 




Figure 6. 12. Boxplots shows the median methylation of PCDHGA12 in each sample of treated 
Jurkat cells at different timepoints compared to untreated control. Three technical replicates at 




Figure 6. 13. Scatter plot shows the methylation of each read of PCDHGA12 within individual 






6.4.6 Impact of long-term effects of ascorbate/decitabine on methylation pattern of 
RASSF1 promoter. 
To verify the reproducibility of the results obtained above, and to determine whether the 
demethylation phenomenon is observed in other genomic areas, the densely methylated 
RASSF1 promoter was examined. 
To investigate the impact of ascorbate and ascorbate together with decitabine on the 
methylation of the RASSF1 promoter, similar methylation analysis was performed for the 
RASSF1 promoter. 
DNA methylation was determined using the protocol described previously (Chapter 5). Briefly, 
Jurkat DNA was digested with SacI and ligated to RASSF1 hairpin linkers followed by two 
PCR amplification steps and sequencing. Figure 2.16 shows the methylation patterns of treated 
RASSF1 hairpin molecules at 0, 2, 4, 6, 24 and 48 h timepoints compared to untreated controls. 
Similarly to PCDHGA12 promoter, RASSF1 promoter showed loss of methylation in decitabine 
and combined ascorbate with decitabine treated cells compared to untreated controls. Ascorbate 
alone induced minimal effects on methylation, while decitabine increased the proportion of 
hemi-methylated reads in time-dependent manner. As before, adding ascorbate to decitabine 
treatment resulted in an increase in the proportions of hemi-methylated and unmethylated reads 
at increasing timepoints compared to decitabine alone (Figure 6.14). A small increase in the 
number of unmethylated reads was observed in untreated and ascorbate treated samples. It was 








Figure 6. 14. Hairpin based analysis of RASSF1 promoter methylation. A) control untreated 
cells; B) cells treated 500 μM ascorbate; C) cells treated with 5 μM decitabine and D) cells 
treated with combined ascorbate/decitabine.  
 
6.4.7 Demethylation and re-methylation response to ascorbate/decitabine treatments. 
To elucidate the chronic effect of ascorbate alone or combined ascorbate/decitabine on the 
demethylation and re-methylation dynamics of the PCDHGA12 promoter, Jurkat cells were 
synchronised and incubated with a single dose of ascorbate or combined ascorbate/decitabine. 
Cells were released from thymidine block and collected at 0 , 2, 4 , 6 h, 12, 24, 48, 72, 96 and 
120 h. The complementary CpG methylation changes were investigated and assessed (Figure 
6.15). Following treatment of Jurkat cells with decitabine and ascorbate, the cells showed a 
substantial decrease of PCDHGA12 methylation over 72 h compared to untreated controls. By 
the fifth day of additive free growth, re-methylation of the PCDHGA12 promoter was observed. 
Nonetheless, cells treated with decitabine or combined ascorbate/decitabine still had lower 







Figure 6. 15. PCDHGA12 gene specific demethylation and re-methylation in Jurkat cells. Cells 
treated with a single dose decitabine or combined ascorbate/decitabine exhibited demethylation 
after treatment. Re-methylation occurred over the 72 h to 120 h timepoints. 
 
The complementary CpG methylation was analysed for each sample, reads were classified as 
methylated, hemi-methylated or unmethylated (section 4.5.2, Chapter 4) and proportions of 
each were plotted (Figure 6.16).  
The gene specific results were verified by global methylation analysis using low coverage 
methylation analysis (PBAT). The PBAT libraries were prepared from the same batch of 
genomic DNA, and sequenced and analysed using the standard protocol (Chapter 7). Global 
DNA methylation results were consistent with the locus-specific methylation results (Figure 
6.16), showing gradual loss of DNA methylation with increasing timepoints in cells treated 








Figure 6. 16. The proportion of hemi-methylated/unmethylated or methylated PCDHGA12 




Figure 6. 17. Global CpG methylation levels (%) of Jurkat DNA treated with decitabine, 
ascorbic acid and combined ascorbic acid and decitabine for 120 h compared to control cells. 
 
 
6.4.8 Summary and conclusion to this point. 
With the power of the hairpin bisulfite technique, we were able to document the kinetics and 
pattern of DNMT1 inhibitor (decitabine) treatment with unparalleled clarity and detail. It was 
expected that decitabine would enhance hemi-methylation during DNA synthesis and we 




demethylation of promoters or evidence of active demethylation which was never seen in 
untreated controls. However, these results were inconsistent and active demethylation was not 
always observed. For example the experiment shown in (Figure 6.8) shows substantial 
unmethylation, whereas minimal unmethylation is seen in Figure 6.15. 
Numerous potential reasons were considered to explain the inconsistent and variable 
demethylation results. First we considered PCR and sequencing artefacts. PCR bias can be 
excluded as only reads with unique hairpin barcodes are aligned during sequencing analysis; 
i.e. each fragment of cellular DNA was represented only once on the final output. Additionally, 
sequencing artefacts can be excluded, as we confirmed the precision and the reproducibility by 
repeating the DNA sequencing for technical replicates and similar mean methylation was 
observed for the technical replicates confirming the reproducibility of the MiSeq sequencing 
(Figure 4.16). 
While we could exclude PCR bias and sequencing artefacts, many other potential experimental 
variables that could affect demethylation should be examined such as the type of culture media, 
iron and alpha-ketoglutarate concentrations or the synergism of these variables. We decided to 
explore the culture conditions and different media components as a possible answer for this 
results variation. Different culture media contain different minerals and essential metals. 
Interestingly, Fe2+ is present at higher concentration in DMEM media, whereas alpha-
ketoglutarate is a component of RPMI+glutamax media. These  two compounds are co-factors 
for TET enzymes, and play a key role in upregulating TET activity and induction of active 
demethylation. 
6.5 Does culture media affect DNA methylation? 
We investigated the effect of different reagents on the methylation of RASSF1 and PCDHGA12 
promoters in Jurkat cells grown in three different culture media: RPMI 1640 (basic culture 
media), DMEM (provides Fe2+) and RPMI+glutamax (provides alpha-ketoglutarate). RASSF1 
and PCDHGA12 hairpin molecules were prepared from treated and untreated genomic DNA at 
different timepoints and sequenced. 
6.5.1 Comparison of RPMI 1640 vs DMEM. 
To better understand the role that different media and their compositions can have in 
modulating DNA methylation, Jurkat cells were grown in different culture media and the effect 




Towards this goal, we compared the methylation of RASSF1 and PCDHGA12 promoters in two 
different batches of Jurkat cells grown in parallel using either RPMI and DMEM. Jurkat cells 
that were used in this study were obtained from either Prof Morison (Dunedin) or Prof Hampton 
(Christchurch). 
6.5.2 Jurkat cells obtained from Dunedin. 
In this experiment we compared the effect of different media on the methylation of RASSF1 
and PCDHGA12 promoters in Jurkat cells obtained from Dunedin laboratories. Briefly, Jurkat 
cells were grown in RPMI or DMEM media. Cells were synchronised by thymidine block for 
18 h, and the cell cycle was initiated by incubation with 50 μM dC. At the time of release cells 
were treated with 500 μM ascorbate, 5 μM decitabine or the combination of ascorbate with 
decitabine (details in Chapter Three). Cells were harvested at 0, 4, 6 and 12 h. Then, RASSF1 
and PCDHGA12 hairpin molecules were prepared from treated and untreated genomic DNA 
(protocol in Chapter Three) and sequenced for DNA methylation analysis. Heatmap outputs of 
BiQ Analyzer showed a high similarity of RASSF1 methylation pattern between the two media 
(Figure 6.18). The proportions of methylated, hemi and unmethylated hairpin reads were 
calculated for each sample at different timepoints for the two experiments (Figure 6.19). We 
conclude that media compositions had no impact on the effect of ascorbate or decitabine 








Figure 6. 18. Methylation of RASSF1 promoter in Jurkat cells grown in two different media, 





Figure 6. 19. The proportion of hemi-methylated/unmethylated or methylated RASSF1 hairpin 





Similarly, the methylation of the PCDHGA12 promoter was examined. PCDHGA12 showed 
little methylation differences between the two media. Interestingly, loss of methylation in 
ascorbate and combined ascorbate/decitabine treated DNA samples was observed at 4 h in cells 
grown in DMEM (Figure 6.20). The proportions of unmethylated hairpin reads were increased 
in cells grown in DMEM media and treated with ascorbate and combined ascorbate/decitabine 
at 4 h (Figure 6.21). Active demethylation represented by complete unmethylated PCDHGA12 
hairpin reads were observed in cells treated with ascorbate and combined ascorbate /decitabine 
at 4, 6 and 12 h timepoints in cells grown in both media. DMEM media provides 0.25 µM 
(ferric nitrate). Adding ascorbate to the DMEM culture media converts the oxidised inactive 
Fe3+ to the reduced active Fe2+ which acts as a co-factor for TET to induce active demethylation. 
Because the level of iron in fetal calf serum (FCS) is not consistent and varies between 
manufacturers, and DMEM media contains iron, we conclude that DMEM media might 




Figure 6. 20. Methylation of PCDHGA12 promoter in Jurkat cells grown in two different media, 







Figure 6. 21. The proportion of hemi-methylated/unmethylated or methylated PCDHGA12 
hairpin reads in Jurkat cells. Comparison of RPMI and DMEM media.  
 
6.5.3 Jurkat cells obtained from Christchurch. 
We then compared the methylation pattern of PCDHGA12 promoter in Jurkat cells obtained 
from Christchurch to determine if the variability in demethylation was related to differences in 
the cell lines. We conducted two experiments in parallel with RPMI and DMEM media. Jurkat 
cells were obtained from Prof Hampton’s laboratory (Christchurch). The cells were 
synchronised (detailed protocol in Chapter Three) and divided into groups. Cells were treated 
with 500 μM ascorbate and 5 μM decitabine or combined ascorbate with decitabine compared 
to untreated control. Cells were harvested at 0, 2, 4, 6, 12 and 24 h.  
There were no differences in the methylation patterns of Christchurch Jurkat cells at the 
PCDHGA12 promoter for cells grown in RPMI or DMEM (Figure 6.22). Cells grown in RPMI 
media displayed a slight increase in the proportion of hemi/unmethylated hairpin reads when 
treated with decitabine and combined ascorbate/decitabine compared to the other media. These 
differences, however, were comparable to those seen between technical replicates as discussed 







Figure 6. 22. The proportion of hemi-methylated/unmethylated or methylated PCDHGA12 
hairpin reads in Jurkat cells obtained from Christchurch. Comparison of RPMI and DMEM 
media.  
 
6.5.4 Comparison of PCDHGA12 methylation in Jurkat cells grown in RPMI Glutamax 
vs RPMI 1640. 
To investigate whether the changes in DNA methylation are dependent on media composition, 
we studied the methylation pattern of PCDHGA12 promoter in Jurkat cells grown in two 
different media, RPMI+glutamax and RPMI 1640. Glutamax media is characterised by 
supplementation with L-glutamine and L-alanine amino acid. Glutamine is an essential nutrient 
for energy production and source of nitrogen for nucleic acid synthesis.  
The two culture media were supplemented with 10% FCS and were investigated in parallel. 
Jurkat cells (Christchurch) were grown, synchronised (details in Chapter Three) and treated in 
standard conditions.  
The methylation pattern of the PCDHGA12 promoter showed no marked differences between 




PCDHGA12 methylation levels in both media (Figure 6.23). We therefore conclude that the 





Figure 6. 23. Methylation of PCDHGA12 promoter in Jurkat cells grown in either RPMI 
Glutamax or RPMI 1640 and treated with different reagents. 
 
6.6 Thymidine synchronisation vs unsynchronisation: effect on demethylation. 
6.6.1 Comparing the effect of synchronised and unsynchronised cells on DNA 
methylation. 
Cells grown in culture exist at all stages of the cell cycle. Cell synchronisation refers to bringing 
cells into the same stage of the cell cycle; for example, excess thymidine will inhibit DNA 
synthesis and cells will be synchronised to the G1 phase. 
In this experiment, two batches of Jurkat cells were prepared to examine if cell synchronisation 
has an impact on the effect of decitabine and ascorbate on DNA methylation. This was an 
attempt to understand the active demethylation using a simplified work stream and fewer 
variables. The experiments were conducted in duplicate.  
Briefly, in the first group, Jurkat cells were synchronised for 22 h with and without ascorbate. 
At the time of release, cells were divided into four subgroups: untreated control; 1 μM 
decitabine; 500 μM ascorbate and combined ascorbate/decitabine. In the second group 




μM ascorbate and combined ascorbate/decitabine. Cells were harvested at 0, 4, 8, 12, 16 and 
24 h. PCDHGA12 hairpin molecules were prepared from DNA for all samples at all timepoints. 
Interestingly, dramatic differences in the methylation pattern of the  PCDHGA12 promoter 
treated with ascorbate/decitabine were observed between synchronised and unsynchronised 
treated Jurkat cells. Synchronised cells showed a marked increase in hemi-methylation in cells 
treated with decitabine and combined ascorbate and decitabine during cell cycle progression 
(Figure 6.24), un synchronised showed no demethylation and heatmaps are not shown. The 
proportions of methylated, hemi-methylated and unmethylated hairpin reads were calculated 
for all treated and untreated samples. The PCDHGA12 promoter of synchronised cells, treated 
with decitabine or combined ascorbate/decitabine, showed a decrease in methylation levels  
represented by an increase in hemi-methylated hairpin reads with increasing time (Figure 
6.25a), compared to a complete absence of decitabine and ascorbate effects in unsynchronised 




Figure 6. 24. The methylation patterns of PCDHGA12 promoter in two biological replicates 
(R1 and R2) of synchronised A) control untreated cells, B) 500 μM ascorbate treated cells, C) 












Figure 6. 25. Methylation of PCDHGA12 promoter. Comparison of A) synchronised Jurkat 
cells treated with ascorbate, decitabine and combined ascorbate/decitabine at the time of release 
for 24,  and B) unsynchronised Jurkat cells treated with ascorbate, decitabine and it is 
combinations for 24 h. 
 
To see whether the phenomenon “loss of methylation” is reproducible, we investigated the 
effect of low dose of decitabine “1 μM decitabine” and 500 μM ascorbate on the methylation 
of the RASSF1 promoter. Interestingly, RASSF1 showed a gradual loss of methylation reflecting 
increase in the number of hemi-methylated reads in a time dependent manner in cells treated 
with decitabine and combined ascorbate/decitabine compared to untreated control cells (Figure 







Figure 6. 26. Methylation pattern of RASSF1 promoter. Synchronised Jurkat cells treated with 
1 μM decitabine, 500 μM ascorbate and combinations of ascorbate/decitabine compared to 
untreated cells. 
 
Marked hemi-methylation was seen the RASSF1 promoter, but complete lack of active 
demethylation , emphasising the variable nature of the experiments. 
6.6.2 Summary and conclusion to this point. 
Active demethylation was observed at 6 h after treatment with ascorbate/decitabine. Decitabine 
induced consistent hemi-methylation percentage during DNA replication in the two tumour 
suppressor genes PCDHGA12 and RASSF1, and the percentage of hemi-methylation increased 
with increasing time. Cell synchronisation is an important and essential step for the induction 
of demethylation. Decitabine and combination of ascorbate/decitabine had no effect on 
unsynchronised Jurkat cells. These were surprising results, as we were expecting a small 
amount of demethylation. The use of unsynchronised cells was not useful and did not make the 
system more simple. Changing the culture media has no significant effect on the percentages 





6.7 Evaluating the methylation patterns of PCDHGA12 and RASSF1 promoters in other 
leukaemia cell lines. 
Since, variable results were observed between experiments in Jurkat cells, we evaluated 
whether other cell lines would show more consistent demethylation results. The methylation 
signatures of PCDHGA12 and RASSF1 that might be serve as a methylation markers for future 
study were investigated in other leukaemia cell lines.  
DNA samples were extracted from six leukaemia cell lines: CCRF-CEM, Molt4, Nalm6, 
RS4;11, HL-60 and MDS. DNA was prepared as before for PCDHGA12 and RASSF1 promoter 
sequencing (Chapter 3). 
Interestingly, PCDHGA12 promoter was densely methylated in all examined cell lines, with 
overall ~ 95% mean methylation (Figure 6.27 ‘upper panel’). In comparison, the RASSF1 
promoter was densely methylated only in Molt4 cells with ~ 95 % mean methylation, but less 
methylated in Nalm6 and MDS (~ 50% mean methylation), and unmethylated in RS4, CEM 
and HL60 cell lines (Figure 6.27 ‘lower panel’). The violin plot below summarises the DNA 
methylation patterns of PCDHGA12 and RASSF1 in different leukaemia cell lines (Figure 
6.28). Therefore, PCDHGA12 gene can be used as a methylated marker for all the examined 
cell lines, whereas RASSF1 genes can only be used with the Molt4 cell line.  
From the cell lines above, Molt4 was selected to study the methylation pattern of 
complementary CpG sites of PCDHGA12 and RASSF1 promoters and Nalm6 and HL60 cell 
lines were selected to study PCDHGA12 promoter. In order to investigate the effect of 
decitabine and ascorbate on DNA demethylation, two experiments were performed and each 
included replicates.  
In the first experiment, Molt4, Nalm6 and HL60 cells were synchronised by a single thymidine 
block for 22 h. At the time of release, cells were washed and loaded with fresh media 
supplemented with 50 µM dC and divided into four group: untreated control; 1 µM decitabine; 
500 µM ascorbate; and combined 500 µM ascorbate and 1 µM decitabine. Cells were harvested 
at 0, 2, 4, 6, 12 and 24 h after release from thymidine block. 
The second experiment was conducted without synchronisation. Molt4, Nalm6 and HL60 cells 
were treated with decitabine or combined ascorbate/decitabine for 24 h compared to untreated 








Figure 6. 27. Methylation pattern of PCDHGA12 promoter in different leukaemia cell lines 
(upper panel). The lower panel shows the methylation pattern of RASSF1 promoter across 
different leukaemia cell lines. (red = methylated, blue = unmethylated, white = missing 
sequence). 
 
         
 
Figure 6. 28. Violin-point plot showing the methylation of all sequencing results of PCDHGA12 
(plotted in blue) and RASSF1 promoters (plotted in red) in leukaemia cell lines. A dotted line 




6.7.1 Impact of ascorbate/decitabine on methylation of PCDHGA12 promoter in Molt4 
cell lines. 
Synchronised Molt4 cells treated with decitabine or combined ascorbate/decitabine showed 
substantial changes in DNA methylation levels with an increase in the percentage of hemi-





Figure 6. 29. Methylation of PCDHGA12 promoter in synchronised Molt4 cell line. Two 
biological replicates (R1 and R2) showed the methylation pattern of PCDHGA12 promoter in 
synchronised A) control untreated cells, B) 500 μM ascorbate treated cells, C) 1 μM decitabine 
treated cells and D) combined ascorbate/decitabine treated cells. 
 
The proportions of methylated, hemi-methylated and unmethylated hairpin reads were 
calculated for all samples. Synchronised Molt4 cell lines treated with decitabine or combined 
ascorbate/decitabine showed an increase in the percentage of hemi-methylated reads at 
increasing timepoints.  The combination of ascorbate with decitabine showed the same degree 




Unsynchronized Molt4 cells showed no effects of decitabine or combined ascorbate/decitabine 
on the methylation pattern of PCDHGA12 except an increase in the percentage of hemi-








Figure 6. 30. Comparison of hairpin based methylation of PCDHGA12 promoter in A) 
synchronised and B) unsynchronised Molt4 cell lines.  
 
The experiment on Molt4 was extended to test and investigate the DNA methylation changes 
on the hypermethylated RASSF1 promoter. Similarly, the RASSF1 promoter showed a 




treated cells. The hemi-methylated effect was observed as early as 4 h after release from 
thymidine block (Figure 6.31). 
 
 
Figure 6. 31. Methylation pattern of RASSF1 promoter. Synchronised Molt4 cells treated with 
1 μM decitabine, 500 μM ascorbate and combination of ascorbate with decitabine compared to 
untreated cells. 
 
6.7.2 Impact of ascorbate/decitabine on PCDHGA12 promoter of Nalm6 cell lines. 
Similar to Molt4 cell lines, synchronised Nalm6 showed marked methylation changes in the 
PCDHGA12 promoter after 1 μM decitabine and combined ascorbate with decitabine treatment 
(Figure 6.32). The proportions of hemi-methylated hairpin reads increased with increasing time 
in cells treated with 1 μM decitabine compared to untreated control. Treatment with ascorbate 
alone had no effect on DNA methylation, and adding ascorbate to decitabine treatment did not 
change the decitabine effect (Figure 6.33a). 
Unsynchronized Nalm6 cells showed no decitabine effect except an increase in the proportion 
of hemi-methylated reads at 24 h with decitabine treatment. Combined ascorbate with 







Figure 6. 32. Methylation of the PCDHGA12 promoter in synchronised Nalm6 cells. Two 
biological replicates (R1 and R2) showed the methylation pattern of PCDHGA12 promoter in 
synchronised A) control untreated cells, B) 500 μM ascorbate treated cells, C) 1 μM decitabine 












Figure 6. 33. Comparison of hairpin based methylation of PCDHGA12 promoter in A) 






6.7.3 Impact of ascorbate/decitabine on PCDHGA12 promoter of HL60 cell lines. 
Interestingly, synchronised HL60 cells treated with 0.5 µM decitabine or combined 
ascorbate/decitabine showed no marked differences on methylation pattern of PCDHGA12 
promoter compared to untreated control (Figure 6.34). A slight increase in the number of hemi-
methylated and unmethylated hairpin reads was observed along decitabine and combined 
ascorbate/decitabine treatment at 16 h by (10% and 15% respectively). 
No differences in the proportions of hemi-methylated or unmethylated PCDHGA12 reads were 




Figure 6. 34. Methylation of PCDHGA12 promoter in synchronised HL60 cell lines. Two 
biological replicates (R1 and R2) showed the methylation pattern of PCDHGA12 promoter in 
synchronised A) control untreated  cells, B) 500 μM ascorbate treated cells, C) 0.5 μM 











Figure 6. 35. Comparison of hairpin based methylation of PCDHGA12 promoter among A) 
synchronised and B) unsynchronised HL60 cell lines. 
 
6.7.4 Summary and conclusion to this point. 
I extended the experiments to investigate the methylation signatures of PCDHGA12 and 
RASSF1 in other leukaemia cell lines. PCDHGA12 was found to be densely methylated in all 
examined cell lines, whereas, RASSF1 was densely methylated in Molt4 and less or 
unmethylated in the other tested cell lines. Demethylation phenomena is not unique to Jurkat 
cells. Similar to Jurkat cells, we observed demethylation effect of decitabine and combined 
ascorbate/decitabine in Molt4 and Nalm6 cell lines. Synchronisation is essential and critical 




unsynchronised except hemi-methylation at 24 h in both cell lines. The experiments showed a 
concordance in the methylation results between Jurkat, Molt4 and Nalm6, which emphasised 
the stability of the experiments system, but active demethylation (complete unmethylation) not 
observed. Interestingly, the  HL60 cell line seems to be resistant to demethylation following 
decitabine treatment, but HL60 were more sensitive to the cytotoxic effects of decitabine, as 
we did not observe any changes in the DNA methylation of PCDHGA12 promoter in 
synchronised and unsynchronised HL60 treated with decitabine alone or combined 
ascorbate/decitabine. It seems that decitabine stops replication of HL60 and therefore there is 
no opportunity for demethylation to occur.  
6.8 Hypermethylated genes identified from 450 K methylation array data set. 
6.8.1 Evaluating the methylation pattern of MARCH11, NEFM, KCNA4, GOLSYN and 
C10orf53 genes in Jurkat cells. 
We were unable to demonstrate a consistent effect of ascorbate/decitabine in some but not all 
experiments on RASSF1 and PCDHGA12 promoters, in that active demethylation was 
observed. We excluded many factors that might cause the variable results such as PCR bias, 
DNA sequencing and co-factor components by using different culture media. We extended our 
investigation to other genes in Jurkat cells. The methylation patterns of MARCH11, NEFM, 
KCNA4, GOLSYN and C10orf53 genes in Jurkat cells were evaluated by MiSeq sequencing to 
determine whether they could be utilised as new methylation markers.  
The genes were identified from publicly available 450 K methylation array data set using  an 
array-based analysis pipeline (called ABC.RAP). The pipeline is R package developed by Dr. 
Abdulmonem Alsaleh (previous PhD student in Morison laboratory) and available on the 
CRAN website (https://cran.r-project.org/web/packages/ABC.RAP/index.html). Primers were 
designed using MethPrimer online tool, primers were designed to amplify 357 bp region of 
NEFM gene, 345 bp region of C10orf53 gene, 329 bp region of GOLSYN gene, 467 bp region 
of MARCH11 gene and 432 bp region of KCNA4 gene. Illumina universal adapter sequences 
were added to each primer.  
To examine these five genes, DNA was extracted from ascorbate and decitabine-treated and 
untreated cells, then bisulfite converted using EZ DNA Methylation Gold Kit, followed by two 
sets of PCR amplification. Amplification of each gene was performed using KAPA HiFi DNA 
polymerase, and the five genes were successfully amplified. Sequencing was done using 




These genes were used to examine the methylation pattern and the sensitivity of these genes to 
decitabine and ascorbate, so the evaluation of these genes did not involve the use of the hairpins. 
6.8.1.1 Evaluation of NEFM methylation. 
DNA methylation analysis (MiSeq sequencing) was performed for NEFM in Jurkat cells. The 
MiSeq sequencing results showed that this gene is densely methylated with a mean methylation 
of 91% (Figure 6.36), suggesting that might be used as a methylated marker for DNA 
demethylation studies. 
 
                   
 
Figure 6. 36. NEFM methylation analysis. A) Agarose gel image confirming successful 1st 
round PCR amplification of NEFM gene (amplicon size 357 bp). B) Image of sequencing results 
showing densely methylated NEFM gene (24 CpG sites) in Jurkat cells (red = methylated CpG, 






6.8.1.2 Evaluation of C10orf53 methylation. 
The sequence was selected within the promoter region of C10orf53. The primers were designed 
to amplify 345 bp of promoter region (30 CpG sites). The region was sequenced for DNA 
methylation analysis, and the gene was found to be completely methylated in Jurkat cells with 




Figure 6. 37. C10orf53 methylation. A) Agarose gel image confirming successful 1st round PCR 
amplification of C10orf53 (amplicon size 345 bp). B) Image of sequencing results showing 
densely methylated C10orf53 in Jurkat cells with mean methylation 97% (30 CpG sites) in 





6.8.1.3 Evaluation of GOLSYN (SYBU) methylation. 
The target region of GOLSYN (also called SYBU) was selected within the promoter region with 
a size of 329 bp and 12 CpG sites. The selected region is densely methylated in B-ALL and less 
methylation level in normal cells (UCSC genome browser). MiSeq sequencing showed highly 
methylated GOLSYN region in untreated Jurkat cells (mean methylation 69%) (Figure 6.38). 
 
            
 
Figure 6. 38. GOLSYN (SYBU) methylation. A) Agarose gel image confirming successful 1st 
round PCR amplification of amplicon size 329 bp. B) Image of sequencing results showing 
densely methylated GOLSYN (12 CpG sites) in Jurkat cells. (red = methylated CpG, blue = 




6.8.1.4 Evaluation of MARCH11 methylation. 
A 467 bp region in MARCH11 containing 41 CpG sites was selected. DNA methylation 
sequencing (MiSeq) was performed for MARCH11 and the results showed that this gene is 
densely methylated in Jurkat cells (mean methylation 91%) (Figure 6.39). Therefore MARCH11 




Figure 6. 39. MARCH11 methylation. A) Agarose gel image confirming successful 1st round 
PCR amplification. B) Image of sequencing results showing densely methylated MARCH11 in 





6.8.1.5 Evaluation of KCNA4 methylation. 
A 432 bp region within the KCNA4 promoter, contains 34 CpG sites was selected. DNA 




Figure 6. 40. KCNA4 methylation. A) Agarose gel image confirming successful 1st round PCR 
amplification of KCNA4. B) Image of sequencing results showing densely methylated NEFM 







6.8.2 Effect of decitabine and ascorbate/decitabine on NEFM, C10orf53, GOLSYN, 
MARCH11and KCNA4 methylation. 
6.8.2.1 Impact of decitabine and combination of ascorbate/decitabine on DNA 
methylation of NEFM. 
DNA methylation analysis was applied to evaluate the DNA methylation changes in control 
and treated Jurkat cells. Briefly, Jurkat cells were synchronised by thymidine block and divided 
into three groups (untreated control, decitabine and ascorbate/decitabine groups). After 
synchronisation cells were washed loaded with fresh media supplemented with 50 μM 2’ 
deoxycytidine. At the time of release cells were treated with decitabine, ascorbate/decitabine or 
untreated. Cells were collected at 0, 12 and 24 h. 
Incubation of Jurkat cells with 5 μM decitabine for 12 and 24 h led to a 40% decrease in 
methylation of NEFM compared to the untreated control. The combined treatment of 500 μM 





Figure 6. 41. DNA methylation of NEFM in Jurkat cells treated with decitabine, ascorbate, or 
combined ascorbate/decitabine for 24 h. (C: Control cells, D: decitabine treated cells, A: 






6.8.2.2 Impact of decitabine and ascorbate on DNA methylation of C10orf53. 
DNA methylation analysis was performed to evaluate the DNA methylation changes after 
exposure to decitabine and combination of ascorbate with decitabine. Interestingly, massive 
loss in DNA methylation was observed in C10orf53 after 12 and 24 h in Jurkat cells  incubated 
with decitabine. Co-treatment of decitabine with ascorbate had no further influence on this 
effect compared to the control. However, treatment with 500 µM ascorbate during 




Figure 6. 42. DNA methylation of C10orf53 in Jurkat cells treated with decitabine, ascorbate 
or ascorbate/decitabine for 24 h. (C: Control cells, D: decitabine treated cells, A: ascorbate 





6.8.2.3 Impact of decitabine and ascorbate on GOLSYN DNA methylation. 
Decitabine time dependently enhances the loss of DNA methylation in GOLSYN gene after 12 
and 24 h incubation compared to untreated control. Co-treatment with ascorbate/decitabine had 




Figure 6. 43. DNA methylation of GOLSYN in Jurkat cells treated with decitabine, ascorbate or 
ascorbate/decitabine for 12 and 24 h. (C: Control cells, D: decitabine treated cells, A: ascorbate 
































6.8.2.4 Impact of decitabine and ascorbate on MARCH11 DNA methylation. 
Reduction in MARCH11 DNA methylation levels occurred in a time dependent manner in 
Jurkat cells incubated with 5 µM decitabine for 12  and 24 h. The reduction in DNA methylation 





Figure 6. 44. DNA methylation of MARCH11 in Jurkat cells treated with decitabine, ascorbate 
or ascorbate/decitabine for 24 h. (C: control cells, D: decitabine treated cells, A: ascorbate 




6.8.2.5 Impact of decitabine and ascorbate on DNA methylation of KCNA4. 
The impact of decitabine and a combination of ascorbate/decitabine on KCNA4 DNA 
methylation was investigated in Jurkat cells. Interestingly, rapid loss in DNA methylation was 
observed in KCNA4 gene after 12  and 24 h in Jurkat cells incubated with decitabine. Co-





Figure 6. 45. DNA methylation of KCNA4 gene in Jurkat cells treated with decitabine, ascorbate 
and ascorbate/decitabine for 12 and 24 h. (C: Control cells, D: decitabine treated cells, A: 
ascorbate treated cells and AD: ascorbate/decitabine treated cells).  
 
6.9 Analysis of publicly available data using ABC.RAP R package. 
To support our finding, other evidence of relevant data from publicly available data set was 
carried out analysed by Dr. Abdulmonem Alsaleh using an array-based analysis pipeline called 
ABC.RAP R package. Briefly, the package utilised probes obtained from 450K analysis, 
filtered non-specific probes, annotated the filtered out probes, measured significantly different 
CpG sites and applied delta beta analysis to measure the differences between treated and control 
samples. The data were extracted from different cohorts and analysed for the effect of 
ascorbate/decitabine. The package applied ‘two sided’ unequal variance Student’s t-test 
analysis to select CpG sites with significant differences in DNA methylation ‘beta value’. The 




decitabine) and untreated control. These data was consistent with our results and supported our 
demethylation finding.   
6.9.1 Global DNA methylation analysis: HCT116 CRC cell line. 
Interestingly, using the ABC.RAP R package, the analysis of publicly available data extracted 
from Li et al.(2016) showed global loss in DNA methylation in cells treated with decitabine 
and combined ascorbate/decitabine compared to control cells. Ascorbate alone had no effect on 
global DNA methylation (Figure 6.46) (Figure 6.47) (Liu et al., 2016). The global effect of 
decitabine alone or in combination with ascorbate are concordant with loss of DNA methylation 




Figure 6. 46. Global DNA methylation analysis of HCT116 CRC cell lines treated with A) 57 
µM ascorbate, B) 300 nM decitabine or C) combined ascorbate/decitabine for 24 h compared 







Figure 6. 47. Distribution of methylation for HCT116 CRC cell line. A) Methylation of 
decitabine treated cells compared to untreated control, and delta beta (the difference of DNA 
methylation between decitabine and untreated control. B) Methylation of ascorbate treated cells 
compared to untreated control, and delta beta between ascorbate treated and untreated control. 
C) Methylation of combined ascorbate with decitabine compared to untreated control, and delta 
beta value, the difference between combined ascorbate with decitabine and untreated control.  
 
Additionally, we compared our methylation results with results from a study by Imanishi et al. 
(2017). This study examined global methylation of U937 haematopoietic cells incubated with 
decitabine for 24 and 72 h.  
Using the ABC.RAP R package, global DNA methylation of U937 cells treated with 5 µM 
decitabine after 24 and 72 h decreased when compared to untreated cells (Figures 6.48 and  







Figure 6. 48. Methylation analysis of U937 cells after 24 h decitabine treatment. A+B) 
Histogram showing the DNA methylation distributions of decitabine and untreated control 
cells, respectively. C) Boxplot showing the DNA methylation of decitabine vs untreated, D) 
The difference in methylation (delta beta values) between decitabine and untreated cells. Data 




Figure 6. 49. Methylation analysis of U937 cells after 72 h decitabine treatment. A+B) 
Histogram showing the DNA methylation distributions of decitabine and untreated control 
cells, respectively. C) Boxplot showing the DNA methylation of decitabine vs untreated, D) 
The difference in methylation between decitabine and untreated cells. Data extracted from 







Active demethylation is defined as the enzymatic removal of a methyl group from cytosine 
nucleotides in DNA. Cytosine analogues, e.g. decitabine and azacytidine, are commonly used 
as demethylating drugs in treating haematological cancers, such as Acute Myeloid Leukaemia 
(AML) and Myelodysplastic syndrome (MDS) (Pleyer & Greil, 2015). 
In this study, we investigated DNA demethylation in a cancer model-Jurkat cells (T-ALL cell 
line). We developed a tractable hairpin bisulfite sequencing assay to investigate active 
demethylation. With this assay, we consistently demonstrated hemi-methylated sequences in 
haematopoietic cell lines treated with decitabine. In addition, we demonstrated active 
demethylation in cells treated with decitabine.  
Through further experiments, we have shown that treatment with ascorbate occasionally 
enhances the demethylation efficacy of decitabine. In line with this data, we observed a 
significant increase in the number of unmethylated reads in Jurkat cells co-incubated with 
ascorbate/decitabine paralleled by an increase in the presence of 5-hydroxymethylcytosine 
compared to untreated cells (Chapter Seven). Combined ascorbate with decitabine induces 
active demethylation resulted by conversion of 5-methyl cytosine to 5-hydroxymethyl cytosine 
leads to upregulate tumour suppressor genes which leads to arresting the cells in G1, S or G/M 
phases of the cell cycle (Sajadian et al., 2016a). It is interesting to know that decitabine alone 
induced active demethylation by enhancing the production of 5-hydroxymethylcytosine at 12 h 
timepoint. Various types of cancer cells exhibited loss of 5-hydroxymethylcytosine which was 
suggested as a demethylation marker for cancer cells (Huang & Rao, 2014; Kroeze et al., 2015). 
The hypomethylating agents decitabine and azacytidine were able to reduce 5-methylcytosine 
levels in colon cancer cells in a concentration-dependent manner and were not affected by the 
addition of ascorbate. Interestingly, the hypomethylating agents alone failed to trigger any 
changes to 5-hydroxymethyl cytosine levels (Gerecke et al., 2018). In contrast, another study 
by Chowdhury (2015) reported that decitabine increased the 5-hydroxymethylcytosine levels 
in HL60 (AML) and TK6 (CML) leukaemia cell lines (Chowdhury et al., 2015b). 
Although, TET proteins depend on two substantial factors Fe2+ and alpha-ketoglutarate in order 
to mediate the iterative oxidation of 5-methylcytosine to 5-hydroxymethyl cytosine and mediate 
active demethylation (Ito et al., 2010; Tahiliani et al., 2009), in the present study, we inferred 
that adding ascorbate to decitabine treatment enhanced the epigenetic activity of decitabine by 




Untreated Jurkat cells are completely ascorbate deficient, and supplementation optimises 
intracellular total and reduced ascorbate concentrations (Figure 6.3). The generation of 5-
hydroxymethyl cytosine is completely absent in untreated Jurkat cells at different timepoints 
during cell cycle progression (Chapter Seven). In lines with other papers, there is a remarkable 
correlation between TET proteins, tumour progression and the production of 5-hydroxymethyl 
cytosine which suggest that TET proteins might act as a tumour suppressor in certain cancer 
types (Haffner et al., 2011; Xu, Wu, et al., 2011).  
Sajadian et al. (2015) observed a significant induction of TET2 and TET3 and 5-hydroxymethyl 
cytosine in HCC cell lines at 20 µM decitabine treatment. Interestingly, combination of 10 µM 
decitabine with ascorbate showed the same degree of epigenetic changes similar to 20 µM 
decitabine, and ascorbate was able to compensate the higher dose of decitabine (Sajadian et al., 
2015b). 
Through further study, Sajadian et al. (2016) showed that co-treatment of hepatocellular 
carcinoma (HCC) cell lines with ascorbate and 5-AZA induced active demethylation and 
production of 5-hydroxymethylcytosine. Furthermore, they postulated that this demethylation 
enhanced expression of GADD45 and decreased expression of Snail, leading to inhibition of 
cyclin B and PCNA expression and induction of cell cycle arrest (Sajadian et al., 2016a). 
We have shown that decitabine consistently induced cell cycle delay after 24 h and hemi-
methylation started as earlier as 2 h. Cell viability decreased in the four leukaemia cell lines 
treated with 5 µM decitabine in a time dependent manner. Furthermore, we observed a dramatic 
cytotoxic increase when Jurkat cells were co-incubated with ascorbate/decitabine represented 
by a sharp decrease in the number of viable cells after co-treatment.  
Here, we extended our study to investigate whether ascorbate can enhance the demethylation 
efficacy of decitabine in another three haematopoietic cell lines: Molt4, Nalm6 and HL60. 
Ascorbate has very little effects on DNA methylation, but with combination of 
ascorbate/decitabine the methylation decreased in Molt4 and Nalm6. Cell synchronisation is an 
essential step in our DNA demethylation experiments. HL60 is resistance to decitabine as we 
did not see a marked effect of decitabine or combined ascorbate/decitabine on global or gene 






Chapter Seven: Effect of decitabine and ascorbate on  DNA 




Whole-genome bisulfite sequencing or ‘WGBS’ is used to measure genome-wide methylation 
and has led to novel discoveries (Olova et al., 2018). However this protocol is expensive and 
impractical for large numbers of samples and typically requires large amounts (5 µg) of DNA 
as starting material, which is sometimes difficult to prepare from many samples, such as early 
embryo and embryonic tissue.  
Alternatively, low-coverage bisulfite sequencing or PBAT,  is cheap, unbiased and efficient, 
requiring only small amounts of input DNA and is able to process large numbers of DNA 
samples. Using modified PBAT (Peat et al., 2014) we quantified global CpG methylation in 
Jurkat cells treated with different reagents. 
5-hydroxymethylcytosine (5-hmC) is the first intermediate epigenetic mark in TET-mediated 
active demethylation (Wu & Zhang, 2011a) and is generated by TET1-3 enzymes catalysed 
oxidation of 5mC (Ito et al., 2010; Tahiliani et al., 2009) (Figure 7.12). As a “sixth” DNA base, 
5-hmC plays an important role in phenotype and gene expression (Shi et al., 2017). 
To assess whether decitabine or/and ascorbate enhance the production of 5-hmC in 
synchronised Jurkat cells, Global Hydroxymethylation ELISA assay was used to quantify 
global 5-hydroxymethylcytosine in treated Jurkat at different timepoints after release from 
synchronisation.  
7.1.1 The aims of this chapter: 
1. To determine the global 5-mC level in Jurkat cells using low coverage bisulfite 
sequencing. 
2. To evaluate the effect of decitabine on global DNA methylation of synchronised Jurkat 
cells. 
3. To investigate the effect of ascorbate and combined ascorbate and decitabine treatments 




4. To determine the global 5-hmC level in Jurkat cells treated with decitabine, ascorbate 
and combined ascorbate and decitabine. 
7.2. Low coverage bisulfite sequencing (post-bisulfite adapter tagging): Experiment one. 
7.2.1 Preparation of PBAT libraries. 
Using PBAT, the genome-wide DNA methylation of cells treated with decitabine and other 
reagents was monitored over 72 h.  
For this experiment, Jurkat cells were grown to 1 x 106 /mL and arrested in G1 phase by 
incubation with 2 mM 2¢-deoxythymidine for 18 h. Arrested cells were washed twice with fresh 
media and divided into two five groups (1: control, 2: 5 µM decitabine, 3: 500 µM glycine 
chloramine, 4: 500 µM ascorbate and 5: 500 µM ascorbate and 5 µM decitabine). Cells were 
supplemented with 2¢-deoxycytidine to initiate DNA synthesis (defined as 0 h). Cells were 
harvested at different timepoints 0, 2, 4, 6, 24, 48 and 72 h.  
The treatment and tissue culture work for this experiment was performed by me in Prof. 
Hampton’s laboratory (University of Otago, Christchurch). 
After DNA purification, global 5-mC levels were determined using PBAT sequencing. Briefly, 
genomic DNA for each sample was bisulfite converted and the DNA was copied by primer 
extension with biotin-labelled random primers. After purification with streptavidin-coated 
DynaBeads and magnetic immobilisation, immobilized first strand was used as a template for 
an additional adapter to create double-strand DNA. PCR was used to add a unique molecular 
barcode and to add sequences necessary for binding to Illumina flow cells. Libraries were 
sequenced on a MiSeq instrument (Illumina) (explained in section 3.5) (Figure 7.1) and 






Figure 7. 1. General PBAT procedure consisting of two rounds of random priming on bisulfite-
treated DNA. Modified from (Miura et al., 2012).  
  
PBAT amplification quality and quantity was checked by running the libraries on 1% agarose 
gel electrophoresis at 140 V for 45 min. (Biotium Gelred stain). The resulting  electrophoresed 
DNA shows a smear from 100 to >1000 bp; the smear consistency suggested that the DNA 
fragments were amplified to the same quantity (Figure 7.2 ‘left panel’). PCR product libraries 
were pooled based on the samples fluorescent intensity of the gel electrophoresis (Figure 7.2 







Figure 7. 2. Agarose gel showing PBAT PCR amplified products of different DNA samples. 
Left panel shows gel electrophoresis of PBAT libraries. Lane 1: DNA ladder (100 bp), lane 2, 
3 and 4 consist of PBAT libraries from 100 bp. Right panel shows the pooled PBAT PCR 
libraries. (Images were taken from Dr. Tim Hore laboratory).  
 
Low coverage 150 bp paired-end Illumina MiSeq sequencing was performed to evaluate the 
global CG methylation levels for all samples. Illumina MiSeq output FASTQ files were 
monitored for read quality by FASTQC before and after quality trimming to remove poor 
quality sequences, and removal of adapter sequences using TrimGalore (v0.4.0, default 
parameters). Trimmed reads were then mapped to the human genome (hg19) and total 
methylation levels in CpG and non-CpG contexts were determined using BISMARK v0.4.0, 
default parameters) (Krueger & Andrews, 2011) with the PBAT option specified by Hore’s 
laboratory. The precision of the methylation measurement increases with the number of 
analysed CpGs. For example at 15000 CpG cells the margin of error (99% confidence interval) 
is ± 1.8 percentage points (Peat et al., 2017).  
7.2.2 Impact of decitabine on global genomic DNA methylation in Jurkat cells. 
The number of analysable CpGs ranged from 1000 to 33,500, except for two samples (ascorbate 
plus and ascorbate minus at 0 h), that had very low CpG calls (9 and 10 calls, respectively) and 







Figure 7. 3. Number of CG calls for Jurkat DNA samples examined by low-coverage 
sequencing.  
 
Quantification of non-CG “methylation” is another parameter measured during PBAT analysis 
to examine the completeness of bisulfite conversion. Because methylation in mammals is 
targeted to CGs, completely converted samples are characterised by low levels of non-CG 
“methylation”. Non-CG “methylation” < 1% in all samples (Figure 7.4).  
 
 
Figure 7. 4. Percent of non-CG “methylation” for Jurkat DNA samples. 
 
All samples had mapping efficiency of 53-67%, which is consistent with previous results 







Figure 7. 5. Mapping efficiency (%) for Jurkat DNA samples. 
 
Low-coverage genome wide sequencing results demonstrated that there is a constant CpG 
methylation level in non-blocked (67%) and in arrested Jurkat cells (68%). As expected, there 
is a gradual loss of CpG methylation in Jurkat cells treated with decitabine and combined 
ascorbate/decitabine in a time-dependent manner following release from cell cycle arrest (from 




Figure 7. 6. Global CpG methylation levels (%) of Jurkat DNA treated with glycine chloramine, 
decitabine, ascorbate and combined ascorbate/decitabine compared to control cells. 
 
Furthermore, incubation of Jurkat cells with 500 µM glycine chloramine or 500 µM ascorbate 




In this study, we performed the low coverage bisulfite sequencing assay to confirm the gene 
specific hairpin bisulfite sequencing results (Figure 7.7) (previously shown in Chapter Six). 
The results of low coverage bisulfite sequencing showed consistent  methylation results in both 
global methylation by PBAT and gene specific hairpin DNA methylation results. Figure 7.6 




Figure 7. 7. Impact of ascorbate/decitabine on DNA methylation of Jurkat cells. Hairpin based 
methylation of PCDHGA12 promoter following single or combined treatment. A) control 
untreated cells; B); cells treated with 5 μM decitabine C) cells treated 500 μM ascorbate and 
D) cells treated with combined ascorbate/decitabine.  
 
7.3 Low-coverage genome wide sequencing PBAT: Experiment Two. 
To confirm these results, PBAT was performed on samples collected from a second 
independent experiment. 
In this experiment, performed by me in Prof Morison’s laboratory (University of Otago, 
Dunedin), Jurkat cells were grown to 1 x 106 /mL and arrested at G1 phase by incubation with 
2 mM 2¢-deoxythymidine for 18 h. Cells were washed twice with fresh media and divided into 
two four groups (Group 1: control, Group 2: 5 µM decitabine, Group 3: 500 µM ascorbic acid 
and Group 4: 500 µM ascorbic acid and 5 µM decitabine). To initiate DNA synthesis cells were 
supplemented with 2¢-deoxycytidine. Cells were harvested at different timepoints 0, 6, 12, 24, 
48, 72, 96 and 120 h. The CG call numbers for this experiment ranging from 14,500 to 50,611 
(Figure 7.8). These results showed that the non-CpG levels was less than 1%, indicating that 












Figure 7. 9. Total non-CG “methylation” levels for Jurkat cells DNA samples. 
 







Figure 7. 10. Mapping efficiency (%) for Jurkat DNA samples. 
 
The results of low coverage bisulfite sequencing demonstrated that there is consistent CpG 
methylation in untreated (control) Jurkat cells across different timepoints (~ 66%). There is a 
gradual loss in CpG methylation levels in Jurkat cells treated with decitabine (44% at 48 h) and 
combined ascorbic acid and decitabine (42% at 48 h) in a time dependent manner after a single 
dose treatment at time zero. There is some recovery in CpG methylation at 72, 96 and 120 h, 
but methylation remains lower than that in the control (Figure 7.11).  
 
 
Figure 7. 11. Global CpG methylation levels (%) of Jurkat DNA treated with decitabine, 






7.4 Low-coverage genome wide sequencing PBAT: experiment three. 
In this experiment, we extended our global methylation analysis to include three more 
haematopoietic cell lines Molt4, Nalm6 and HL60 in addition to Jurkat cells. The DNA samples 
were extracted and prepared for low coverage bisulfite sequencing from treated and untreated 
samples of the three cell lines (details of the treatment and cultural conditions in Chapter Three). 
The samples had a good mapping efficiency ranging between 51.7% to 59.7 %, and CG call 
numbers ranging from 15,000 to 25,000. 
The results of low coverage bisulfite sequencing confirmed the results of gene-specific 
methylation. Ascorbate had no effect on global methylation of the four examined cell lines 
compared to untreated cells. Jurkat, Molt4 and Nalm6 showed a decrease in global methylation 
at 12 or/and 24 h ranging between 10% to 30% in decitabine and combined ascorbate/decitabine 
treatment compared to untreated. Interestingly, decitabine and combined ascorbate/decitabine 
had no effect on the methylation of HL60, consistent with the results obtained by gene-specific 




Figure 7. 12. Global CpG methylation levels of A) Jurkat cells, B) Molt4 cells, C) Nalm6 cells 
and D) HL60 cells treated with decitabine, ascorbic acid and combined ascorbic acid and 




7.5 Determination of genome-wide 5-hydroxymethylcytosine levels. 
TET proteins usually catalyse the first step of active demethylation, by oxidising 5-mC into 5-
hmC (Figure 7.13). The level of 5-hmC is tissue specific, ranging from undetectable levels in 
cultured cell lines to 0.6 % of DNA in human brain tissues (Globisch, Munzel, et al., 2010). A 
global decrease in 5-hmC content has been shown in nearly all cancers and has been proposed 
as a molecular marker and therapeutic target of cancer (Chen, Shen, et al., 2013; Haffner et al., 
2011; Jin et al., 2011; Yang et al., 2013). 5-hmC was similarly depleted in bone marrow samples 
from patients with haematopoietic malignancies (Ko et al., 2010; Liu, Zhang, et al., 2013). 
 
                             
 
Figure 7. 13. Generation of 5-hydroxymethylcytosine by oxidation of 5-methylcytosine 
catalysed by the TET1, 2 or 3 enzymes. 
 
Conventional bisulfite treatment does not differentiate between 5-mC and 5-hmC, as 5-mC is 
unmodified by bisulfite and 5-hmC is modified to cytosine methylene sulfonate (CMS). Due to 
DNA polymerase recognition, they are both ‘read’ as cytosine after sequencing (Figure 7.14). 
In contrast, cytosine, 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) are ‘read’ as 




Figure 7. 14. Summary of the effect of bisulfite treatment on modified cytosines. Following 
bisulfite conversion and sequencing, both 5-mC (red) and 5-hmC (orange) are ‘read’ as cytosine 




7.5.1 Global hydroxymethylcytosine quantification. 
7.5.1.1 Method: 
Quantification of global 5-hydroxymethylcytosine was done using the MethylFlash™ Global 
Hydroxymethylation (5-hmC) ELISA Easy Kit Colorimetric (EPIGENETIK), according to the 
manufacturer’s protocol. This assay has high analytical sensitivity with a detection limit for 
hydroxymethylated DNA as low as 0.01% from 100 ng input DNA and high specificity to 5-
hmC with no cross reactivity to methylated or unmethylated cytosine. 
Briefly, the protocol consists of three steps:  
Step 1. 100 ng of sample DNA was bound to a high DNA affinity treated wells;  
Step 2. the hydroxylated portion of DNA was detected using a 5-hmC monoclonal 
antibody-based detection complex;  
Step 3. 5-hmC was quantified by absorbance in a microplate spectrophotometer (Chapter 
Three, Section 3.8).  
A standard curve was generated by plotting the optical density OD values at 450 nm versus the 
standards at each percentage point and the slope of the line was determined using linear 




Figure 7. 15. Standard curve generated using included 5-hmC standards. The slope was 
determined using linear regression. The portion of the standard curve that is relevant to the 
measured samples is shown.  
 




















Ascorbate is a potent activator of the TET proteins, and has been proposed to lead to an increase 
of genome-wide hydroxymethylation levels in ascorbate treated cells (Blaschke et al., 2013). 
In this study, we assayed the amount of genome wide DNA hydroxymethylation in Jurkat cells 
after treatment with ascorbate and decitabine. Jurkat cells treated with combined ascorbate and 
decitabine showed a gradual increase in 5-hmC levels; 0.03% at 4 h, 0.34% at 8 h followed by 
reduction to 0.05% at 12 h compared to undetectable level in control cells. Decitabine alone 
caused negligible 5-hmC at 8h, but surprisingly, caused an increase in 5-hmC levels 0.12% (12 
fold) at 12 h. Ascorbate was able to increase 5-hmC levels 0.04% at 0 h (after 18 h incubation 
with Jurkat cells during synchronisation) compared to control. Notably, greater 5-hmC levels 
were achieved with ascorbate and decitabine combinatorial treatments than decitabine alone. 
Interestingly, although decitabine caused only negligible 5-hmC at timepoint 8 h when applied 




Figure 7. 16. Bar blot showing the percentage of 5-hmC in different samples at multiple 
timepoints (5-hmC/total DNA (A+G+C+T) (left axis). The right axis shows 5-hmC as a 
percentage of cytosines. Cytosine content is 21% in human. Hydroxymethylation levels 
(absorbance) of DNA samples that were less than the negative control were assigned to zero 
(C: control, A: ascorbate, D: decitabine and AD: ascorbate + decitabine treated cells. Values 
are means of duplicates.  
 
The amount of 5-hmC as a percentage of cytosine was calculated by dividing the calculated 5-








Epigenetic modification is a well-studied hallmark of cancer development. The well-known 
cytosine analogue, demethylating drug decitabine, is effective against haematological 
malignancies such as myelodysplastic syndrome and AML (Pleyer & Greil, 2015). Previous 
efforts concentrated on the treatment of tumour malignancies used high doses of decitabine in 
cancer cells. Study by Kantarjian (2007) showed that decitabine was associated with a survival 
advantage compared with intensive chemotherapy on patients with high risk MDS (Kantarjian 
et al., 2007). In contrast, the high doses of decitabine, led to cytotoxic induction without 
modulating the epigenetic pattern  (Fenaux et al., 2010; Pohlmann et al., 2002; Schwartsmann 
et al., 2000; Seymour et al., 2010). 
In this study, the gene specific sequencing results obtained from hairpin-bisulfite sequencing 
(Chapter 5 and 6) were validated using PBAT or low coverage global bisulfite sequencing. 
From the PBAT results, we were able to determine global DNA methylation levels and to study 
the kinetics of DNA demethylation in Jurkat cells after treatment with ascorbate and/or 
decitabine. One limitation of PBAT is that it cannot determine the proportions of DNA hemi-
methylation and therefore cannot determine the mechanism for loss of methylation, as hemi-
methylated DNA strands are separated into single strands during bisulfite treatment. 
Although, the WGBS method is a powerful method to analyse global DNA methylation levels, 
its cost is prohibitive and requires large amounts of starting DNA, whereas PBAT provides 
whole-genome bisulfite sequencing for low DNA input (100 ng) and at low cost. We 
constructed PBAT sequencing libraries for 64 samples from two experiments. The protocol 
yielded variable CG calls for all samples in the first experiment except for two samples where 
the CG call was low. In the second experiment, the protocol yielded more than 15,000 CG calls 
for each sample. In addition non CG “methylation” was less than 1% for both experiments 
indicating efficient bisulfite conversion 99% across the genome. 
There were comparable levels of global DNA methylation for all control samples and 
timepoints within the two experiments, indicating the precision of the PBAT protocol. We 
observed loss of global DNA methylation in Jurkat cells, Molt4 cells and Nalm6 cells  treated 
with decitabine or a combination of ascorbate/decitabine at increasing timepoints. The largest 
proportion of demethylation occurred at 72 h with around 60% loss methylation in Jurkat cells 
treated with decitabine or combined ascorbate/decitabine compared to untreated controls. The 
PBAT result corroborated the targeted, hairpin bisulfite sequencing results (Chapter 5), thus 




Our results show that incubation of Jurkat cells with 500 µM glycine chloramine had little effect 
on global CG methylation levels. There was only a small reduction in global CpG methylation 
(4%) at 6 h. The reduction in methylation was then confirmed by hairpin DNA sequencing 
which showed an increase in the percentage of DNA hemi-methylation in Jurkat cells treated 
with glycine chloramine at 6 h post release from cell cycle arrest (results not shown). 
Interestingly, a previous study by Dr. Helena Magrath from the Morison laboratory 
(unpublished data) showed active demethylation in Jurkat cells as early as 2 h post release from 
cell cycle arrest after treatment with glycine chloramine. Another study by Dr. Karina 
O’Connor showed that glycine chloramine inhibited DNA methylation by 35% compared with 
control Jurkat cells. The difference in demethylating activity of glycine chloramine between 
our experiment and the previous experiments may be because glycine chloramine is a short 
acting oxidant and inclined to degradation which leads to failure of inhibition of DNMT1. 
Therefore, in this research we studied the efficacy of hypomethylating agent decitabine and the 
concomitant treatment of decitabine/ascorbate to introduce epigenetic modifications in Jurkat 
cells. We investigated whether ascorbate can enhance the demethylating actions of decitabine.  
Ascorbate has been shown to act as a potent essential co-factor for the TET enzymes, which 
mediate the first step of active DNA demethylation by oxidation of 5-mC to generate 5-hmC 
(Figure 7.15). We found reduced DNA methylation levels as early as 6 h after release from cell 










Although, sodium bisulfite treatment is considered the gold standard for measuring DNA 
methylation, one primary limitation of this method is its inability to distinguish between 5-mC 
and 5-hmC and measuring both modified bases as methylated. 
To elucidate whether the epigenetic activity of TET enzymes was increased by the combination 
treatment of ascorbate and decitabine, genome-wide changes in DNA hydroxymethylation 
states were assessed. 
Remarkably, combination treatment of decitabine and ascorbate resulted in an increase in 5-
hmC at 4 h and 8 h, suggesting some synergism and additive effect between decitabine and 
ascorbate. Decitabine alone failed to elicit any changes to 5-hmC levels at 4 h with only 
negligible effects at 8 h. Interestingly, decitabine alone induced an increase of 5-hmC levels in 
Jurkat cells after 12 h. Diminished TET activity in the absence of ascorbate suggesting further 
mechanisms are at play, that ascorbate is not an essential co-factor for TET enzyme activity.  
The presence of hemi-methylated DNA strands after decitabine treatment, induced TET 
enzymes activity, which is consistent with previous study that showed decitabine induced an 
increase in 5-hmC levels in HL60 and TK6 leukaemia cell lines (Chowdhury et al., 2015b). 
Furthermore, Gerecke et al (2018) used LC-MS/MS to demonstrate that ascorbate was not 
involved in the passive DNA hypomethylation mediated by the action of decitabine, but was 
involved in the global increase of 5-hmC (Gerecke et al., 2018). 
Minor et al. (2013) showed that ascorbate enhanced 5-hmC generation in a dose dependent 
manner in mouse embryonic fibroblasts (MEFs), and that ascorbate could rapidly (< 1 h) induce 
significant TET dependent generation of 5-hmC, suggesting a direct involvement of ascorbate 
in the catalytic activity of TET proteins (Minor et al., 2013). A similar study on MEFs, reported 
that ascorbate induces TET mediated production of 5-hmC, and the effect was independent of 
iron or 2-oxoglutarate levels (Dickson et al., 2013). Treatment with vitamin C at physiological 
levels increased 5-hmC in five cancer cell lines, with the biggest yield seen in MCF7 cells. 
Interestingly, combination treatment of ascorbate and decitabine further increased 5-hmC levels 
by about twofold compared with ascorbate alone in four of the cell lines, suggesting the 
involvement of TET enzymes in enhancing the production of 5-hmC (Liu et al., 2016). A study 
by Sajadian et al. showed that 5-azacytidine is able to trigger TET-dependent active 
demethylation in hepatocellular carcinoma HCC with concomitant significant changes in 5-
hmC/mC (Sajadian et al., 2015a). 
Our study clearly showed that the addition of ascorbate to decitabine treatment increased the 




Thus, our data suggested a mechanism between ascorbate and the hemi-methylation status by 
decitabine: firstly, that ascorbate up-regulated TET proteins; and secondly, the hemi-
methylation status enhanced TET proteins to hydroxylate 5-mC to 5-hmC at 8 h, compared to 
negligible 5-hmC levels in decitabine treatment alone.   
The reduction in global DNA hydroxymethylation at 12 h in Jurkat cells treated with 
combinatorial treatments of decitabine and ascorbate suggests that ascorbate enhanced TET 
enzyme to induce further oxidation of 5-hmC to 5-fC and 5-caC. It is known that cancer patients 
are vitamin C deficient and their tumour tissues are depleted of 5-hmC compared to 
corresponding normal tissue, suggesting the importance of ascorbate in cancer treatment (Sant 







Chapter Eight: Discussion and future directions. 
 
 
Previously, the Morison laboratory had observed DNA demethylation after exposure to glycine 
chloramine or decitabine in dividing Jurkat cells. Using a low throughput hairpin bisulfite 
sequencing assay, we had demonstrated hemi-methylation of densely methylated promoter 
regions after DNA synthesis in cells exposed to glycine chloramine or decitabine. Although 
this hemi-methylation was expected for decitabine, the mechanism by which glycine 
chloramine, an oxidative agent, is able to induce demethylation is unknown. Furthermore, using 
this low throughput assay, we surprisingly detected a small proportion of sequences which were 
fully demethylated. At the time of these results, demethylation mechanisms were largely 
unknown; however contemporaneous results from early embryo development studies suggested 
that the TET proteins were involved in active demethylation processes. 
To validate these initial results, I modified the hairpin bisulfite sequencing assay to utilise high-
throughput, next generation sequencing protocols, thus enabling the generation of thousands of 
reads per experiment and permitting documentation of methylation for both complementary 
DNA strands. Furthermore, we developed a bioinformatics workflow to facilitate rapid analysis 
of our sequencing results. An additional benefit of our assay is that examination of the random 
nucleotide hairpin sequence reveals any over-amplification of reads and our bioinformatic 
workflow will remove these non-unique (over-amplified) sequences, i.e. PCR bias. 
This study is unique in both aims and methodology, with the hairpin bisulfite sequencing assay 
revealing complementary strand methylation states. This research is the first to have 
investigated the complementary effects of ascorbate and decitabine on DNA methylation in 
somatic cells.  
Here we summarise the outcome of this study: 
Firstly, we developed a unique hairpin sequencing model system to observe methylation 
changes in complementary DNA strands; this model can generate thousands of unique 




Secondly, we established and developed a bioinformatic workflow to analyse hairpin bisulfite 
sequencing data, initially using the online Galaxy platform, but later with more efficient 
UNIX command line tools in combination with the R statistical platform. 
Thirdly, we documented the kinetics of DNMT inhibitor treatment, which has never before 
been observed in such detail and clarity. 
Fourthly, we documented the presence of hemi-methylation as early as 2 h after release from 
cell cycle arrest.  
Fifthly, we documented active DNA demethylation in somatic cells treated with ascorbate and 
decitabine. 
Sixthly, this study is the first to document the generation of 5-hmC in Jurkat cells after 
combined ascorbate/decitabine treatment, suggesting that the availability of ascorbate 
may enhance the efficacy of decitabine treatment in cancer.  
And finally, we demonstrated that a novel effect of decitabine producing hemi-methylation, is 
to induce TET-mediated active demethylation, as shown by increasing global 5-hmC 
levels. 
DNA methylation is believed to be stable and necessary to maintain differentiation, regulation 
of gene expression and cellular identity of fully differentiated, somatic cells. Nevertheless, 
dysregulation of DNA methylation has been documented in many cancers and likely contributes 
to tumorigenesis (Lio et al., 2019). The loss or gain of methylation is a prognostic marker in 
various types of cancer (Bochtler et al., 2017; Rasmussen & Helin, 2016). Recently, changing 
the balance of DNA methylation or demethylation of aberrantly methylated tumour suppressor 
gene promoters has become of interest to many cancer researchers.  
The phenomena of DNA methylation (de-novo and maintenance methylation) are well 
characterised in mammals; however, the mechanism for reversal of methylation or 
demethylation was less clear. Many studies have started to unravel the mechanism of DNA 
demethylation by focusing on the methylation changes that occur during early embryonic 
development. These studies have revealed two mechanisms that result in the loss of 
methylation. The first mechanism is termed replication-dependent or passive demethylation and 
relies on failure to reproduce CpG methylation and therefore, dilution of 5-mC during 
successive rounds of cell division, and the second mechanism is replication-independent or 
active demethylation, which requires enzymatic activity to modify and replace the 5-mC with 




DNA demethylation in early development, the extent to which it occurs in somatic cells remains 
unclear (Ho et al., 2017; Ooi & Bestor, 2008; Rose et al., 2014).  
In our laboratory, we have focused on mechanisms of DNA demethylation. We have used a 
model system Jurkat cells (a T cell leukaemia cell line) that expresses all three TET enzymes 
(Kalender Atak et al., 2012; Ko et al., 2011).  
Using this in vitro model, we observed a rapid DNA demethylation, as early as 2 h after release 
from thymidine block, in Jurkat cells exposed to oxidative stress. This observation confirmed 
unpublished data by Karina O’Connor (2009) indicating that oxidative stress induced by 
glycine chloramine treatment, reduced DNA methylation in the first 6 h of DNA replication 
without affecting the cell growth. This early loss of methylation is most likely due to active 
demethylation, and most probably occurred by the activity of the existing TET enzymes.  
To investigate this process of active demethylation and to test whether TET enzymes were 
involved, a high throughput barcoded hairpin bisulfite sequencing technique was developed to 
study the methylation pattern of complementary DNA strands. This advanced version of our 
original hairpin bisulfite sequencing technique provides a direct assessment of the methylation 
status of complementary strands, by covalently linking complementary DNA strands together 
with a DNA hairpin linker and generating thousands of unique barcoded sequences for each 
amplicon. From these sequencing data, we were able to document the process of DNA 
demethylation throughout the cell cycle and beyond. 
8.1 Decitabine enhances hemi-methylation and active demethylation. 
Decitabine is a well-known hypomethylating and anti-proliferative drug frequently used in the 
treatment of leukaemia (Badar et al., 2015). The mechanism of decitabine action as a specific 
inhibitor of DNMT1 was proposed many years ago, but not fully explained in detail (Raj et al., 
2007; Santi et al., 1984). Here, with the power of our hairpin bisulfite sequencing assay, we 
were able to describe the kinetics and pattern of DNMT1 inhibitor treatment. Our results show 
that decitabine, similar to glycine chloramine, was able to enhance DNA hemi-methylation in 
PCDHGA12 as early as 2 h after treatment (N.B. we define CpG site hemi-methylation as the 
lack of a methyl group on one strand, and retention of methylation on the other strand. 
Additionally, hemi-methylation levels increased as DNA replication proceeded. Even though 
these results were predicted by previous studies, the kinetics of decitabine-induced hemi-




In addition, a delay in cell cycle progression was observed at 24 h in decitabine-treated cells, 
represented by increased number of daughter cells in S phase. This delay might be due to ability 
of decitabine to stall DNA polymerase, and allowing time for DNA repair processes to remove 
the decitabine from DNA (Ubhi & Brown, 2019). Decitabine stalled DNA replications forks 
are transient, the cells are able to resolve them and continue replication via DNA repair 
response. For instance, previous reports showed that the deoxycytidine analogues cytarabine 
and gemcitabine can compete directly with dCTP for incorporation into newly synthesised 
DNA, leading to delay in replication fork progression or even termination of some replication 
forks (Huang et al., 1991; Richardson et al., 2004).  
To confirm the loss of methylation observed in gene-specific sequencing analysis, we 
performed a low coverage methylation sequencing assay (PBAT) to detect changes in global 
DNA methylation. We observed a gradual loss in global DNA methylation in synchronised 
Jurkat cells treated with decitabine, confirming the results from locus-specific studies. This 
finding is consistent with previous reports that decitabine enhanced loss of global methylation 
of colorectal cancer cells and leukaemia cells (Mossman et al., 2010; Öz et al., 2014; Yang et 
al., 2004). 
8.2 Ascorbate induces more demethylation in decitabine treated cells. 
Ascorbate appears to act as a co-factor for the TET enzymes by reducing the inactive Fe3+ to 
the active Fe2+, thus playing an important role in active DNA demethylation (Hore et al., 2016). 
Intriguingly, the normal ascorbate concentration in human plasma is ~50 µM, whereas standard 
cell culture media is ascorbate deficient, suggesting that the addition of ascorbate to treatment 
protocols may increase the clinical efficacy of such drugs in patients with leukaemia.  
We have observed an increase (40%) in unmethylated hairpin reads of the PCDHGA12 
promoter after treatment with ascorbate/decitabine compared to untreated controls. To the best 
of our knowledge, this is the first report of ascorbate enhancing the efficacy of decitabine to 
induce active DNA demethylation in somatic cells. A previous study has shown that treating 
mouse embryonic fibroblasts (MEF) with 10 µM ascorbate enhanced a rapid and significant 
generation of 5-hmC after as little as 1 h. These observed results were not unique to MEFs as 
the same results were obtained in different cell line HEK-293T and HeLa cells treated with 
ascorbate (Minor et al., 2013). Additionally, our results are consistent with another previous 
report demonstrating that ascorbate can directly enhance the catalytic activity of TET 
dioxygenases for the oxidation of 5-mC (Yin et al., 2013). Ascorbate is a cofactor for a large 




ascorbate plays a role in reducing the inactive Fe3+ to the active Fe2+ and maintaining enzyme 
cycling (Hore et al., 2016; Ito et al., 2010; Markolovic et al., 2015; Yin et al., 2013). 
Interestingly, contrasting results were published by Dickson (2013), who showed that ascorbate 
induced demethylation by generation of 5-hmC independent of the levels of iron (Dickson et 
al., 2013), whereas, Tahiliani (2009) reported that hydroxylation of 5-mC mediated by TET 
enzymes was not affected by ascorbate, and that TET proteins can oxidise 5-mC at the same 
rate and efficiency in the presence or absence of ascorbate (Tahiliani et al., 2009). 
It was reported that glutathione, another antioxidant reagent, was unable to affect the generation 
of 5-hmC in MEFs (Minor et al., 2013), thus suggesting that the effect of ascorbate on both 
DNA demethylation and 5-hmC levels is specifically TET-mediated, and not through its role 
as a general antioxidant. It is known that TET activity is intimately linked to the TCA 
‘tricarboxylic acid cycle’ metabolite products, and dysregulation of the TCA enzymes is 
relevant to TET activity in cancers. For example, mutations of fumarate hydratase or succinate 
dehydrogenase can result in accumulation of fumarate and succinate, respectively, and impede 
the activity of a variety of a-ketoglutarate dependent enzymes, including TET (Xiao et al., 
2012).  
Treatment of cells with decitabine alone or in combination with ascorbate is only transient, as 
both reagents are unstable in cell culture conditions (Chepda et al., 2001; Rogstad et al., 2009). 
The observed re-methylation of the PCDHGA12 hairpin molecules at 96 and 120 h after 
decitabine and combined ascorbate/decitabine treatments suggests re-methylation by the de 
novo methyltransferases DNMT3A and DNMT3B (Uysal et al., 2017), or that outgrowth of 
partially demethylated cells has occurred. 
The clinical relevance of our study is that it supports the premise that ascorbate is necessary to 
enhance the efficacy of decitabine by promoting the function of TET. Some patients with 
haematological cancers are treated with demethylating drugs such as decitabine. Given that 
cancer patients are often markedly ascorbate (vitamin C) deficient, the addition of ascorbate to 
treatment protocols may increase the clinical efficacy (or toxicity) of such drugs in such 
patients. 
8.3 Genome-wide 5-hmC content increased following decitabine and combined 
ascorbate/decitabine treatments. 
While, global 5-mC constitutes 4-5% of cytosine in normal adult tissue, 5-hmC concentration 




al., 2010). However, 5-hmC levels are dysregulated in cancer, and were depleted in carcinomas  
from prostate, colon, liver, brain, breast, skin, lung, melanoma and in many haematopoietic 
malignancies (Rodger et al., 2014). In general, the distribution of 5-hmC within the genome is 
associated with gene transcription, and depletion is associated with poorer prognosis, 
suggesting that 5-hmC has a role in suppressing tumour progression (Guo et al., 2011b; Wu, 
D'Alessio, Ito, Wang, et al., 2011; Wu & Zhang, 2011b; Xu, Wu, et al., 2011). However, 5-
hmC function was dependent on genome location; firstly, location in gene bodies was correlated 
positively with gene expression and secondly, location at gene promoters was associated gene 
repression (Wu, D'Alessio, Ito, Wang, et al., 2011).  
We observed a rapid active demethylation in the densely methylated PCDHGA12 and RASSF1 
promoters in synchronised Jurkat cells after incubation with decitabine and combined 
ascorbate/decitabine, and we predicted that this was mediated by TET activity. Because TET 
proteins mediate the first oxidation step of 5-mC to 5-hmC, we aimed to confirm the 
involvement of TETs in our observed locus-specific active demethylation. Conventional 
bisulfite conversion treatment is unable to differentiate between 5-mC and 5-hmC as both of 
them are read as cytosine after sequencing.  
Using an enzyme immunoassay, we measured the global DNA content of 5-hmC in treated and 
untreated synchronised Jurkat cells at different timepoints during DNA replication. Simply, 5-
hmC levels were undetectable in untreated Jurkat cells during all timepoints, consistent with 
previous observations of 5-hmC deficiency in cancer cells. This deficiency may be due to high 
intrinsic TET activity, which facilitates rapid oxidation of 5-hmC to 5-fC and 5-caC. This 
speculation is supported by several reports showing that the highest levels of 5-hmC were 
present in the least proliferative tissues, such as the brain (Globisch, Munzel, et al., 2010; Guo 
et al., 2011a; Kriaucionis & Heintz, 2009; Szwagierczak et al., 2010). 
Decitabine-treated cells exhibited very low levels of 5-hmC at 4 and 8 h respectively, but 
surprisingly, a marked increase at 12 h after decitabine treatment. This increase suggested that 
the decitabine-induced hemi-methylation enhanced TET-induced oxidation of 5-mC to 5-hmC 
and facilitated active demethylation. This result is consistent with others showing that the 
treatment of haematopoietic cell lines with decitabine decreased 5-mC content, but increased 
in 5-hmC levels (Vető et al., 2018). Additionally, a study by Chowdhury and colleagues 
demonstrated that decitabine not only reduced the global 5-mC levels but also promoted an 
anomalous increase in 5-hmC, 5-fC and 5-caC in acute myeloid leukaemia (Chowdhury et al., 




hepatocellular carcinoma cell line (HCC) led to a significant increase in 5-hmC positive cells 
after 24 and 48 h, accompanied by a significant increase in TET2 and TET3 expression 
(Sajadian et al., 2015b). 
Intriguingly, we found an increase in global 5-hmC levels in cells treated with ascorbate at 0 h 
(the time of release from cell cycle arrest, but after 18 h incubation with ascorbate during 
synchronisation) and with combined ascorbate/decitabine treated cells at 4 h after release from 
cell cycle arrest. Surprisingly, the global 5-hmC level was increased markedly at 8 h in cells 
treated with the combined ascorbate/decitabine. This rapid increase of 5-hmC strongly 
supported the involvement of TET enzymes in this hydroxymethylation process, and most 
likely that ascorbate promotes upregulation of TET activity and accelerates the generation of 
5-hmC. This finding was consistent with several reports showing an increase in the 5-hmC 
levels in cells incubated with ascorbate or combined ascorbate/decitabine. A study by Nair 
(2016) showed that ascorbate efficiently accelerated the activity of TET2 to induce iterative 
oxidation reactions by converting 5-mC into unmodified cytosine (Nair et al., 2016). Moreover, 
Chowdhury and colleagues also showed that TET enzymes have partial selectivity for hemi-
methylated CpG dinucleotides which could led to such changes in 5-hmC content (Chowdhury 
et al., 2015a).  
Importantly, we demonstrated that decitabine enhanced active demethylation, defined by the 
full removal of methyl groups from both complementary DNA strands. This study is the first 
to report active demethylation in somatic cells treated with decitabine. Our results demonstrate 
that decitabine is capable of erasing the epigenetic memory of somatic cells by affecting TET 
activity to induce hemi-methylation and active DNA demethylation.  
 
Although we never observed demethylation in untreated, control cells, we did observe some 
variability between experiments which might be attributed to differences in culture conditions 
(media composition, O2 levels, pH, etc.), PCR bias, sequencing artefacts or other unidentified 
factors combined that might have direct effect on DNA demethylation, e.g. BER, UHRF2 or / 
and APOBEC activities. To explore these potential variations, we conducted several replicate 
experiments to exclude most of the possible factors that might cause this variation. For example, 
PCR bias could be excluded, as we are using the hairpin barcode within each individual read, 
to remove all non-unique and repeated reads (reads sharing the same hairpin barcode). As we 
had changed the media composition from RPMI1640 to RPMI1640+glutamax and from 




versus DMEM media (the media provides iron), or RPMI1640 versus RPMI1640+glutamax 
(the media provides L-alanine and L-glutamine, and minimise toxic ammonia build up and 
improve cell viability and growth).  
Interestingly, we observed ~50% full unmethylated reads (active demethylation) of 
PCDHGA12 promoter at 4 h in Jurkat cells grown in DMEM media and treated with ascorbate 
and combined ascorbate/decitabine. This demethylation might be attributed to the iron content 
of DMEM media, and with the addition of ascorbate accelerating the recycling of Fe3+ into the 
active form Fe2+, acting as a co-factor for TET activity. No differences in the DNA methylation 
results between Jurkat cells grown in RPMI1640 vs RPMI1640+glutamax. 
To exclude ‘Jurkat cell specific activity’, we repeated the experiments in other haematopoietic 
cell lines. In three out of four studied cell lines (Jurkat, Molt4 and Nalm6), a marked gene-
specific as well as genome-wide demethylation was observed. Methylation was reduced by 
more than 50% in Jurkat cells treated with decitabine and with combined ascorbate/decitabine 
at 72 h, and was in the form of hemi- and fully unmethylated hairpin reads. Methylation was 
reduced in Molt4 and Nalm6 cell lines treated for 24 h with decitabine or combined 
ascorbate/decitabine, the loss of methylation is represented by gradual increase in hemi-
methylated sequences (~ 50% in Molt4 at 16 h, and 30% in Nalm6 at 12h) and few 
unmethylated sequences with increasing time. However, gene-specific methylation analysis for 
HL60 cells, showed little demethylation (~ 5-10% after 0.5 or 5 µM decitabine treatments). The 
reason for this resistance to demethylation of HL60 cells is unknown, but may be due to their 
sensitivity and observed cytotoxicity with decitabine treatment, and might be due to differences 
in cell surface transporters or receptors between HL60 and Jurkat, Molt4 (T-cell leukaemia) or 
Nalm6 (B-cells leukaemia). The combined use of decitabine and ascorbate may be an 
advantageous in enhancing the demethylation effect in decitabine resistant cells. 
It is widely recognised that proliferative cells such as cancerous cells can metabolise glutamine 
as source of energy (Daye & Wellen, 2012). Glutamine metabolism goes through two 
deamination steps, which are sequentially catalysed by two enzymes glutaminase and glutamine 
dehydrogenase and result in the generation of a-ketoglutarate (Corbet & Feron, 2017; Daye & 
Wellen, 2012). An increased level of a-ketoglutarate provides TET enzymes with a sufficient 
quantity to be upregulated and initiate oxidation of 5-mC to its oxidative derivatives, suggesting 
the addition of a-ketoglutarate to the culture media may increase TET activity during ascorbate 




However, our observations indicate that the DNMT inhibitor decitabine might not be the only 
substance that affects DNA methylation and induces rapid active demethylation. Perhaps 
activation of existing enzymes may occur during this process which led to this demethylation 
phenomenon. 
DNA methyltransferase enzymes DNMT1, DNMT3a and DNMT3b are the key controller of 
DNA methylation (Uysal et al., 2017), and these DNMTs are controlled by many factors such 
as folate level and the redox state of enzymes as well as the ratio of the methyl donor SAM to 
SAH. Changing in these regulatory factors results in up or down regulation of DNMTs or 
dysregulation of its function. An in vitro study by Chen (2013) reported that oxidative stress 
can switch the function of human and mouse DNMTs from DNA methylase activity to 
demethylase activity in the presence of calcium ions and in the absence of reducing agents 
(Chen, Wang, et al., 2013). Further investigation of factors that affect demethylation is clearly 
needed. 
8.4. Clinical relevance. 
Recent evidence suggests that there is a remarkable correlation between decreased TET 
expression and decreased 5-hmC content, resulted in progression of tumour, suggesting the 
possibility that the TETs act as tumour suppressor proteins in some cancer types (Haffner et al., 
2011; Xu, Wu, et al., 2011). The TET family of proteins were identified due to TET being a 
frequent translocation target in leukaemia. Another study reported that TET2 gene but not TET1 
or TET3 was frequently mutated in leukaemia, and acted as a relevant tumour suppressor gene 
(Delhommeau et al., 2009). TET1 mutations have been reported in T-cell ALL (Kalender Atak 
et al., 2012), and also decreased expression of TET1 has been observed in prostate and breast 
cancer (Hsu et al., 2012). Muller and his colleagues found that TET1 is frequently either not 
expressed or localised outside the nucleus, which suggested that the exclusion of TET1 from 
the nucleus resulted in depletion of 5-hmC in tumours, and also indicated that TET1 is required 
to maintain 5-hmC marks (Muller et al., 2012).  
Decitabine is used in the treatment of acute myeloid leukaemia. He and colleague showed that 
decitabine is an effective therapeutic alternative drug with acceptable side effects in early AML 
patients (He et al., 2017). A recent study compared the efficacy of a 5-day and 10-day schedule 
treatments in old patients with newly diagnosed AML, the result suggested that 10-day schedule 
of decitabine treatment led to better outcomes than 5-day schedule (Short et al., 2019). As in 




effect on proliferation, apoptosis and TET expression in HL60 and NB4 human leukaemia cells 
compared to decitabine alone (Zhao et al., 2018).  
8.5. Conclusions. 
The results of this study provide evidence that supports our hypotheses. We observed active 
demethylation in somatic cells after treatment with decitabine. Ascorbate increased 
demethylation. Demethylation was accompanied by increase in 5-hmC and presumably 
involved TET proteins. 
8.6. Future work. 
We observed variability of the results which might be attributed to differences in culture 
conditions (media composition, O2 levels, pH, etc.), PCR bias, sequencing artefacts or other. 
This is a mystery and further work needs to be undertaken to identify the missing variables. 
Potentially, they could be: 
1. Oxygen is an essential factor for TET enzymes, and oxygen shortage (hypoxia) play an 
important role in tumour biology. For example, about one third of tumour area has an 
oxygen level below 0.5% (Thienpont, Steinbacher, et al., 2016). However, purified TET 
enzymes require more than 2% oxygen to function normally, and hypoxic environment 
(0.5% O2) reduced the activity of TET to half (Thienpont, Steinbacher, et al., 2016). In 
contrast, Lin and colleagues (2017) demonstrated that hypoxia upregulates the 
expression of TET enzymes and catalyse the conversion of 5-mC to 5-hmC in 
hepatoblastoma (HepG2) cells (Lin et al., 2017). Oxygen concentration might have a 
direct / or indirect effect on the variation in our results, and use of hypoxia chamber is 
an option for future experiments to maintain the O2 concentration. 
2. Visualise changes in TET expression after different treatments using different 
techniques like qPCR and Western blotting. Or visualise changes in activity by using 
an in vitro TET activity assay. This should be investigated by measuring TET activity 
after decitabine and ascorbate treatments at different timepoints including early 
timepoints such as 15, 30, 45, 60 and 90 minutes.  
3. Direct measurement of TET-mediate methylcytosine oxidation by Knocking down TET 
expression using siRNA.   





5. Extend the study to design hairpin molecules to include more genes and more cell lines 
with extended timepoints. Some genes are more sensitive to decitabine, and cell lines 
may show variation in their response to decitabine.  
6. Gene-specific 5-hydroxymethycytosine assay. An assay to directly and efficiently 
monitor and measure TET activity is lacking. Chemical modification of cytosine bases 
or enzymatic detection have been described and could be used with modification of the 
hairpin assay (Giehr et al., 2018). 
7. Study the effects/kinetics of ascorbate treatment during cell growth. This could be 
investigated by studying the redox state of ascorbate and measuring the degradation rate 
of the oxidised form of ascorbate. Furthermore, more research is needed to determine 






Appendix 1. Terminal analysis script. 
These scripts were established and developed by Morison laboratory members Rob Weeks, 
Luke Bridgman, Suzan Almomani and myself. The scripts were used to process the raw files 






































for filenameF in *_R1_001.fastq.gz; 
do  
mkdir "${filenameF%_R1_001.fastq.gz}";  
mv -f "$filenameF" "${filenameF%_R1_001.fastq.gz}";  
 done;  
# sets up ‘for…loop’ for all files ending with *_R1_001.fastq.gz, makes a directory 
with the file name, and moves the files into their directory. 
 
for filenameF in *_R2_001.fastq.gz;  
 do 
 mv -f "$filenameF" "${filenameF%_R2_001.fastq.gz}";  
 cd ./"${filenameF%_R2_001.fastq.gz}";  
# sets up ‘for…loop’ for files ending with *_R2_001.fastq.gz and moves them to the 
previously created directory  
 
 for filenameF in *_R1_001.fastq.gz;  
 do  
 for filenameR in *_R2_001.fastq.gz;  
 do  
pear -f $filenameF -r $filenameR -o ${filenameF%_R1_001.fastq.gz};  
# Do pear, joins paired-end sequence files, and outputs to the current directory. 
 
       for filename in *.assembled.fastq;  
      do  
 mkdir ./${filename/%.assembled.fastq};  
# Downloads the assembled files, makes new directory inside the present working 
directory, named for the assembled files. 
 
cat < $filename |  
fastx_barcode_splitter.pl --bcfile 
~/Downloads/FPrimers1.txt --bol --mismatches 2 \  --
prefix                        
./${filename%.assembled.fastq}/ 
${filename%.assembled.fastq}_ --suffix .fastq; 
# splits against the forward first round primer sequence (only F primer needed as 
the two files have already been joined using Pear.  
 
mkdir ./Filtered_by_quality;  
 mkdir ./FastQC;  
fastqc ./${filename%.assembled.fastq}/*.fastq --
outdir=./FastQC;  
 done;   
 cd ../;  
 done;  
 done;  
done &&  
# Make directory with name ‘filter by quality. And make another directory with name 
’FASTQC’ run FASTQC against the barcoded-split.fastq files and output to the 
directory FASTQC. 
 
for d in ./*/*001/ ; do (cd "$d" && for filename in *.fastq; do fastq_quality_filter 
-Q33 -q 30 -p 80 -i $filename -o ${filename/%.fastq/f.fastq} -v ; done ; cd ../ ; mv 
./*/*f.fastq ./Filtered_by_quality; cd ./Filtered_by_quality;  
  
# filter the barcoded-split files by quality, for phred score >30 for 80% of read 




















































   for filename2 in *.fastq;  
        do awk '{if(NR%4==2) print;}' < $filename2 |  
 




  awk  
 
     '{sub(/GTGATGT|.TGATGT|G.GATGT|GT.ATGT|GTG.TGT|GTGA.GT| 
            GTGAT.T|GTGATG./,".")}; 1'   
     
# with 1 mismatch allow collapsing for the liker sequence immediately before the 
14 bp molecular barcode. 
 
 
| sort -t . -k 2.1,2.14 -u | cat -n | sed 's/^/>/' | tr "[\t]" "\n" > 
${filename2/%.fastq/.fasta}; rm ./*unmatchedf.fasta; done);  
 
     done && for d in ./*/Filtered_by_quality/ ;  
         do (cd "$d" && for filename in *PCDHGf.fasta;  
              do mkdir ./${filename/%f.fasta};  
                      java -jar ~/Downloads/BiQ_Analyzer.jar -nogui  
  -rseq ~/Downloads/PCDHG12.fasta -bseq $filename -outdir  
       




   ./${filename/%f.fasta}   
        -sortcgmeth -desc -minas 1000; done); done && 
               for d in ./*/*/*/ ; do (cd "$d" && cut -f 4 < results.tsv | 
                         sed -e 's/\(.\)/\1 /g' |  
                                 sed 1d > methylation.tsv);  
                                              done 
# sort the files in the output directory, minimum alignment score (1000). 
 
# For RASSF1 we used the same script, and changed the linker sequence 
before the molecular barcode 
 
    awk  
                 '{sub(/TGTGATGT|T.TGATGT|TG.GATGT|TGT.ATGT|TGTG.TGT| 




# Make new directory called “filename RASSF1” and run BiQ Analyser java 










# To extract the methylation data from the result files. Change directory 
into  “methylation.tsv” 
 
 
for d in */Filtered_by_quality/; do cd $d && for d2 in */; do cd $d2  
        && mv "methylation.tsv" "${d2%/}_methylation.tsv"; cd ..; done; cd ..; cd ..; done  
                 && mkdir Methylation && 
                       mv */Filtered_by_quality/*/*_methylation.tsv Methylation/ 
 
# Then prefix any file called “methylation.tsv” with the name of the 
directory that file is in. 
 
 
# To extract the heatmap from the output files. Change directory into  
“heatmap.png” 
 
for d in */Filtered_by_quality/; do cd $d && for d2 in */; do cd $d2 
         && mv "heatmap.png" "${d2%/}_heatmap.png"; cd ..; done; cd ..; cd ..; done 
                  && mkdir Heatmap &&  
                         mv */Filtered_by_quality/*/*_heatmap.png Heatmap/ 
 
# Then prefix the file called “heatmap.png” with the name of the directory 





Appendix 2. R methylation script. 
The script was used to calculate the proportion of strands that are methylated, hemi-









# Creates a list of files ending with “methylation.tsv”  
 
setwd("~/Desktop/Methylation") 
filenames = list.files(pattern = '*_methylation.tsv', full.names = F) 
 
# The first line of the R script creates a list of filenames in the directory Methylation 
 
 
Meth_to_table <- function(filenames){ 
  # The function Meth_to_table is created, which is then applied to the list "filenames" 
  results <- data.frame() 
  # An empty dataframe called "results" is created 
  for(i in 1:length(filenames)){ 
    # A for loop is invoked - this will run for every file listed in "filenames". 
    dat <- read.table(filenames[i], quote="\"", comment.char="", header = FALSE) 
    dat <- data.frame(lapply(dat, as.character), stringsAsFactors=FALSE) 
    dat <- data.frame(lapply(dat, as.numeric), stringsAsFactors=FALSE) 
 
    # The data from each "*_methylation.tsv" file is read into R and called "dat", and all characters changed to character form, then 
back to numeric - this changes all uncalled "X" values from BiQAnalyser to N/As - these can then be ignored by RStudio. 
 
    dat_T <- data.frame(Forward = ifelse(rowSums(dat[,1:(ncol(dat)/2)], na.rm=T) > (0.25*ncol(dat)), "1", "0")) 
 
    # Next, a new dataframe is created called dat_T - this has one column called Forward. It reads the columns from 1 to the 
number of columns in "dat" divided by two. For these columns it then sums the values. If the total of these columns is greater than 
1/4 of the total number of columns in the dataframe "dat", then a "1" is recorded in the column "Forward". If not, then a "0" is 
recorded. In this way, the "parent" strand is called as being either methylated (1) or unmethylated (0). 
 
    dat_T <- transform(dat_T, Reverse = ifelse(rowSums(dat[,(ncol(dat)/2+1):ncol(dat)], na.rm=T) > (0.25*ncol(dat)), "1", "0")) 
    # Then, a new column called "Reverse" is added to the dataframe "dat_T". A function to call the "daughter" strand as being 
methylated (1) or unmethylated (0) is invoked, as in the previous line - except this runs for the last half of the dataframe "dat", not 
the first. 
 
    dat_T <- data.frame(lapply(dat_T, as.character), stringsAsFactors=FALSE) 
    dat_T <- data.frame(lapply(dat_T, as.numeric), stringsAsFactors=FALSE) 
    # Then all values are converted to numeric again to force N/As. 
     
    dat_Strand <- data.frame(Strand = rowSums(dat_T[,1:2])) 
    # Next, a new dataframe called dat_Strand is created. This has only one column, called "Strand". This column contains the sum 
of each row from the previous table "dat_T". This gives three values: 0, 1, and 2. 
     
    dat_Meth <- data.frame(Unmethylated = (sum(dat_Strand$Strand == "0"))/(sum(dat_Strand$Strand == "0", dat_Strand$Strand 
== "1", dat_Strand$Strand =="2")), Hemimethylated = (sum(dat_Strand$Strand == "1"))/(sum(dat_Strand$Strand == "0", 
dat_Strand$Strand == "1", dat_Strand$Strand =="2")), Methylated = (sum(dat_Strand$Strand == "2"))/(sum(dat_Strand$Strand 
== "0", dat_Strand$Strand == "1", dat_Strand$Strand =="2"))) 
 
    # Next, a new dataframe called dat_Meth is created. This calls the proportions of the column "Strand" that are methylated, 
hemimethylated, and unmethylated. It has three columns. The first is called "Unmethylated", and contains the proportion of 
"Strand" that is equivalent to "0" - i.e., both parent and daughter strand are unmethylated. The second is called "Hemimethylated", 
and contains the proportion of "Strand" that is equivalent to "1" - i.e., one of the parent or daughter strand is methylated and one 
unmethylated. The third is called "Methylated", and contains the proportion of "Strand" that is equivalent to "2" - i.e., both the 
parent and daughter strand are methylated. 
     
    results <- rbind(results, dat_Meth) 
    # Next, the proportions calculated for the dataframe "dat_Meth" are pasted onto the end of the dataframe "results". 
  } 
  write.table(results, file = "output3.csv", row.names = filenames, append = FALSE, col.names = NA, sep = ", ") 
   
# Once the for loop has ended, the contents of the dataframe "results" are output to the directory "Methylation" in the file 
"output.csv". Each row in "output.csv" is labelled with the name of the file that its data came from, in the initial list "filenames".  




# This runs the function "Meth_to_table", on the list "filenames". 
 





Appendix 3. Supplementary table. 
Supplementary Table1. Details of cell lines. 




Cell type: T cell leukaemia 
Origin: Peripheral blood of 14-year old 
boy. 
Doubling time: 25-35 hours 
Maximal density: 1.5 x 106 
cells/ml 
Morphology: round Cells 





Cell type: T cell leukaemia 
Origin: Peripheral blood of 19-year old 
man. 
Doubling time: 36 hours 
Maximal density: 0.5-1.3 x 
106 cells/ml 
Morphology: round Cells 




Cell type: B cell precursor leukaemia 
Origin: Peripheral blood of 19-year old 
man. 
Doubling time: 40 hours 
Maximal density: 1.0-2.0 x 
106 cells/ml 
Morphology: single, small 





Cell type: acute myeloid leukaemia 
Origin: Peripheral blood of 35-year old 
woman. 
Doubling time: about 40 hours 
Maximal density: 1.5-2.0 x 
106 cells/ml 
Morphology: round single 
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